{"data":{"filter_options":{"titles":[{"name":"Managing Partner Atlanta Office","value":"Managing Partner Atlanta Office"},{"name":"Partner","value":"Partner"},{"name":"Partner / Head of Pro Bono","value":"Partner / Head of Pro Bono"},{"name":"Partner / Chief Operating Officer","value":"Partner / Chief Operating Officer"},{"name":"Partner / General Counsel","value":"Partner / General Counsel"},{"name":"Partner / Dir. E-Discovery Ops","value":"Partner / Dir. E-Discovery Ops"},{"name":"Partner / Chairman, Saudi Arabia Practice","value":"Partner / Chairman, Saudi Arabia Practice"},{"name":"K\u0026S Talent Partner","value":"K\u0026S Talent Partner"},{"name":"Partner / Chief Human Resources Officer","value":"Partner / Chief Human Resources Officer"},{"name":"Chairman","value":"Chairman"},{"name":"Senior Counsel","value":"Senior Counsel"},{"name":"Associate Director, E-Discovery Operations","value":"Associate Director, E-Discovery Operations"},{"name":"Counsel","value":"Counsel"},{"name":"Senior Associate","value":"Senior Associate"},{"name":"Associate","value":"Associate"},{"name":"Senior Attorney","value":"Senior Attorney"},{"name":"Senior Lawyer","value":"Senior Lawyer"},{"name":"Attorney","value":"Attorney"},{"name":"Senior Counsel and Policy Advisor","value":"Senior Counsel and Policy Advisor"},{"name":"Managing Director - Capital Solutions","value":"Managing Director - Capital Solutions"},{"name":"Senior Government Relations Advisor","value":"Senior Government Relations Advisor"},{"name":"Associate General Counsel","value":"Associate General Counsel"},{"name":"Senior Advisor","value":"Senior Advisor"},{"name":"Patent Agent","value":"Patent Agent"},{"name":"Consultant","value":"Consultant"},{"name":"Government Relations Advisor","value":"Government Relations Advisor"},{"name":"Chief of Lateral Partner Recruiting \u0026 Integration","value":"Chief of Lateral Partner Recruiting \u0026 Integration"},{"name":"Chief Financial Officer","value":"Chief Financial Officer"},{"name":"Chief Information Officer","value":"Chief Information Officer"},{"name":"Chief Revenue Officer","value":"Chief Revenue Officer"},{"name":"Chief Recruiting Officer","value":"Chief Recruiting Officer"},{"name":"Chief Lawyer Talent Development Officer","value":"Chief Lawyer Talent Development Officer"},{"name":"Chief Marketing Officer","value":"Chief Marketing Officer"},{"name":"Tax Consultant","value":"Tax Consultant"},{"name":"Director of Community Affairs","value":"Director of Community Affairs"},{"name":"Director of Facilities \u0026 Admin Operations","value":"Director of Facilities \u0026 Admin Operations"},{"name":"Senior Office Manager","value":"Senior Office Manager"},{"name":"Director of Operations","value":"Director of Operations"},{"name":"Pro Bono Deputy","value":"Pro Bono Deputy"},{"name":"Director of Office Operations","value":"Director of Office Operations"},{"name":"Director of Operations Europe","value":"Director of Operations Europe"},{"name":"Law Clerk","value":"Law Clerk"},{"name":"Deputy General Counsel","value":"Deputy General Counsel"}],"schools":[{"name":"(Commercial Law), in front of Monash University, Australia","value":3045},{"name":"Aberystwyth University","value":3004},{"name":"Albany Law School","value":2118},{"name":"American University Washington College of Law","value":3042},{"name":"American University, Washington College of Law","value":3024},{"name":"Appalachian School of Law","value":2891},{"name":"Ateneo de Manila University","value":2914},{"name":"Ave Maria School of Law","value":2892},{"name":"Baylor University School of Law","value":181},{"name":"Benjamin N. Cardozo School of Law","value":2619},{"name":"Binghamton University","value":3002},{"name":"Boston College Law School","value":245},{"name":"Boston University School of Law","value":247},{"name":"BPP Law School Leeds","value":2642},{"name":"BPP Law School London","value":2782},{"name":"BPP University","value":2984},{"name":"Brooklyn Law School","value":2705},{"name":"Cairo University, Law School","value":2962},{"name":"California Western School of Law","value":315},{"name":"Capital University Law School","value":327},{"name":"Case Western Reserve University School of Law","value":345},{"name":"Cecil C. Humphreys School of Law","value":2235},{"name":"Chapman University School of Law","value":377},{"name":"Charleston School of Law","value":2910},{"name":"City Law School, London","value":2998},{"name":"City Law School","value":2857},{"name":"Clark University","value":3006},{"name":"Cleveland-Marshall College of Law","value":426},{"name":"Columbia University School of International and Public Affairs","value":3008},{"name":"Columbia University School of Law","value":485},{"name":"Columbia University","value":3126},{"name":"Columbus School of Law, Catholic University of America","value":3010},{"name":"Columbus School of Law","value":350},{"name":"Concord Law School of Kaplan University","value":1026},{"name":"Cornell Law School","value":512},{"name":"Creighton University School of Law","value":518},{"name":"Creighton University","value":3025},{"name":"Cumberland School of Law","value":1759},{"name":"CUNY School of Law","value":2893},{"name":"David A. Clarke School of Law","value":2399},{"name":"Deakin University School of Law","value":2907},{"name":"DePaul University College of Law","value":565},{"name":"DePaul University College of Law","value":3060},{"name":"Dickinson School of Law","value":2719},{"name":"Drake University Law School","value":609},{"name":"Duke University School of Law","value":613},{"name":"Duquesne University School of Law","value":614},{"name":"Dwayne O. Andreas School of Law","value":173},{"name":"Edinburgh Law School","value":3160},{"name":"Emory University School of Law","value":659},{"name":"ESADE Business and Law School – Universidad Ramon Llull","value":3215},{"name":"Fachseminare von Fürstenberg","value":2918},{"name":"Faculté Libre de Droit, Université Catholique de Lille","value":3055},{"name":"Faculty of Law, University of Zagreb","value":2983},{"name":"Faculty of Law","value":2944},{"name":"Faculty of Law","value":3039},{"name":"Federal University of Rio de Janeiro","value":3022},{"name":"Federal University of Rio Grande do Sul School of Law (Brazil)","value":3062},{"name":"Florida A\u0026M University College of Law","value":699},{"name":"Florida Coastal School of Law","value":2894},{"name":"Florida International College of Law","value":707},{"name":"Florida State University College of Law","value":720},{"name":"Fordham University School of Law","value":722},{"name":"Franklin Pierce Law Center","value":734},{"name":"Friedrich-Schiller-Universität Jena","value":3015},{"name":"George Mason University School of Law","value":752},{"name":"George Washington University Law School","value":753},{"name":"Georgetown University Law Center","value":755},{"name":"Georgia State University College of Law","value":761},{"name":"Ghent Law School","value":2793},{"name":"Golden Gate University School of Law","value":770},{"name":"Gonzaga University School of Law","value":772},{"name":"Graduate Institute of International and Development Studies, Geneva","value":2997},{"name":"Hamline University School of Law","value":811},{"name":"Harvard Law School","value":824},{"name":"Hebrew University of Jerusalem Faculty of Law","value":2994},{"name":"Hofstra University School of Law","value":858},{"name":"Howard University School of Law","value":872},{"name":"Huazhong University of Science and Technology","value":3016},{"name":"Humboldt University of Berlin","value":3012},{"name":"Indiana University School of Law","value":2711},{"name":"Indiana University School of Law","value":890},{"name":"International Association of Privacy Professionals","value":3009},{"name":"J. Reuben Clark Law School","value":262},{"name":"Jacob D. Fuchsberg Law Center","value":2084},{"name":"James Cook University of North Queensland","value":3034},{"name":"Jean Moulin University Lyon 3, France","value":2938},{"name":"Johns Hopkins Bloomberg School of Public Health","value":2992},{"name":"Justus-Liebig-Universität Gießen Rechtswissenschaft (Germany)","value":3063},{"name":"Kansas City School of Law","value":2247},{"name":"Keio University","value":2968},{"name":"Kent College of Law","value":883},{"name":"Kline School of Law","value":611},{"name":"KU Leuven","value":3007},{"name":"Levin College of Law","value":2189},{"name":"Lewis and Clark Law School","value":1089},{"name":"Liberty University School of Law","value":1094},{"name":"Lincoln College of Law","value":2253},{"name":"LL.M. in International Crime and Justice UNICRI","value":2937},{"name":"Loyola Law School","value":2895},{"name":"Loyola University Chicago School of Law","value":1135},{"name":"Loyola University New Orleans College of Law","value":1136},{"name":"Marquette University Law School","value":1176},{"name":"McGeorge School of Law","value":2402},{"name":"McGill University","value":2659},{"name":"Melbourne Law School","value":2899},{"name":"Mercer University Walter F. George School of Law","value":1221},{"name":"Mexico Autonomous Institute of Technology","value":2996},{"name":"Michael E. Moritz College of Law","value":2728},{"name":"Michigan State University College of Law","value":1245},{"name":"Mississippi College School of Law","value":1285},{"name":"Moscow State University","value":2815},{"name":"National and Kapodistrian University of Athens","value":3032},{"name":"National Law University Jodhpur","value":3020},{"name":"National University of Singapore, Faculty of Law","value":2662},{"name":"New England School of Law","value":2886},{"name":"New York Law School","value":1403},{"name":"New York University School of Law","value":1406},{"name":"Norman Adrian Wiggins School of Law","value":323},{"name":"North Carolina Central University School of Law","value":1417},{"name":"Northeastern University School of Law","value":1430},{"name":"Northern Illinois University College of Law","value":1432},{"name":"Northwestern Pritzker School of Law","value":1451},{"name":"Notre Dame Law School","value":2278},{"name":"Ohio Northern University Law School","value":3036},{"name":"Oklahoma City University School of Law","value":1487},{"name":"Osgoode Hall Law School","value":3124},{"name":"Pace University School of Law","value":1516},{"name":"Panteion University","value":3033},{"name":"Paul M. Hebert Law Center","value":2713},{"name":"Pennsylvania State University, Dickinson School of Law","value":1562},{"name":"Pepperdine University School of Law","value":1570},{"name":"Pettit College of Law","value":1473},{"name":"Pontificia Universidad Catolica de Chile","value":3203},{"name":"Pontificia Universidad Catolica del Peru","value":3011},{"name":"Pontificia Universidad Javeriana","value":3013},{"name":"Pontificia Universidade Catolica de Sao Paulo","value":3095},{"name":"Prince Sultan University College of Law","value":3167},{"name":"Queens College, Cambridge","value":3003},{"name":"Quinnipiac University School of Law","value":1626},{"name":"Ralph R. Papitto School of Law","value":1686},{"name":"Regent University School of Law","value":1649},{"name":"Rice University","value":3043},{"name":"Ruprecht-Karls-Universität Heidelberg","value":3049},{"name":"Rutgers University School of Law-Newark","value":1699},{"name":"Rutgers University School of Law","value":1697},{"name":"S.J. Quinney College of Law","value":2408},{"name":"Saint Louis University School of Law","value":1732},{"name":"Salmon P. Chase College of Law","value":1433},{"name":"Sandra Day O'Connor College of Law","value":103},{"name":"Santa Clara University School of Law","value":1771},{"name":"Seattle University School of Law","value":1787},{"name":"Seton Hall University School of Law","value":1790},{"name":"Shepard Broad Law Center","value":1460},{"name":"South Texas College of Law","value":2721},{"name":"Southern Illinois University School of Law","value":1849},{"name":"Southern Methodist University Dedman School of Law","value":1852},{"name":"Southern University Law Center","value":1857},{"name":"Southwestern Law School","value":1876},{"name":"St. John's University School of Law","value":2724},{"name":"St. Mary's University School of Law","value":1896},{"name":"St. Thomas University School of Law","value":1746},{"name":"Stanford Law School","value":1904},{"name":"Stetson University College of Law","value":1910},{"name":"Sturm College of Law","value":2184},{"name":"Suffolk University Law School","value":1921},{"name":"Syracuse University College of Law","value":1956},{"name":"Temple University Beasley School of Law","value":1974},{"name":"Texas A\u0026M School of Law","value":1980},{"name":"Texas Tech University School of Law","value":1994},{"name":"Texas Wesleyan University School of Law","value":1996},{"name":"The College of Law Australia","value":3091},{"name":"The College of Law, London","value":2935},{"name":"The John Marshall Law School","value":2034},{"name":"The Judge Advocate General's Legal Center and School","value":2896},{"name":"The Ohio State University Moritz College of Law","value":2990},{"name":"The University of Akron School of Law","value":2143},{"name":"The University of Alabama School of Law","value":2045},{"name":"The University of Birmingham, U.K.","value":2796},{"name":"The University of Iowa College of Law","value":2206},{"name":"The University of Texas School of Law","value":2055},{"name":"The University of Tulsa College of Law","value":2407},{"name":"Thomas Jefferson School of Law","value":685},{"name":"Thomas M. Cooley Law School","value":2729},{"name":"Thurgood Marshall School of Law","value":1992},{"name":"Tianjin University of Commerce","value":2995},{"name":"Tulane University Law School","value":2113},{"name":"UC Davis School of Law","value":2160},{"name":"UCLA School of Law","value":2162},{"name":"Universidad Católica de Honduras","value":2916},{"name":"Universidad Francisco Marroquin","value":3090},{"name":"Universidad Panamericana","value":2904},{"name":"Universidad Torcuato di Tella","value":3035},{"name":"Universidade de São Paulo, Faculdade de Direito","value":3028},{"name":"Universidade Presbiteriana Mackenzie","value":2977},{"name":"Università Commerciale Luigi Bocconi","value":3135},{"name":"University at Buffalo Law School","value":1928},{"name":"University College Dublin Law School","value":2900},{"name":"University of Alberta Faculty of Law","value":3088},{"name":"University of Amsterdam","value":2980},{"name":"University of Arizona, James E. Rogers College of Law","value":2149},{"name":"University of Arkansas School of Law","value":2154},{"name":"University of Baltimore School of Law","value":2156},{"name":"University of California College of the Law","value":3196},{"name":"University of California Hastings College of Law","value":2158},{"name":"University of California Irvine School of Law","value":2161},{"name":"University of California, Berkeley, School of Law","value":2159},{"name":"University of California, Davis","value":3019},{"name":"University of Cambridge, U.K","value":2991},{"name":"University of Canterbury","value":2981},{"name":"University of Central Florida","value":3027},{"name":"University of Chester Law School","value":3005},{"name":"University of Chicago Law School","value":2174},{"name":"University of Chicago","value":3038},{"name":"University of Cincinnati College of Law","value":2175},{"name":"University of Colorado School of Law","value":2177},{"name":"University of Connecticut School of Law","value":2180},{"name":"University of Dayton School of Law","value":2182},{"name":"University of Detroit Mercy School of Law","value":2185},{"name":"University of East Anglia","value":3000},{"name":"University of Florida, Levin College of Law","value":3188},{"name":"University of Georgia School of Law","value":2190},{"name":"University of Houston Law Center","value":2197},{"name":"University of Hull","value":3040},{"name":"University of Idaho College of Law","value":2201},{"name":"University of Illinois College of Law","value":2204},{"name":"University of Kansas School of Law","value":2208},{"name":"University of Kentucky College of Law","value":2210},{"name":"University of La Verne College of Law","value":2211},{"name":"University of Law, London","value":2999},{"name":"University of Lethbridge","value":3030},{"name":"University of Louisville Brandeis School of Law","value":2214},{"name":"University of Maine School of Law","value":2391},{"name":"University of Maryland School of Law","value":2224},{"name":"University of Miami School of Law","value":2236},{"name":"University of Michigan Law School","value":2237},{"name":"University of Minnesota Law School","value":2243},{"name":"University of Mississippi School of Law","value":2244},{"name":"University of Missouri School of Law","value":2246},{"name":"University of Montana School of Law","value":2048},{"name":"University of Nebraska College of Law","value":2744},{"name":"University of New Mexico School of Law","value":2262},{"name":"University of North Carolina School of Law","value":2266},{"name":"University of North Dakota School of Law","value":2271},{"name":"University of Oklahoma Law Center","value":2747},{"name":"University of Oregon School of Law","value":2281},{"name":"University of Pennsylvania Law School","value":2282},{"name":"University of Pittsburgh School of Law","value":2354},{"name":"University of Richmond School of Law","value":2370},{"name":"University of San Diego School of Law","value":2377},{"name":"University of San Francisco School of Law","value":2378},{"name":"University of South Carolina School of Law","value":2750},{"name":"University of South Dakota School of Law","value":2387},{"name":"University of Southern California Gould School of Law","value":3051},{"name":"University of St. Thomas School of Law","value":2751},{"name":"University of Sydney Law School","value":3031},{"name":"University of Tennessee College of Law","value":2051},{"name":"University of the West of England, Bristol","value":3001},{"name":"University of Toledo College of Law","value":2406},{"name":"University of Toronto","value":2912},{"name":"University of Utah","value":3026},{"name":"University of Virginia School of Law","value":2410},{"name":"University of Washington School of Law","value":2412},{"name":"University of Wisconsin Law School","value":2419},{"name":"University of Wyoming College of Law","value":2429},{"name":"University of Zürich","value":3037},{"name":"University Paris Dauphine","value":2976},{"name":"University Paris II Assas","value":2975},{"name":"University Paris II Assas","value":3052},{"name":"USC Gould School of Law","value":2389},{"name":"Utrecht University","value":3085},{"name":"Valparaiso University School of Law","value":2441},{"name":"Vanderbilt University School of Law","value":2442},{"name":"Vermont Law School","value":2451},{"name":"Villanova University School of Law","value":2454},{"name":"Wake Forest University School of Law","value":2471},{"name":"Washburn University School of Law","value":2482},{"name":"Washington and Lee University School of Law","value":2484},{"name":"Washington College of Law","value":61},{"name":"Washington University in St. Louis School of Law","value":2489},{"name":"Wayne State University Law School","value":2493},{"name":"West Virginia University College of Law","value":2517},{"name":"Western New England College School of Law","value":2528},{"name":"Western State College of Law","value":2897},{"name":"Wharton School of Business","value":3044},{"name":"Whittier Law School","value":2564},{"name":"Widener University Delaware Law School","value":2569},{"name":"Willamette University College of Law","value":2573},{"name":"William \u0026 Mary Law School","value":462},{"name":"William H. Bowen School of Law","value":2150},{"name":"William Mitchell College of Law","value":2758},{"name":"William S. Boyd School of Law","value":2256},{"name":"William S. Richardson School of Law","value":2195},{"name":"Wilmington University","value":2993},{"name":"Yale Law School","value":2605}],"offices":[{"name":"Abu Dhabi","value":13},{"name":"Atlanta","value":1},{"name":"Austin","value":12},{"name":"Brussels","value":23},{"name":"Charlotte","value":8},{"name":"Chicago","value":21},{"name":"Dallas","value":28},{"name":"Denver","value":22},{"name":"Dubai","value":6},{"name":"Frankfurt","value":9},{"name":"Geneva","value":15},{"name":"Houston","value":4},{"name":"London","value":5},{"name":"Los Angeles","value":19},{"name":"Miami","value":25},{"name":"New York","value":3},{"name":"Northern Virginia","value":24},{"name":"Paris","value":14},{"name":"Riyadh","value":27},{"name":"Sacramento","value":20},{"name":"San Francisco","value":10},{"name":"Silicon Valley","value":11},{"name":"Singapore","value":16},{"name":"Sydney","value":26},{"name":"Tokyo","value":18},{"name":"Washington, D.C.","value":2}],"capabilities":[{"name":"Corporate, Finance and Investments","value":"cg-1"},{"name":null,"value":72},{"name":null,"value":26},{"name":null,"value":40},{"name":null,"value":27},{"name":null,"value":80},{"name":null,"value":28},{"name":null,"value":35},{"name":null,"value":10},{"name":null,"value":134},{"name":null,"value":121},{"name":null,"value":78},{"name":null,"value":29},{"name":null,"value":32},{"name":null,"value":31},{"name":null,"value":33},{"name":null,"value":126},{"name":null,"value":36},{"name":null,"value":82},{"name":null,"value":37},{"name":null,"value":115},{"name":"Government Matters","value":"cg-2"},{"name":null,"value":1},{"name":null,"value":6},{"name":null,"value":71},{"name":null,"value":21},{"name":null,"value":23},{"name":null,"value":116},{"name":null,"value":24},{"name":null,"value":135},{"name":null,"value":25},{"name":null,"value":110},{"name":null,"value":20},{"name":null,"value":11},{"name":"Trial and Global Disputes","value":"cg-3"},{"name":null,"value":129},{"name":null,"value":2},{"name":null,"value":38},{"name":null,"value":3},{"name":null,"value":5},{"name":null,"value":19},{"name":null,"value":7},{"name":null,"value":4},{"name":null,"value":136},{"name":null,"value":13},{"name":null,"value":14},{"name":null,"value":15},{"name":null,"value":17},{"name":null,"value":18},{"name":null,"value":16},{"name":"Industries / Issues","value":"cg-4"},{"name":null,"value":133},{"name":null,"value":106},{"name":null,"value":124},{"name":null,"value":111},{"name":null,"value":132},{"name":null,"value":131},{"name":null,"value":102},{"name":null,"value":125},{"name":null,"value":127},{"name":null,"value":107},{"name":null,"value":112},{"name":null,"value":105},{"name":null,"value":109},{"name":null,"value":103},{"name":null,"value":128},{"name":null,"value":123},{"name":null,"value":118}]},"title_id":null,"school_id":null,"office_id":null,"capability_id":"cg-2","extra_filter_id":null,"extra_filter_type":null,"q":null,"starts_with":"D","per_page":12,"people":[{"id":426320,"version":1,"owner_type":"Person","owner_id":2435,"payload":{"bio":"\u003cp\u003eAmina Dammann specializes in environmental law and litigation.\u0026nbsp; She has extensive experience representing multinational corporations in the automotive, energy and pharma sectors.\u0026nbsp; Her practice includes defending clients in governmental investigations and enforcement actions, as well as in federal and state court litigation.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eAmina has many years of experience representing German and U.S. blue chip companies in both U.S. and German proceedings, as well as in transnational matters. A particular focus of her practice is on advising German companies facing litigation or governmental investigations in the United States. This includes representing German clients before U.S. agencies such as the U.S. Environmental Protection Agency (EPA) and the California Air Resources Board (CARB); it also involves coordinating parallel proceedings in the United States and Germany.\u0026nbsp; Amina \u0026nbsp;holds U.S. degrees from Harvard and Texas and has also obtained the two German state exams in law as well as a doctorate in law from Frankfurt University.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublications and Awards\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u0026bull;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u003cem\u003eVacating Arbitration Awards for Mistake of Fact\u003c/em\u003e, 27 Review of Litigation 441\u0026ndash;512 (2008); honored with the Vinson \u0026amp; Elkins LLP Outstanding Note Award\u003c/p\u003e\n\u003cp\u003e\u0026bull;\u0026nbsp; Die Beschwerdekammern der europ\u0026auml;ischen Agenturen [The Boards of Appeal of the European Agencies], Peter Lang, 2004; honored with the Baker \u0026amp; McKenzie Award for best dissertation in the area of business law\u003c/p\u003e","slug":"amina-dammann","email":"adammann@kslaw.com","phone":null,"matters":["\u003cp class=\"Base\"\u003eAmina Dammann\u0026rsquo;s experience includes the following matters:\u003c/p\u003e","\u003cp\u003eRepresented German car manufacturer in environmental enforcement action before the U.S. Environmental Protection Agency and the California Air Resources Board;\u003c/p\u003e","\u003cp class=\"Base\"\u003eRepresented German car manufacturer in litigation and governmental investigations regarding disputes over diesel emissions standards;\u003c/p\u003e","\u003cp\u003eRepresented New General Motors in litigation relating to ignition switch;\u003c/p\u003e","\u003cp\u003e\u003cem\u003eS3 Graphics Co., Ltd. v. ATI Technologies ULC, et al.\u0026nbsp;\u0026nbsp;\u003c/em\u003eRepresentation of AMD in patent ownership dispute, filed in the District of Delaware;\u003c/p\u003e","\u003cp\u003e\u003cem\u003eAdvanced Micro Devices, Inc., et al. v. S3 Graphics Co., Ltd., et al.\u003c/em\u003e Representation of AMD in patent ownership dispute, filed in the District of Delaware;\u003c/p\u003e","\u003cp\u003eRepresented Chevron in litigation arising out of an explosion at a refinery;\u003c/p\u003e","\u003cp\u003eRepresented oil refinery owner in arbitration dispute arising out of a refinery construction project in Colombia;\u003c/p\u003e","\u003cp\u003eRepresented global wind farm developer in arbitration dispute arising out of a long-term turbine service agreement;\u003c/p\u003e","\u003cp\u003e\u003cem\u003eKeranos, LLC v. Analog Devices, Inc., et al.\u003c/em\u003e Representation of Microchip and other defendants in patent infringement suit involving memory cell technology, filed in the Eastern District of Texas;\u003c/p\u003e","\u003cp\u003e\u003cem\u003eMicrochip Technology Inc. et al. v. United Module Corp. et al.\u003c/em\u003e(and related cases).\u0026nbsp; Representation of Microchip, Silicon Storage Technology and other declaratory judgment plaintiffs in patent infringement suit involving memory cell technology, pending in the Eastern District of Texas;\u003c/p\u003e","\u003cp\u003e\u003cem\u003eOccidental Chemical Corporation v. Louisiana Public Service Commission et al.\u003c/em\u003e: Representation of Occidental in litigation to assert rights of qualifying facilities under the Public Utility Regulatory Policies Act, filed in the Middle District of Louisiana;\u003c/p\u003e","\u003cp\u003e\u003cem\u003eJD Wind et al. v. Public Utility Commission of Texas et al.\u003c/em\u003e: Representation of Occidental in state and federal litigation involving the appropriate electric rate that must be paid to wind-generating facilities under the Public Utility Regulatory Policies Act and implementing regulations, filed in Texas state and federal courts.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eOccidental Chemical Corp. v. Entergy Louisiana LLC and the Louisiana Public Service Commission\u003c/em\u003e: Representation of Occidental involving the proper methodology for calculating avoided cost payments to qualifying facilities under the Public Utility Regulatory Policies Act, filed in the Middle District of Louisiana.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eAMEC/Zachry Crushed Stone Contractors Joint Venture et al. v. CEMEX Construction Material Florida, LLC\u003c/em\u003e: Representation of CEMEX in a lawsuit concerning a plant construction with multi-million dollar cost overrun and construction delays, filed in Florida state court (Business Court Division).\u003c/p\u003e","\u003cp\u003e\u003cem\u003eKing Pharmaceuticals, Inc. and Meridian Medical Technologies, Inc. v. Intelliject, Inc.\u003c/em\u003e: Representation of patent holder in a paragraph IV patent infringement lawsuit regarding auto-injector technology, filed in the District of Delaware.\u003c/p\u003e","\u003cp\u003e\u003cem\u003ePennfield Oil Company d/b/a Pennfield Animal Health v. Alpharma Inc.\u003c/em\u003e: Representation of Alpharma in a false advertising action arising from Alpharma advertisements that report the results of pharmaceutical research studies, filed in the District of Nebraska.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eAlpharma Inc. v. Wyeth\u003c/em\u003e: Representation of Alpharma in a lawsuit regarding the breach of a trademark license agreement and the infringement of Alpharma\u0026rsquo;s trademarks, filed in the Southern District of New York.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":71,"guid":"71.capabilities","index":0,"source":"capabilities"},{"id":5,"guid":"5.capabilities","index":1,"source":"capabilities"},{"id":7,"guid":"7.capabilities","index":2,"source":"capabilities"},{"id":102,"guid":"102.capabilities","index":3,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":4,"source":"capabilities"},{"id":13,"guid":"13.capabilities","index":5,"source":"capabilities"},{"id":762,"guid":"762.smart_tags","index":6,"source":"smartTags"},{"id":1270,"guid":"1270.smart_tags","index":7,"source":"smartTags"},{"id":1303,"guid":"1303.smart_tags","index":8,"source":"smartTags"}],"is_active":true,"last_name":"Dammann","nick_name":"Amina","clerkships":[],"first_name":"Amina","title_rank":9999,"updated_by":196,"law_schools":[],"middle_name":"S.","name_suffix":"","recognitions":null,"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eAmina Dammann specializes in environmental law and litigation.\u0026nbsp; She has extensive experience representing multinational corporations in the automotive, energy and pharma sectors.\u0026nbsp; Her practice includes defending clients in governmental investigations and enforcement actions, as well as in federal and state court litigation.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eAmina has many years of experience representing German and U.S. blue chip companies in both U.S. and German proceedings, as well as in transnational matters. A particular focus of her practice is on advising German companies facing litigation or governmental investigations in the United States. This includes representing German clients before U.S. agencies such as the U.S. Environmental Protection Agency (EPA) and the California Air Resources Board (CARB); it also involves coordinating parallel proceedings in the United States and Germany.\u0026nbsp; Amina \u0026nbsp;holds U.S. degrees from Harvard and Texas and has also obtained the two German state exams in law as well as a doctorate in law from Frankfurt University.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublications and Awards\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u0026bull;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u003cem\u003eVacating Arbitration Awards for Mistake of Fact\u003c/em\u003e, 27 Review of Litigation 441\u0026ndash;512 (2008); honored with the Vinson \u0026amp; Elkins LLP Outstanding Note Award\u003c/p\u003e\n\u003cp\u003e\u0026bull;\u0026nbsp; Die Beschwerdekammern der europ\u0026auml;ischen Agenturen [The Boards of Appeal of the European Agencies], Peter Lang, 2004; honored with the Baker \u0026amp; McKenzie Award for best dissertation in the area of business law\u003c/p\u003e","matters":["\u003cp class=\"Base\"\u003eAmina Dammann\u0026rsquo;s experience includes the following matters:\u003c/p\u003e","\u003cp\u003eRepresented German car manufacturer in environmental enforcement action before the U.S. Environmental Protection Agency and the California Air Resources Board;\u003c/p\u003e","\u003cp class=\"Base\"\u003eRepresented German car manufacturer in litigation and governmental investigations regarding disputes over diesel emissions standards;\u003c/p\u003e","\u003cp\u003eRepresented New General Motors in litigation relating to ignition switch;\u003c/p\u003e","\u003cp\u003e\u003cem\u003eS3 Graphics Co., Ltd. v. ATI Technologies ULC, et al.\u0026nbsp;\u0026nbsp;\u003c/em\u003eRepresentation of AMD in patent ownership dispute, filed in the District of Delaware;\u003c/p\u003e","\u003cp\u003e\u003cem\u003eAdvanced Micro Devices, Inc., et al. v. S3 Graphics Co., Ltd., et al.\u003c/em\u003e Representation of AMD in patent ownership dispute, filed in the District of Delaware;\u003c/p\u003e","\u003cp\u003eRepresented Chevron in litigation arising out of an explosion at a refinery;\u003c/p\u003e","\u003cp\u003eRepresented oil refinery owner in arbitration dispute arising out of a refinery construction project in Colombia;\u003c/p\u003e","\u003cp\u003eRepresented global wind farm developer in arbitration dispute arising out of a long-term turbine service agreement;\u003c/p\u003e","\u003cp\u003e\u003cem\u003eKeranos, LLC v. Analog Devices, Inc., et al.\u003c/em\u003e Representation of Microchip and other defendants in patent infringement suit involving memory cell technology, filed in the Eastern District of Texas;\u003c/p\u003e","\u003cp\u003e\u003cem\u003eMicrochip Technology Inc. et al. v. United Module Corp. et al.\u003c/em\u003e(and related cases).\u0026nbsp; Representation of Microchip, Silicon Storage Technology and other declaratory judgment plaintiffs in patent infringement suit involving memory cell technology, pending in the Eastern District of Texas;\u003c/p\u003e","\u003cp\u003e\u003cem\u003eOccidental Chemical Corporation v. Louisiana Public Service Commission et al.\u003c/em\u003e: Representation of Occidental in litigation to assert rights of qualifying facilities under the Public Utility Regulatory Policies Act, filed in the Middle District of Louisiana;\u003c/p\u003e","\u003cp\u003e\u003cem\u003eJD Wind et al. v. Public Utility Commission of Texas et al.\u003c/em\u003e: Representation of Occidental in state and federal litigation involving the appropriate electric rate that must be paid to wind-generating facilities under the Public Utility Regulatory Policies Act and implementing regulations, filed in Texas state and federal courts.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eOccidental Chemical Corp. v. Entergy Louisiana LLC and the Louisiana Public Service Commission\u003c/em\u003e: Representation of Occidental involving the proper methodology for calculating avoided cost payments to qualifying facilities under the Public Utility Regulatory Policies Act, filed in the Middle District of Louisiana.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eAMEC/Zachry Crushed Stone Contractors Joint Venture et al. v. CEMEX Construction Material Florida, LLC\u003c/em\u003e: Representation of CEMEX in a lawsuit concerning a plant construction with multi-million dollar cost overrun and construction delays, filed in Florida state court (Business Court Division).\u003c/p\u003e","\u003cp\u003e\u003cem\u003eKing Pharmaceuticals, Inc. and Meridian Medical Technologies, Inc. v. Intelliject, Inc.\u003c/em\u003e: Representation of patent holder in a paragraph IV patent infringement lawsuit regarding auto-injector technology, filed in the District of Delaware.\u003c/p\u003e","\u003cp\u003e\u003cem\u003ePennfield Oil Company d/b/a Pennfield Animal Health v. Alpharma Inc.\u003c/em\u003e: Representation of Alpharma in a false advertising action arising from Alpharma advertisements that report the results of pharmaceutical research studies, filed in the District of Nebraska.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eAlpharma Inc. v. Wyeth\u003c/em\u003e: Representation of Alpharma in a lawsuit regarding the breach of a trademark license agreement and the infringement of Alpharma\u0026rsquo;s trademarks, filed in the Southern District of New York.\u003c/p\u003e"]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":4206}]},"capability_group_id":2},"created_at":"2025-05-26T04:50:54.000Z","updated_at":"2025-05-26T04:50:54.000Z","searchable_text":"Dammann{{ FIELD }}Amina Dammann’s experience includes the following matters:{{ FIELD }}Represented German car manufacturer in environmental enforcement action before the U.S. Environmental Protection Agency and the California Air Resources Board;{{ FIELD }}Represented German car manufacturer in litigation and governmental investigations regarding disputes over diesel emissions standards;{{ FIELD }}Represented New General Motors in litigation relating to ignition switch;{{ FIELD }}S3 Graphics Co., Ltd. v. ATI Technologies ULC, et al.  Representation of AMD in patent ownership dispute, filed in the District of Delaware;{{ FIELD }}Advanced Micro Devices, Inc., et al. v. S3 Graphics Co., Ltd., et al. Representation of AMD in patent ownership dispute, filed in the District of Delaware;{{ FIELD }}Represented Chevron in litigation arising out of an explosion at a refinery;{{ FIELD }}Represented oil refinery owner in arbitration dispute arising out of a refinery construction project in Colombia;{{ FIELD }}Represented global wind farm developer in arbitration dispute arising out of a long-term turbine service agreement;{{ FIELD }}Keranos, LLC v. Analog Devices, Inc., et al. Representation of Microchip and other defendants in patent infringement suit involving memory cell technology, filed in the Eastern District of Texas;{{ FIELD }}Microchip Technology Inc. et al. v. United Module Corp. et al.(and related cases).  Representation of Microchip, Silicon Storage Technology and other declaratory judgment plaintiffs in patent infringement suit involving memory cell technology, pending in the Eastern District of Texas;{{ FIELD }}Occidental Chemical Corporation v. Louisiana Public Service Commission et al.: Representation of Occidental in litigation to assert rights of qualifying facilities under the Public Utility Regulatory Policies Act, filed in the Middle District of Louisiana;{{ FIELD }}JD Wind et al. v. Public Utility Commission of Texas et al.: Representation of Occidental in state and federal litigation involving the appropriate electric rate that must be paid to wind-generating facilities under the Public Utility Regulatory Policies Act and implementing regulations, filed in Texas state and federal courts.{{ FIELD }}Occidental Chemical Corp. v. Entergy Louisiana LLC and the Louisiana Public Service Commission: Representation of Occidental involving the proper methodology for calculating avoided cost payments to qualifying facilities under the Public Utility Regulatory Policies Act, filed in the Middle District of Louisiana.{{ FIELD }}AMEC/Zachry Crushed Stone Contractors Joint Venture et al. v. CEMEX Construction Material Florida, LLC: Representation of CEMEX in a lawsuit concerning a plant construction with multi-million dollar cost overrun and construction delays, filed in Florida state court (Business Court Division).{{ FIELD }}King Pharmaceuticals, Inc. and Meridian Medical Technologies, Inc. v. Intelliject, Inc.: Representation of patent holder in a paragraph IV patent infringement lawsuit regarding auto-injector technology, filed in the District of Delaware.{{ FIELD }}Pennfield Oil Company d/b/a Pennfield Animal Health v. Alpharma Inc.: Representation of Alpharma in a false advertising action arising from Alpharma advertisements that report the results of pharmaceutical research studies, filed in the District of Nebraska.{{ FIELD }}Alpharma Inc. v. Wyeth: Representation of Alpharma in a lawsuit regarding the breach of a trademark license agreement and the infringement of Alpharma’s trademarks, filed in the Southern District of New York.{{ FIELD }}Amina Dammann specializes in environmental law and litigation.  She has extensive experience representing multinational corporations in the automotive, energy and pharma sectors.  Her practice includes defending clients in governmental investigations and enforcement actions, as well as in federal and state court litigation.\nAmina has many years of experience representing German and U.S. blue chip companies in both U.S. and German proceedings, as well as in transnational matters. A particular focus of her practice is on advising German companies facing litigation or governmental investigations in the United States. This includes representing German clients before U.S. agencies such as the U.S. Environmental Protection Agency (EPA) and the California Air Resources Board (CARB); it also involves coordinating parallel proceedings in the United States and Germany.  Amina  holds U.S. degrees from Harvard and Texas and has also obtained the two German state exams in law as well as a doctorate in law from Frankfurt University. \nPublications and Awards\n•   Vacating Arbitration Awards for Mistake of Fact, 27 Review of Litigation 441–512 (2008); honored with the Vinson \u0026amp; Elkins LLP Outstanding Note Award\n•  Die Beschwerdekammern der europäischen Agenturen [The Boards of Appeal of the European Agencies], Peter Lang, 2004; honored with the Baker \u0026amp; McKenzie Award for best dissertation in the area of business law Partner Frankfurt University  The University of Texas at Austin The University of Texas School of Law Harvard University Harvard Law School Texas Federal Republic of Germany Amina Dammann’s experience includes the following matters: Represented German car manufacturer in environmental enforcement action before the U.S. Environmental Protection Agency and the California Air Resources Board; Represented German car manufacturer in litigation and governmental investigations regarding disputes over diesel emissions standards; Represented New General Motors in litigation relating to ignition switch; S3 Graphics Co., Ltd. v. ATI Technologies ULC, et al.  Representation of AMD in patent ownership dispute, filed in the District of Delaware; Advanced Micro Devices, Inc., et al. v. S3 Graphics Co., Ltd., et al. Representation of AMD in patent ownership dispute, filed in the District of Delaware; Represented Chevron in litigation arising out of an explosion at a refinery; Represented oil refinery owner in arbitration dispute arising out of a refinery construction project in Colombia; Represented global wind farm developer in arbitration dispute arising out of a long-term turbine service agreement; Keranos, LLC v. Analog Devices, Inc., et al. Representation of Microchip and other defendants in patent infringement suit involving memory cell technology, filed in the Eastern District of Texas; Microchip Technology Inc. et al. v. United Module Corp. et al.(and related cases).  Representation of Microchip, Silicon Storage Technology and other declaratory judgment plaintiffs in patent infringement suit involving memory cell technology, pending in the Eastern District of Texas; Occidental Chemical Corporation v. Louisiana Public Service Commission et al.: Representation of Occidental in litigation to assert rights of qualifying facilities under the Public Utility Regulatory Policies Act, filed in the Middle District of Louisiana; JD Wind et al. v. Public Utility Commission of Texas et al.: Representation of Occidental in state and federal litigation involving the appropriate electric rate that must be paid to wind-generating facilities under the Public Utility Regulatory Policies Act and implementing regulations, filed in Texas state and federal courts. Occidental Chemical Corp. v. Entergy Louisiana LLC and the Louisiana Public Service Commission: Representation of Occidental involving the proper methodology for calculating avoided cost payments to qualifying facilities under the Public Utility Regulatory Policies Act, filed in the Middle District of Louisiana. AMEC/Zachry Crushed Stone Contractors Joint Venture et al. v. CEMEX Construction Material Florida, LLC: Representation of CEMEX in a lawsuit concerning a plant construction with multi-million dollar cost overrun and construction delays, filed in Florida state court (Business Court Division). King Pharmaceuticals, Inc. and Meridian Medical Technologies, Inc. v. Intelliject, Inc.: Representation of patent holder in a paragraph IV patent infringement lawsuit regarding auto-injector technology, filed in the District of Delaware. Pennfield Oil Company d/b/a Pennfield Animal Health v. Alpharma Inc.: Representation of Alpharma in a false advertising action arising from Alpharma advertisements that report the results of pharmaceutical research studies, filed in the District of Nebraska. Alpharma Inc. v. Wyeth: Representation of Alpharma in a lawsuit regarding the breach of a trademark license agreement and the infringement of Alpharma’s trademarks, filed in the Southern District of New York.","searchable_name":"Amina S. Dammann","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":196,"capability_group_featured":null,"home_page_featured":null},{"id":437104,"version":1,"owner_type":"Person","owner_id":6127,"payload":{"bio":"\u003cp\u003eAnne Dana is a partner in King \u0026amp; Spalding\u0026rsquo;s Global Human Capital \u0026amp; Compliance practice. She is an innovative litigator whose practice focuses on complex employment litigation, defending management against claims of discrimination, harassment, and retaliation under federal, state and city laws. Anne represents employers in state and federal courts in New York, arbitration panels, and federal, state and city agencies. These include the Equal Employment Opportunity Commission, New York State Division of Human Rights, and New York City Human Rights Commission. She also represents clients in disputes involving claims of fraud, breach of contract, breach of fiduciary duty, and whistleblowing. A former commercial litigator, Anne has experience with complex commercial litigation.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eAnne counsels clients generally on a wide range of employment issues, including disciplinary actions and terminations, employment and separation agreements, employment policies and practices, internal complaints and investigations of alleged employee misconduct, and litigation avoidance.\u003c/p\u003e\n\u003cp\u003eAnne also extensively advises clients on compliance with harassment and discrimination laws around the country, including on mandatory policies, nondisclosure agreements and confidentiality provisions, training requirements, and other notice and poster requirements. She regularly conducts anti-harassment trainings, conducts investigations in response to internal complaints, and negotiates settlement and separation agreements in accordance with these laws. Anne helps track the development of laws in this area from proposed legislation through enforcement and is a thought leader in the era of #MeToo litigation.\u003c/p\u003e\n\u003cp\u003eAnne represents clients in a diverse range of industries, including banking and finance, telecommunications, entertainment, health care, hospitality, food service, retail, and higher education.\u003c/p\u003e","slug":"anne-dana","email":"adana@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":121,"guid":"121.capabilities","index":0,"source":"capabilities"},{"id":15,"guid":"15.capabilities","index":1,"source":"capabilities"},{"id":107,"guid":"107.capabilities","index":2,"source":"capabilities"},{"id":109,"guid":"109.capabilities","index":3,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":4,"source":"capabilities"},{"id":11,"guid":"11.capabilities","index":5,"source":"capabilities"},{"id":1199,"guid":"1199.smart_tags","index":6,"source":"smartTags"},{"id":81,"guid":"81.capabilities","index":7,"source":"capabilities"}],"is_active":true,"last_name":"Dana","nick_name":"Anne","clerkships":[],"first_name":"Anne","title_rank":9999,"updated_by":202,"law_schools":[{"id":613,"meta":{"degree":"J.D.","honors":"","is_law_school":"1","graduation_date":"2011-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"R.","name_suffix":"","recognitions":null,"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eAnne Dana is a partner in King \u0026amp; Spalding\u0026rsquo;s Global Human Capital \u0026amp; Compliance practice. She is an innovative litigator whose practice focuses on complex employment litigation, defending management against claims of discrimination, harassment, and retaliation under federal, state and city laws. Anne represents employers in state and federal courts in New York, arbitration panels, and federal, state and city agencies. These include the Equal Employment Opportunity Commission, New York State Division of Human Rights, and New York City Human Rights Commission. She also represents clients in disputes involving claims of fraud, breach of contract, breach of fiduciary duty, and whistleblowing. A former commercial litigator, Anne has experience with complex commercial litigation.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eAnne counsels clients generally on a wide range of employment issues, including disciplinary actions and terminations, employment and separation agreements, employment policies and practices, internal complaints and investigations of alleged employee misconduct, and litigation avoidance.\u003c/p\u003e\n\u003cp\u003eAnne also extensively advises clients on compliance with harassment and discrimination laws around the country, including on mandatory policies, nondisclosure agreements and confidentiality provisions, training requirements, and other notice and poster requirements. She regularly conducts anti-harassment trainings, conducts investigations in response to internal complaints, and negotiates settlement and separation agreements in accordance with these laws. Anne helps track the development of laws in this area from proposed legislation through enforcement and is a thought leader in the era of #MeToo litigation.\u003c/p\u003e\n\u003cp\u003eAnne represents clients in a diverse range of industries, including banking and finance, telecommunications, entertainment, health care, hospitality, food service, retail, and higher education.\u003c/p\u003e"},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":9156}]},"capability_group_id":2},"created_at":"2025-09-11T13:44:55.000Z","updated_at":"2025-09-11T13:44:55.000Z","searchable_text":"Dana{{ FIELD }}Anne Dana is a partner in King \u0026amp; Spalding’s Global Human Capital \u0026amp; Compliance practice. She is an innovative litigator whose practice focuses on complex employment litigation, defending management against claims of discrimination, harassment, and retaliation under federal, state and city laws. Anne represents employers in state and federal courts in New York, arbitration panels, and federal, state and city agencies. These include the Equal Employment Opportunity Commission, New York State Division of Human Rights, and New York City Human Rights Commission. She also represents clients in disputes involving claims of fraud, breach of contract, breach of fiduciary duty, and whistleblowing. A former commercial litigator, Anne has experience with complex commercial litigation.\nAnne counsels clients generally on a wide range of employment issues, including disciplinary actions and terminations, employment and separation agreements, employment policies and practices, internal complaints and investigations of alleged employee misconduct, and litigation avoidance.\nAnne also extensively advises clients on compliance with harassment and discrimination laws around the country, including on mandatory policies, nondisclosure agreements and confidentiality provisions, training requirements, and other notice and poster requirements. She regularly conducts anti-harassment trainings, conducts investigations in response to internal complaints, and negotiates settlement and separation agreements in accordance with these laws. Anne helps track the development of laws in this area from proposed legislation through enforcement and is a thought leader in the era of #MeToo litigation.\nAnne represents clients in a diverse range of industries, including banking and finance, telecommunications, entertainment, health care, hospitality, food service, retail, and higher education. Partner New York University New York University School of Law Duke University Duke University School of Law Duke University Duke University School of Law New York","searchable_name":"Anne R. Dana","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":444001,"version":1,"owner_type":"Person","owner_id":7205,"payload":{"bio":"\u003cp\u003eRob DeConti is a partner in King \u0026amp; Spalding\u0026rsquo;s healthcare practice, specializing in government healthcare fraud investigations, compliance, diligence, the False Claims Act, the Anti-Kickback Statute (AKS), and regulatory compliance and enforcement issues in relation to healthcare transactions. Rob is an expert on all aspects of the Department of Health and Human Services (HHS) Office of Inspector General (OIG) administrative remedies and initiatives, including mandatory and permissive exclusion authorities, the Civil Monetary Penalties Law, the Emergency Medical Treatment and Labor Act (EMTALA), corporate integrity agreements, Select Agent investigations, drug price reporting cases, and HHS OIG\u0026rsquo;s health care, grant, and contractor self-disclosure protocols. Rob has been a frequent presenter for many years at major national healthcare and life sciences conferences, conveying the government\u0026rsquo;s enforcement and compliance priorities.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eWith over 25 years of experience, including as the former Chief Counsel to HHS OIG, Rob advises healthcare and life sciences companies on complex regulatory and compliance issues. As the highest-ranking attorney for OIG, Rob served as a nationwide expert on the federal government\u0026rsquo;s development and implementation of health care compliance strategies for health care entities and compliance oversight by health care boards of directors. Rob oversaw all OIG legal services related to audits, investigations, fraud enforcement, and industry guidance. From early in his career as a line attorney with primary responsibility for OIG\u0026rsquo;s pneumonia upcoding national project, Rob has been significantly involved in many of the federal government\u0026rsquo;s major healthcare fraud and compliance initiatives over the past 25 years. As Chief Counsel, Rob served as the lead Deputy Inspector General for OIG\u0026rsquo;s updated compliance program guidance documents, setting forth best practices for entities that do business with the Federal health care programs, including Medicare and Medicaid.\u003c/p\u003e\n\u003cp\u003eBefore his role as Chief Counsel, he served for more than a decade as an Assistant Inspector General (AIG) for Legal Affairs. In that position, he was the signatory for OIG advisory opinions on the application of OIG's fraud and abuse authorities, including under the AKS, to the requesting party's existing or proposed business arrangements. He was also responsible for leading OIG\u0026rsquo;s legal work related to waivers of certain fraud and abuse laws for purposes of testing new health care payment and service delivery models developed by CMS. He has led OIG\u0026rsquo;s negotiation of Corporate Integrity Agreements (CIAs), with a wide range of providers from across the health care industry. From 2012 to 2016, he served as the OIG signatory on behalf of HHS for all False Claims Act (including qui tam) settlements and CIAs nationwide.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ePrior to becoming AIG in 2012, Rob was the Chief of the Administrative and Civil Remedies Branch, the largest of three branches in the Office of Counsel.\u003c/p\u003e\n\u003cp\u003eIn 2007, Rob served as a Special Trial Attorney in DOJ\u0026rsquo;s Fraud Section, Criminal Division, where he prosecuted matters in connection with phase one of the Medicare Fraud Strike Force in the Southern District of Florida. In that role, Rob was co-counsel for the jury trial leading to conviction on all five criminal counts, including soliciting and receiving kickbacks, of a durable medical equipment company owner who conspired with two Miami pharmacies in a scheme to bill Medicare for expensive inhalation medications. Prior to working at OIG, he worked in the general counsel\u0026rsquo;s office at a managed care organization.\u003c/p\u003e","slug":"robert-deconti","email":"rdeconti@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":24,"guid":"24.capabilities","index":0,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":1,"source":"capabilities"},{"id":21,"guid":"21.capabilities","index":2,"source":"capabilities"},{"id":23,"guid":"23.capabilities","index":3,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":4,"source":"capabilities"},{"id":826,"guid":"826.smart_tags","index":5,"source":"smartTags"}],"is_active":true,"last_name":"DeConti","nick_name":"Rob","clerkships":[],"first_name":"Robert","title_rank":9999,"updated_by":202,"law_schools":[{"id":3042,"meta":{"degree":"J.D.","honors":"","is_law_school":"1","graduation_date":"1999-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"K.","name_suffix":"","recognitions":[{"title":"HHS Secretary’s Award for Distinguished Service","detail":""},{"title":"HHS Secretary’s Award for Meritorious Service","detail":""},{"title":"Inspector General’s Bronze Medal for Outstanding Employee of the Year (multiple awards)","detail":""},{"title":"Inspector General’s Award for Fighting Fraud, Waste, and Abuse","detail":""},{"title":"President’s Council on Integrity and Efficiency Award for Excellence","detail":""},{"title":"Office of Inspector General Cooperative Achievement Award (multiple awards)","detail":""},{"title":"Inspector General’s Exceptional Achievement Award (multiple awards)","detail":""}],"linked_in_url":"https://www.linkedin.com/in/robertdeconti","seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eRob DeConti is a partner in King \u0026amp; Spalding\u0026rsquo;s healthcare practice, specializing in government healthcare fraud investigations, compliance, diligence, the False Claims Act, the Anti-Kickback Statute (AKS), and regulatory compliance and enforcement issues in relation to healthcare transactions. Rob is an expert on all aspects of the Department of Health and Human Services (HHS) Office of Inspector General (OIG) administrative remedies and initiatives, including mandatory and permissive exclusion authorities, the Civil Monetary Penalties Law, the Emergency Medical Treatment and Labor Act (EMTALA), corporate integrity agreements, Select Agent investigations, drug price reporting cases, and HHS OIG\u0026rsquo;s health care, grant, and contractor self-disclosure protocols. Rob has been a frequent presenter for many years at major national healthcare and life sciences conferences, conveying the government\u0026rsquo;s enforcement and compliance priorities.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eWith over 25 years of experience, including as the former Chief Counsel to HHS OIG, Rob advises healthcare and life sciences companies on complex regulatory and compliance issues. As the highest-ranking attorney for OIG, Rob served as a nationwide expert on the federal government\u0026rsquo;s development and implementation of health care compliance strategies for health care entities and compliance oversight by health care boards of directors. Rob oversaw all OIG legal services related to audits, investigations, fraud enforcement, and industry guidance. From early in his career as a line attorney with primary responsibility for OIG\u0026rsquo;s pneumonia upcoding national project, Rob has been significantly involved in many of the federal government\u0026rsquo;s major healthcare fraud and compliance initiatives over the past 25 years. As Chief Counsel, Rob served as the lead Deputy Inspector General for OIG\u0026rsquo;s updated compliance program guidance documents, setting forth best practices for entities that do business with the Federal health care programs, including Medicare and Medicaid.\u003c/p\u003e\n\u003cp\u003eBefore his role as Chief Counsel, he served for more than a decade as an Assistant Inspector General (AIG) for Legal Affairs. In that position, he was the signatory for OIG advisory opinions on the application of OIG's fraud and abuse authorities, including under the AKS, to the requesting party's existing or proposed business arrangements. He was also responsible for leading OIG\u0026rsquo;s legal work related to waivers of certain fraud and abuse laws for purposes of testing new health care payment and service delivery models developed by CMS. He has led OIG\u0026rsquo;s negotiation of Corporate Integrity Agreements (CIAs), with a wide range of providers from across the health care industry. From 2012 to 2016, he served as the OIG signatory on behalf of HHS for all False Claims Act (including qui tam) settlements and CIAs nationwide.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ePrior to becoming AIG in 2012, Rob was the Chief of the Administrative and Civil Remedies Branch, the largest of three branches in the Office of Counsel.\u003c/p\u003e\n\u003cp\u003eIn 2007, Rob served as a Special Trial Attorney in DOJ\u0026rsquo;s Fraud Section, Criminal Division, where he prosecuted matters in connection with phase one of the Medicare Fraud Strike Force in the Southern District of Florida. In that role, Rob was co-counsel for the jury trial leading to conviction on all five criminal counts, including soliciting and receiving kickbacks, of a durable medical equipment company owner who conspired with two Miami pharmacies in a scheme to bill Medicare for expensive inhalation medications. Prior to working at OIG, he worked in the general counsel\u0026rsquo;s office at a managed care organization.\u003c/p\u003e","recognitions":[{"title":"HHS Secretary’s Award for Distinguished Service","detail":""},{"title":"HHS Secretary’s Award for Meritorious Service","detail":""},{"title":"Inspector General’s Bronze Medal for Outstanding Employee of the Year (multiple awards)","detail":""},{"title":"Inspector General’s Award for Fighting Fraud, Waste, and Abuse","detail":""},{"title":"President’s Council on Integrity and Efficiency Award for Excellence","detail":""},{"title":"Office of Inspector General Cooperative Achievement Award (multiple awards)","detail":""},{"title":"Inspector General’s Exceptional Achievement Award (multiple awards)","detail":""}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":12841}]},"capability_group_id":2},"created_at":"2025-12-05T05:02:32.000Z","updated_at":"2025-12-05T05:02:32.000Z","searchable_text":"DeConti{{ FIELD }}{:title=\u0026gt;\"HHS Secretary’s Award for Distinguished Service\", :detail=\u0026gt;\"\"}{{ FIELD }}{:title=\u0026gt;\"HHS Secretary’s Award for Meritorious Service\", :detail=\u0026gt;\"\"}{{ FIELD }}{:title=\u0026gt;\"Inspector General’s Bronze Medal for Outstanding Employee of the Year (multiple awards)\", :detail=\u0026gt;\"\"}{{ FIELD }}{:title=\u0026gt;\"Inspector General’s Award for Fighting Fraud, Waste, and Abuse\", :detail=\u0026gt;\"\"}{{ FIELD }}{:title=\u0026gt;\"President’s Council on Integrity and Efficiency Award for Excellence\", :detail=\u0026gt;\"\"}{{ FIELD }}{:title=\u0026gt;\"Office of Inspector General Cooperative Achievement Award (multiple awards)\", :detail=\u0026gt;\"\"}{{ FIELD }}{:title=\u0026gt;\"Inspector General’s Exceptional Achievement Award (multiple awards)\", :detail=\u0026gt;\"\"}{{ FIELD }}Rob DeConti is a partner in King \u0026amp; Spalding’s healthcare practice, specializing in government healthcare fraud investigations, compliance, diligence, the False Claims Act, the Anti-Kickback Statute (AKS), and regulatory compliance and enforcement issues in relation to healthcare transactions. Rob is an expert on all aspects of the Department of Health and Human Services (HHS) Office of Inspector General (OIG) administrative remedies and initiatives, including mandatory and permissive exclusion authorities, the Civil Monetary Penalties Law, the Emergency Medical Treatment and Labor Act (EMTALA), corporate integrity agreements, Select Agent investigations, drug price reporting cases, and HHS OIG’s health care, grant, and contractor self-disclosure protocols. Rob has been a frequent presenter for many years at major national healthcare and life sciences conferences, conveying the government’s enforcement and compliance priorities. \nWith over 25 years of experience, including as the former Chief Counsel to HHS OIG, Rob advises healthcare and life sciences companies on complex regulatory and compliance issues. As the highest-ranking attorney for OIG, Rob served as a nationwide expert on the federal government’s development and implementation of health care compliance strategies for health care entities and compliance oversight by health care boards of directors. Rob oversaw all OIG legal services related to audits, investigations, fraud enforcement, and industry guidance. From early in his career as a line attorney with primary responsibility for OIG’s pneumonia upcoding national project, Rob has been significantly involved in many of the federal government’s major healthcare fraud and compliance initiatives over the past 25 years. As Chief Counsel, Rob served as the lead Deputy Inspector General for OIG’s updated compliance program guidance documents, setting forth best practices for entities that do business with the Federal health care programs, including Medicare and Medicaid.\nBefore his role as Chief Counsel, he served for more than a decade as an Assistant Inspector General (AIG) for Legal Affairs. In that position, he was the signatory for OIG advisory opinions on the application of OIG's fraud and abuse authorities, including under the AKS, to the requesting party's existing or proposed business arrangements. He was also responsible for leading OIG’s legal work related to waivers of certain fraud and abuse laws for purposes of testing new health care payment and service delivery models developed by CMS. He has led OIG’s negotiation of Corporate Integrity Agreements (CIAs), with a wide range of providers from across the health care industry. From 2012 to 2016, he served as the OIG signatory on behalf of HHS for all False Claims Act (including qui tam) settlements and CIAs nationwide. \nPrior to becoming AIG in 2012, Rob was the Chief of the Administrative and Civil Remedies Branch, the largest of three branches in the Office of Counsel.\nIn 2007, Rob served as a Special Trial Attorney in DOJ’s Fraud Section, Criminal Division, where he prosecuted matters in connection with phase one of the Medicare Fraud Strike Force in the Southern District of Florida. In that role, Rob was co-counsel for the jury trial leading to conviction on all five criminal counts, including soliciting and receiving kickbacks, of a durable medical equipment company owner who conspired with two Miami pharmacies in a scheme to bill Medicare for expensive inhalation medications. Prior to working at OIG, he worked in the general counsel’s office at a managed care organization. Partner HHS Secretary’s Award for Distinguished Service  HHS Secretary’s Award for Meritorious Service  Inspector General’s Bronze Medal for Outstanding Employee of the Year (multiple awards)  Inspector General’s Award for Fighting Fraud, Waste, and Abuse  President’s Council on Integrity and Efficiency Award for Excellence  Office of Inspector General Cooperative Achievement Award (multiple awards)  Inspector General’s Exceptional Achievement Award (multiple awards)  University of Virginia  American University Washington College of Law American University Washington College of Law District of Columbia Virginia Virginia State Bar American Health Law Association Government Attorney-at-Large, American Bar Association Health Law Section Council, 2022-2025 Government Liaison to the Health Care Compliance Association, Board of Directors, 2008-2012","searchable_name":"Robert K. DeConti (Rob)","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":435271,"version":1,"owner_type":"Person","owner_id":1973,"payload":{"bio":"\u003cp\u003eDan Donovan specializes in congressional, state attorneys general and parallel government investigations. A former Chief Investigative Counsel in the Senate, Dan co-chairs\u0026nbsp;our Government Advocacy and Congressional Investigations practices perennially recognized by \u003cem\u003eChambers USA\u003c/em\u003e: \u0026ldquo;King \u0026amp; Spalding is best known for its impressive congressional investigations practice, with several dedicated members working exclusively in this area.\u0026rdquo; Dan is ranked Band 1 for Congressional Investigations by \u003cem\u003eChambers USA \u003c/em\u003eand Tier 1 \u003cem\u003eLegal 500 US\u003c/em\u003e.\u0026nbsp; He\u0026nbsp;has two decades of crisis management experience with government investigations, involving significant legal, public relations and political risks.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eDan represents leading companies, individuals, trade associations, and nonprofit entities and provides effective crisis management counsel. He works at the forefront of controversial and politicized national and state policy issues that frequently lead to investigations and litigation, including congressional, multi-state and federal agency enforcement actions. Particularly experienced in anticipating and responding to congressional committee requests and subpoenas, Dan prepares clients for high-profile hearings and guides them through the unique challenges presented by congressional and parallel government investigations.\u003c/p\u003e\n\u003cp\u003eBefore joining the firm, Dan served as Senior Investigative Counsel to Senator Charles Grassley, then Chairman of the Committee on Finance. While serving in the U.S. Senate, Dan managed congressional investigations and oversight hearings. In this role, Dan directed investigations focused on statutory and regulatory compliance, including drug and device safety, drug pricing, and waste, fraud and abuse in Medicare, Medicaid and other government programs. He also handled policy and legislative matters, including the False Claims Act, the Food, Drug, and Cosmetic Act, Medicare and Medicaid programs, and related statutes. Dan also served as Chief Investigative Counsel to the Senate Committee on Small Business, where he managed consumer fraud and small business protection investigations and hearings. He began his congressional career as a Staff Assistant on the Senate Committee on Governmental Affairs, chaired by Senator Fred Thompson, working on the special investigation into the 1996 federal election campaigns.\u003c/p\u003e\n\u003cp\u003eDan also provides strategic policy and legislative counsel, and is a frequent speaker on congressional oversight and investigations.\u003c/p\u003e","slug":"daniel-donovan","email":"ddonovan@kslaw.com","phone":null,"matters":["\u003cp\u003eExperience representing numerous clients under investigation by Republican-controlled Senate and House Committees, including Senate Banking, Commerce, Finance, HELP, Homeland Security, Judiciary, Permanent Subcommittee on Investigations, Special Committee on Aging, and House Education and the Workforce, Energy \u0026amp; Commerce, Financial Services, Judiciary, Oversight and Reform, Select Subcommittee on the Coronavirus Crisis, Select Committee on CCP, and Ways \u0026amp; Means, among others.\u003c/p\u003e","\u003cp\u003eProviding advice and counsel with respect to congressional oversight activity to leading companies in private sector industries, including accounting, auto, banking, consulting, defense, energy, fashion, food, healthcare provider, higher education, insurance, medical device, pharmaceutical, private equity, and tech, among others.\u003c/p\u003e","\u003cp\u003eRepresenting\u0026nbsp;\u003cstrong\u003ea variety of clients\u003c/strong\u003e\u0026nbsp;in connection with investigations relating to allegations of government fraud, food and product safety and recalls, cybersecurity breaches, product pricing, clinical research, off-label promotion, direct-to-consumer advertising, payments to physicians, and financial conflicts of interest.\u003c/p\u003e","\u003cp\u003eRepresenting\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003emultiple pharmaceutical companies\u003c/strong\u003e\u0026nbsp;in connection with congressional and state attorneys general drug pricing investigations.\u003c/p\u003e","\u003cp\u003eRepresenting\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea variety of clients\u003c/strong\u003e\u0026nbsp;on healthcare policy and legislative issues.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea major university\u003c/strong\u003e\u0026nbsp;and\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003epharmaceutical company\u003c/strong\u003e\u0026nbsp;in connection with the Select Panel on Infant Lives (authorized under the House Energy and Commerce Committee) investigation relating to fetal tissue research.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea global financial institution\u003c/strong\u003e\u0026nbsp;in connection with an investigation by the Senate Permanent Subcommittee on Investigations, regarding international tax matters.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea Big Four accounting firm\u003c/strong\u003e\u0026nbsp;in a Senate Finance Committee investigation of a University\u0026rsquo;s handling of federal funds.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003emultiple pharmaceutical companies\u003c/strong\u003e\u0026nbsp;in House and Senate investigations related to Affordable Care Act enactment and implementation.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003emedical device companies\u003c/strong\u003e\u0026nbsp;in connection with House and Senate committee investigations into 510(k) regulatory issues, direct-to-consumer advertising, and payments to physicians.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea leading clean energy technology company\u003c/strong\u003e\u0026nbsp;in connection with a Senate investigation into Department of Energy grant program.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea major oil company\u003c/strong\u003e\u0026nbsp;in connection with congressional investigations.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea health insurer\u003c/strong\u003e\u0026nbsp;in House and Senate investigations related to Affordable Care Act implementation.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea coalition of food product companies\u003c/strong\u003e\u0026nbsp;in connection with congressional inquiries relating to food safety and regulatory issues.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea medical society\u003c/strong\u003e\u0026nbsp;in connection with Senate committee investigations in payments to physicians.\u003c/p\u003e","\u003cp\u003eRepresented individuals in connection with House and Senate committee inquiries and ethics investigations.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[{"id":3464}]},"expertise":[{"id":23,"guid":"23.capabilities","index":0,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":1,"source":"capabilities"},{"id":687,"guid":"687.smart_tags","index":2,"source":"smartTags"},{"id":111,"guid":"111.capabilities","index":3,"source":"capabilities"},{"id":1199,"guid":"1199.smart_tags","index":4,"source":"smartTags"},{"id":106,"guid":"106.capabilities","index":5,"source":"capabilities"},{"id":6,"guid":"6.capabilities","index":6,"source":"capabilities"},{"id":71,"guid":"71.capabilities","index":7,"source":"capabilities"},{"id":107,"guid":"107.capabilities","index":8,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":9,"source":"capabilities"},{"id":750,"guid":"750.smart_tags","index":10,"source":"smartTags"},{"id":761,"guid":"761.smart_tags","index":11,"source":"smartTags"},{"id":17,"guid":"17.capabilities","index":12,"source":"capabilities"},{"id":80,"guid":"80.capabilities","index":13,"source":"capabilities"},{"id":122,"guid":"122.capabilities","index":14,"source":"capabilities"},{"id":128,"guid":"128.capabilities","index":15,"source":"capabilities"},{"id":1261,"guid":"1261.smart_tags","index":16,"source":"smartTags"},{"id":1270,"guid":"1270.smart_tags","index":17,"source":"smartTags"}],"is_active":true,"last_name":"Donovan","nick_name":"Dan","clerkships":[],"first_name":"Daniel","title_rank":9999,"updated_by":202,"law_schools":[],"middle_name":"F.","name_suffix":"","recognitions":[{"title":"Band 1 Top Ranked Lawyer, Government Relations: Congressional Investigations - USA - Nationwide","detail":"Chambers USA, 2021-2024"},{"title":"“[Daniel] provides superb service and is an absolutely indispensable partner. He is incredibly responsive.”","detail":"Chambers USA"},{"title":"Tier 1 Government Relations: Congressional Investigations","detail":"Legal 500 US, 2024"},{"title":"“Life Sciences Star” White-Collar/Govt. Investigations","detail":"LMG Life Sciences, 2024"},{"title":"GIR 100","detail":"Global Investigations Review, 2024"},{"title":"Tier 1 for Government Relations Practice","detail":"Best Lawyers, 2024"},{"title":"“[W]e have complete confidence in his ability to manage complex issues and communicate with our senior leaders.”","detail":"Chambers USA"},{"title":"“King \u0026 Spalding is best known for its impressive congressional investigations practice.”","detail":"Chambers USA, 2008-2024"},{"title":"“Daniel is an expert in Congressional investigations and is always able to keep a calm head”","detail":"Chambers USA, 2021-2024"},{"title":"“Daniel provides extremely good insight into the Congressional process and can convey it to high-level executives.”","detail":"Chambers USA"},{"title":"“[A]ctive in high-profile congressional investigations, and includes ... experts such as Daniel Donovan”","detail":"Legal 500 US"},{"title":"King \u0026 Spalding has “a strong track in congressional investigations … Daniel Donovan is a key contact”","detail":"Legal 500 US"},{"title":"Nationwide Government Relations Practice Ranking","detail":"Chambers USA 2008-2024"},{"title":"Leading Government Relations Lawyer","detail":"Legal 500 US, 2020-2024"},{"title":"Crisis Management and Government Oversight Practice Award","detail":"National Law Journal 2021"},{"title":"“Law Firm of the Year” for Government Relations","detail":"US News \u0026 World Report"}],"linked_in_url":"https://www.linkedin.com/in/dan-donovan-214322a/","seodescription":"Dan Donovan specializes in congressional, state attorneys general and parallel government investigations. Read more about him.","primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eDan Donovan specializes in congressional, state attorneys general and parallel government investigations. A former Chief Investigative Counsel in the Senate, Dan co-chairs\u0026nbsp;our Government Advocacy and Congressional Investigations practices perennially recognized by \u003cem\u003eChambers USA\u003c/em\u003e: \u0026ldquo;King \u0026amp; Spalding is best known for its impressive congressional investigations practice, with several dedicated members working exclusively in this area.\u0026rdquo; Dan is ranked Band 1 for Congressional Investigations by \u003cem\u003eChambers USA \u003c/em\u003eand Tier 1 \u003cem\u003eLegal 500 US\u003c/em\u003e.\u0026nbsp; He\u0026nbsp;has two decades of crisis management experience with government investigations, involving significant legal, public relations and political risks.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eDan represents leading companies, individuals, trade associations, and nonprofit entities and provides effective crisis management counsel. He works at the forefront of controversial and politicized national and state policy issues that frequently lead to investigations and litigation, including congressional, multi-state and federal agency enforcement actions. Particularly experienced in anticipating and responding to congressional committee requests and subpoenas, Dan prepares clients for high-profile hearings and guides them through the unique challenges presented by congressional and parallel government investigations.\u003c/p\u003e\n\u003cp\u003eBefore joining the firm, Dan served as Senior Investigative Counsel to Senator Charles Grassley, then Chairman of the Committee on Finance. While serving in the U.S. Senate, Dan managed congressional investigations and oversight hearings. In this role, Dan directed investigations focused on statutory and regulatory compliance, including drug and device safety, drug pricing, and waste, fraud and abuse in Medicare, Medicaid and other government programs. He also handled policy and legislative matters, including the False Claims Act, the Food, Drug, and Cosmetic Act, Medicare and Medicaid programs, and related statutes. Dan also served as Chief Investigative Counsel to the Senate Committee on Small Business, where he managed consumer fraud and small business protection investigations and hearings. He began his congressional career as a Staff Assistant on the Senate Committee on Governmental Affairs, chaired by Senator Fred Thompson, working on the special investigation into the 1996 federal election campaigns.\u003c/p\u003e\n\u003cp\u003eDan also provides strategic policy and legislative counsel, and is a frequent speaker on congressional oversight and investigations.\u003c/p\u003e","matters":["\u003cp\u003eExperience representing numerous clients under investigation by Republican-controlled Senate and House Committees, including Senate Banking, Commerce, Finance, HELP, Homeland Security, Judiciary, Permanent Subcommittee on Investigations, Special Committee on Aging, and House Education and the Workforce, Energy \u0026amp; Commerce, Financial Services, Judiciary, Oversight and Reform, Select Subcommittee on the Coronavirus Crisis, Select Committee on CCP, and Ways \u0026amp; Means, among others.\u003c/p\u003e","\u003cp\u003eProviding advice and counsel with respect to congressional oversight activity to leading companies in private sector industries, including accounting, auto, banking, consulting, defense, energy, fashion, food, healthcare provider, higher education, insurance, medical device, pharmaceutical, private equity, and tech, among others.\u003c/p\u003e","\u003cp\u003eRepresenting\u0026nbsp;\u003cstrong\u003ea variety of clients\u003c/strong\u003e\u0026nbsp;in connection with investigations relating to allegations of government fraud, food and product safety and recalls, cybersecurity breaches, product pricing, clinical research, off-label promotion, direct-to-consumer advertising, payments to physicians, and financial conflicts of interest.\u003c/p\u003e","\u003cp\u003eRepresenting\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003emultiple pharmaceutical companies\u003c/strong\u003e\u0026nbsp;in connection with congressional and state attorneys general drug pricing investigations.\u003c/p\u003e","\u003cp\u003eRepresenting\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea variety of clients\u003c/strong\u003e\u0026nbsp;on healthcare policy and legislative issues.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea major university\u003c/strong\u003e\u0026nbsp;and\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003epharmaceutical company\u003c/strong\u003e\u0026nbsp;in connection with the Select Panel on Infant Lives (authorized under the House Energy and Commerce Committee) investigation relating to fetal tissue research.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea global financial institution\u003c/strong\u003e\u0026nbsp;in connection with an investigation by the Senate Permanent Subcommittee on Investigations, regarding international tax matters.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea Big Four accounting firm\u003c/strong\u003e\u0026nbsp;in a Senate Finance Committee investigation of a University\u0026rsquo;s handling of federal funds.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003emultiple pharmaceutical companies\u003c/strong\u003e\u0026nbsp;in House and Senate investigations related to Affordable Care Act enactment and implementation.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003emedical device companies\u003c/strong\u003e\u0026nbsp;in connection with House and Senate committee investigations into 510(k) regulatory issues, direct-to-consumer advertising, and payments to physicians.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea leading clean energy technology company\u003c/strong\u003e\u0026nbsp;in connection with a Senate investigation into Department of Energy grant program.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea major oil company\u003c/strong\u003e\u0026nbsp;in connection with congressional investigations.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea health insurer\u003c/strong\u003e\u0026nbsp;in House and Senate investigations related to Affordable Care Act implementation.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea coalition of food product companies\u003c/strong\u003e\u0026nbsp;in connection with congressional inquiries relating to food safety and regulatory issues.\u003c/p\u003e","\u003cp\u003eRepresented\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003ea medical society\u003c/strong\u003e\u0026nbsp;in connection with Senate committee investigations in payments to physicians.\u003c/p\u003e","\u003cp\u003eRepresented individuals in connection with House and Senate committee inquiries and ethics investigations.\u003c/p\u003e"],"recognitions":[{"title":"Band 1 Top Ranked Lawyer, Government Relations: Congressional Investigations - USA - Nationwide","detail":"Chambers USA, 2021-2024"},{"title":"“[Daniel] provides superb service and is an absolutely indispensable partner. He is incredibly responsive.”","detail":"Chambers USA"},{"title":"Tier 1 Government Relations: Congressional Investigations","detail":"Legal 500 US, 2024"},{"title":"“Life Sciences Star” White-Collar/Govt. Investigations","detail":"LMG Life Sciences, 2024"},{"title":"GIR 100","detail":"Global Investigations Review, 2024"},{"title":"Tier 1 for Government Relations Practice","detail":"Best Lawyers, 2024"},{"title":"“[W]e have complete confidence in his ability to manage complex issues and communicate with our senior leaders.”","detail":"Chambers USA"},{"title":"“King \u0026 Spalding is best known for its impressive congressional investigations practice.”","detail":"Chambers USA, 2008-2024"},{"title":"“Daniel is an expert in Congressional investigations and is always able to keep a calm head”","detail":"Chambers USA, 2021-2024"},{"title":"“Daniel provides extremely good insight into the Congressional process and can convey it to high-level executives.”","detail":"Chambers USA"},{"title":"“[A]ctive in high-profile congressional investigations, and includes ... experts such as Daniel Donovan”","detail":"Legal 500 US"},{"title":"King \u0026 Spalding has “a strong track in congressional investigations … Daniel Donovan is a key contact”","detail":"Legal 500 US"},{"title":"Nationwide Government Relations Practice Ranking","detail":"Chambers USA 2008-2024"},{"title":"Leading Government Relations Lawyer","detail":"Legal 500 US, 2020-2024"},{"title":"Crisis Management and Government Oversight Practice Award","detail":"National Law Journal 2021"},{"title":"“Law Firm of the Year” for Government Relations","detail":"US News \u0026 World Report"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":9964}]},"capability_group_id":2},"created_at":"2025-08-14T15:45:04.000Z","updated_at":"2025-08-14T15:45:04.000Z","searchable_text":"Donovan{{ FIELD }}{:title=\u0026gt;\"Band 1 Top Ranked Lawyer, Government Relations: Congressional Investigations - USA - Nationwide\", :detail=\u0026gt;\"Chambers USA, 2021-2024\"}{{ FIELD }}{:title=\u0026gt;\"“[Daniel] provides superb service and is an absolutely indispensable partner. He is incredibly responsive.”\", :detail=\u0026gt;\"Chambers USA\"}{{ FIELD }}{:title=\u0026gt;\"Tier 1 Government Relations: Congressional Investigations\", :detail=\u0026gt;\"Legal 500 US, 2024\"}{{ FIELD }}{:title=\u0026gt;\"“Life Sciences Star” White-Collar/Govt. Investigations\", :detail=\u0026gt;\"LMG Life Sciences, 2024\"}{{ FIELD }}{:title=\u0026gt;\"GIR 100\", :detail=\u0026gt;\"Global Investigations Review, 2024\"}{{ FIELD }}{:title=\u0026gt;\"Tier 1 for Government Relations Practice\", :detail=\u0026gt;\"Best Lawyers, 2024\"}{{ FIELD }}{:title=\u0026gt;\"“[W]e have complete confidence in his ability to manage complex issues and communicate with our senior leaders.”\", :detail=\u0026gt;\"Chambers USA\"}{{ FIELD }}{:title=\u0026gt;\"“King \u0026amp; Spalding is best known for its impressive congressional investigations practice.”\", :detail=\u0026gt;\"Chambers USA, 2008-2024\"}{{ FIELD }}{:title=\u0026gt;\"“Daniel is an expert in Congressional investigations and is always able to keep a calm head”\", :detail=\u0026gt;\"Chambers USA, 2021-2024\"}{{ FIELD }}{:title=\u0026gt;\"“Daniel provides extremely good insight into the Congressional process and can convey it to high-level executives.”\", :detail=\u0026gt;\"Chambers USA\"}{{ FIELD }}{:title=\u0026gt;\"“[A]ctive in high-profile congressional investigations, and includes ... experts such as Daniel Donovan”\", :detail=\u0026gt;\"Legal 500 US\"}{{ FIELD }}{:title=\u0026gt;\"King \u0026amp; Spalding has “a strong track in congressional investigations … Daniel Donovan is a key contact”\", :detail=\u0026gt;\"Legal 500 US\"}{{ FIELD }}{:title=\u0026gt;\"Nationwide Government Relations Practice Ranking\", :detail=\u0026gt;\"Chambers USA 2008-2024\"}{{ FIELD }}{:title=\u0026gt;\"Leading Government Relations Lawyer\", :detail=\u0026gt;\"Legal 500 US, 2020-2024\"}{{ FIELD }}{:title=\u0026gt;\"Crisis Management and Government Oversight Practice Award\", :detail=\u0026gt;\"National Law Journal 2021\"}{{ FIELD }}{:title=\u0026gt;\"“Law Firm of the Year” for Government Relations\", :detail=\u0026gt;\"US News \u0026amp; World Report\"}{{ FIELD }}Experience representing numerous clients under investigation by Republican-controlled Senate and House Committees, including Senate Banking, Commerce, Finance, HELP, Homeland Security, Judiciary, Permanent Subcommittee on Investigations, Special Committee on Aging, and House Education and the Workforce, Energy \u0026amp; Commerce, Financial Services, Judiciary, Oversight and Reform, Select Subcommittee on the Coronavirus Crisis, Select Committee on CCP, and Ways \u0026amp; Means, among others.{{ FIELD }}Providing advice and counsel with respect to congressional oversight activity to leading companies in private sector industries, including accounting, auto, banking, consulting, defense, energy, fashion, food, healthcare provider, higher education, insurance, medical device, pharmaceutical, private equity, and tech, among others.{{ FIELD }}Representing a variety of clients in connection with investigations relating to allegations of government fraud, food and product safety and recalls, cybersecurity breaches, product pricing, clinical research, off-label promotion, direct-to-consumer advertising, payments to physicians, and financial conflicts of interest.{{ FIELD }}Representing multiple pharmaceutical companies in connection with congressional and state attorneys general drug pricing investigations.{{ FIELD }}Representing a variety of clients on healthcare policy and legislative issues.{{ FIELD }}Represented a major university and pharmaceutical company in connection with the Select Panel on Infant Lives (authorized under the House Energy and Commerce Committee) investigation relating to fetal tissue research.{{ FIELD }}Represented a global financial institution in connection with an investigation by the Senate Permanent Subcommittee on Investigations, regarding international tax matters.{{ FIELD }}Represented a Big Four accounting firm in a Senate Finance Committee investigation of a University’s handling of federal funds.{{ FIELD }}Represented multiple pharmaceutical companies in House and Senate investigations related to Affordable Care Act enactment and implementation.{{ FIELD }}Represented medical device companies in connection with House and Senate committee investigations into 510(k) regulatory issues, direct-to-consumer advertising, and payments to physicians.{{ FIELD }}Represented a leading clean energy technology company in connection with a Senate investigation into Department of Energy grant program.{{ FIELD }}Represented a major oil company in connection with congressional investigations.{{ FIELD }}Represented a health insurer in House and Senate investigations related to Affordable Care Act implementation.{{ FIELD }}Represented a coalition of food product companies in connection with congressional inquiries relating to food safety and regulatory issues.{{ FIELD }}Represented a medical society in connection with Senate committee investigations in payments to physicians.{{ FIELD }}Represented individuals in connection with House and Senate committee inquiries and ethics investigations.{{ FIELD }}Dan Donovan specializes in congressional, state attorneys general and parallel government investigations. A former Chief Investigative Counsel in the Senate, Dan co-chairs our Government Advocacy and Congressional Investigations practices perennially recognized by Chambers USA: “King \u0026amp; Spalding is best known for its impressive congressional investigations practice, with several dedicated members working exclusively in this area.” Dan is ranked Band 1 for Congressional Investigations by Chambers USA and Tier 1 Legal 500 US.  He has two decades of crisis management experience with government investigations, involving significant legal, public relations and political risks.\nDan represents leading companies, individuals, trade associations, and nonprofit entities and provides effective crisis management counsel. He works at the forefront of controversial and politicized national and state policy issues that frequently lead to investigations and litigation, including congressional, multi-state and federal agency enforcement actions. Particularly experienced in anticipating and responding to congressional committee requests and subpoenas, Dan prepares clients for high-profile hearings and guides them through the unique challenges presented by congressional and parallel government investigations.\nBefore joining the firm, Dan served as Senior Investigative Counsel to Senator Charles Grassley, then Chairman of the Committee on Finance. While serving in the U.S. Senate, Dan managed congressional investigations and oversight hearings. In this role, Dan directed investigations focused on statutory and regulatory compliance, including drug and device safety, drug pricing, and waste, fraud and abuse in Medicare, Medicaid and other government programs. He also handled policy and legislative matters, including the False Claims Act, the Food, Drug, and Cosmetic Act, Medicare and Medicaid programs, and related statutes. Dan also served as Chief Investigative Counsel to the Senate Committee on Small Business, where he managed consumer fraud and small business protection investigations and hearings. He began his congressional career as a Staff Assistant on the Senate Committee on Governmental Affairs, chaired by Senator Fred Thompson, working on the special investigation into the 1996 federal election campaigns.\nDan also provides strategic policy and legislative counsel, and is a frequent speaker on congressional oversight and investigations. Daniel Donovan lawyer Partner Band 1 Top Ranked Lawyer, Government Relations: Congressional Investigations - USA - Nationwide Chambers USA, 2021-2024 “[Daniel] provides superb service and is an absolutely indispensable partner. He is incredibly responsive.” Chambers USA Tier 1 Government Relations: Congressional Investigations Legal 500 US, 2024 “Life Sciences Star” White-Collar/Govt. Investigations LMG Life Sciences, 2024 GIR 100 Global Investigations Review, 2024 Tier 1 for Government Relations Practice Best Lawyers, 2024 “[W]e have complete confidence in his ability to manage complex issues and communicate with our senior leaders.” Chambers USA “King \u0026amp; Spalding is best known for its impressive congressional investigations practice.” Chambers USA, 2008-2024 “Daniel is an expert in Congressional investigations and is always able to keep a calm head” Chambers USA, 2021-2024 “Daniel provides extremely good insight into the Congressional process and can convey it to high-level executives.” Chambers USA “[A]ctive in high-profile congressional investigations, and includes ... experts such as Daniel Donovan” Legal 500 US King \u0026amp; Spalding has “a strong track in congressional investigations … Daniel Donovan is a key contact” Legal 500 US Nationwide Government Relations Practice Ranking Chambers USA 2008-2024 Leading Government Relations Lawyer Legal 500 US, 2020-2024 Crisis Management and Government Oversight Practice Award National Law Journal 2021 “Law Firm of the Year” for Government Relations US News \u0026amp; World Report University of Rochester  American University Washington College of Law District of Columbia Maryland Experience representing numerous clients under investigation by Republican-controlled Senate and House Committees, including Senate Banking, Commerce, Finance, HELP, Homeland Security, Judiciary, Permanent Subcommittee on Investigations, Special Committee on Aging, and House Education and the Workforce, Energy \u0026amp; Commerce, Financial Services, Judiciary, Oversight and Reform, Select Subcommittee on the Coronavirus Crisis, Select Committee on CCP, and Ways \u0026amp; Means, among others. Providing advice and counsel with respect to congressional oversight activity to leading companies in private sector industries, including accounting, auto, banking, consulting, defense, energy, fashion, food, healthcare provider, higher education, insurance, medical device, pharmaceutical, private equity, and tech, among others. Representing a variety of clients in connection with investigations relating to allegations of government fraud, food and product safety and recalls, cybersecurity breaches, product pricing, clinical research, off-label promotion, direct-to-consumer advertising, payments to physicians, and financial conflicts of interest. Representing multiple pharmaceutical companies in connection with congressional and state attorneys general drug pricing investigations. Representing a variety of clients on healthcare policy and legislative issues. Represented a major university and pharmaceutical company in connection with the Select Panel on Infant Lives (authorized under the House Energy and Commerce Committee) investigation relating to fetal tissue research. Represented a global financial institution in connection with an investigation by the Senate Permanent Subcommittee on Investigations, regarding international tax matters. Represented a Big Four accounting firm in a Senate Finance Committee investigation of a University’s handling of federal funds. Represented multiple pharmaceutical companies in House and Senate investigations related to Affordable Care Act enactment and implementation. Represented medical device companies in connection with House and Senate committee investigations into 510(k) regulatory issues, direct-to-consumer advertising, and payments to physicians. Represented a leading clean energy technology company in connection with a Senate investigation into Department of Energy grant program. Represented a major oil company in connection with congressional investigations. Represented a health insurer in House and Senate investigations related to Affordable Care Act implementation. Represented a coalition of food product companies in connection with congressional inquiries relating to food safety and regulatory issues. Represented a medical society in connection with Senate committee investigations in payments to physicians. Represented individuals in connection with House and Senate committee inquiries and ethics investigations.","searchable_name":"Daniel F. Donovan (Dan)","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":431883,"version":1,"owner_type":"Person","owner_id":3969,"payload":{"bio":"\u003cp\u003eA partner in our FDA and Life Sciences practice, Lisa has almost 25\u0026nbsp;years of experience developing regulatory, legislative and litigation solutions for companies selling FDA-regulated products (i.e., drugs, devices, biologics, cosmetics, and tobacco). \u0026nbsp;She has served as an advisor to high-level public officials and C-suite executives on complex regulatory, policy, and litigation issues.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003ePreviously, Lisa served as a Senior Policy Advisor in the FDA Commissioner\u0026rsquo;s Office and as the Deputy Chief of Staff to the Commissioner of Food and Drugs. In these roles, she provided strategic counsel on the agency\u0026rsquo;s most significant and complex issues. These included off-label marketing, mobile medical apps/digital health, opioid misuse and abuse, in vitro diagnostics and next generation sequencing, cosmetic legislation and regulation, and antimicrobial drug development and use. During her tenure at the FDA, she also worked closely with Congress, the Department of Health and Human Services, the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC) and the Drug Enforcement Administration (DEA).\u003c/p\u003e\n\u003cp\u003eLisa is a frequent author and speaker on topics including:\u0026nbsp; digital health, advertising and promoting drugs and devices, remedying unfair competition in the drug and device space, women\u0026rsquo;s health issues, admissibility of 510(k)s in product liability lawsuits, preemption, in vitro diagnostics, the 21st Century Cures Act, and other topics. Lisa is Chambers ranked for Pharmaceutical/Medical Products Law. She also has been repeatedly recognized by Legal 500 as a Next Generation Partner and as a Recommended Key Lawyer for FDA Regulatory Law (2017, 2019, 2020, 2021, 2022, 2023, 2024) and for Government Relations (2016). Legal 500 has distinguished her for her expertise in digital health/AI and in pre-market strategies, and praised for her \u0026ldquo;unending enthusiasm to take on client\u0026rsquo;s causes as her own.\"\u003c/p\u003e","slug":"lisa-dwyer","email":"ldwyer@kslaw.com","phone":null,"matters":["\u003cp\u003eFocus on Digital Health/Telehealth\u003c/p\u003e","\u003cp\u003eFocus on In Vitro Diagnostic Tests and Laboratory Developed Tests\u003c/p\u003e","\u003cp\u003eFDA/FTC regulation of advertising and promotion\u003c/p\u003e","\u003cp\u003ePre-market development (drugs and devices (including digital health products))\u003c/p\u003e","\u003cp\u003eFDA product submissions (drugs and devices (including digital health products))\u003c/p\u003e","\u003cp\u003eDevelops regulatory, legislative and litigation solutions for unfair competition in the drug/device space\u003c/p\u003e\n\u003cp\u003e- Lanham Act\u003c/p\u003e\n\u003cp\u003e- Unfair trade practice statutes (state and federal)\u003c/p\u003e","\u003cp\u003eEngages FDA and Congress on key issues related to FDA-regulated products\u003c/p\u003e","\u003cp\u003eResponds to FDA/FTC inquires, FDA warning letters, and FDA 483s\u003c/p\u003e","\u003cp\u003eExperience remedying cGMP issues at facilities making OTC and Rx drugs and cosmetics\u003c/p\u003e","\u003cp\u003eCo-Chairs Women's Health Initiative\u003c/p\u003e","\u003cp\u003eMember of Cannabis Steering Committee\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[{"id":53}]},"expertise":[{"id":2,"guid":"2.capabilities","index":0,"source":"capabilities"},{"id":3,"guid":"3.smart_tags","index":1,"source":"smartTags"},{"id":23,"guid":"23.capabilities","index":2,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":3,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":4,"source":"capabilities"},{"id":21,"guid":"21.capabilities","index":5,"source":"capabilities"},{"id":970,"guid":"970.smart_tags","index":6,"source":"smartTags"},{"id":112,"guid":"112.capabilities","index":7,"source":"capabilities"},{"id":122,"guid":"122.capabilities","index":8,"source":"capabilities"},{"id":1193,"guid":"1193.smart_tags","index":9,"source":"smartTags"},{"id":1202,"guid":"1202.smart_tags","index":10,"source":"smartTags"},{"id":1206,"guid":"1206.smart_tags","index":11,"source":"smartTags"},{"id":1223,"guid":"1223.smart_tags","index":12,"source":"smartTags"},{"id":133,"guid":"133.capabilities","index":13,"source":"capabilities"}],"is_active":true,"last_name":"Dwyer","nick_name":"Lisa","clerkships":[],"first_name":"Lisa","title_rank":9999,"updated_by":202,"law_schools":[{"id":753,"meta":{"degree":"J.D.","honors":"honors","is_law_school":"1","graduation_date":"1998-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"M.","name_suffix":"","recognitions":[{"title":"Next Generation Lawyer","detail":"Legal 500, 2017 and 2019"},{"title":"Recognition for Government Relations ","detail":"Legal 500, 2016"},{"title":"FDA Commissioner’s Special Citation, Issuance of the Draft Guidance for Laboratory Developed Tests ","detail":"FDA Award Ceremony, 2015"},{"title":"FDA Group Recognition Award, Publishing FDA Strategic Priorities 2014–2018 Document","detail":"FDA Award Ceremony, 2015"},{"title":"FDA Commissioner’s Special Citation, Issuance of the Unique Device Identification (UDI) System Final Rule ","detail":"FDA Award Ceremony, 2014"},{"title":"FDA Group Recognition Award, FDA Language Access Plan Working Group","detail":"FDA Award Ceremony, 2014"},{"title":"FDA Group Recognition Award, Good Guidance Practices-Best Practices Working Group (Group Leader)","detail":"FDA Award Ceremony, 2012"},{"title":"FDA Group Recognition Award, Menu Labeling Working Group","detail":"CFSAN/FDA Award Ceremony, 2011"}],"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eA partner in our FDA and Life Sciences practice, Lisa has almost 25\u0026nbsp;years of experience developing regulatory, legislative and litigation solutions for companies selling FDA-regulated products (i.e., drugs, devices, biologics, cosmetics, and tobacco). \u0026nbsp;She has served as an advisor to high-level public officials and C-suite executives on complex regulatory, policy, and litigation issues.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003ePreviously, Lisa served as a Senior Policy Advisor in the FDA Commissioner\u0026rsquo;s Office and as the Deputy Chief of Staff to the Commissioner of Food and Drugs. In these roles, she provided strategic counsel on the agency\u0026rsquo;s most significant and complex issues. These included off-label marketing, mobile medical apps/digital health, opioid misuse and abuse, in vitro diagnostics and next generation sequencing, cosmetic legislation and regulation, and antimicrobial drug development and use. During her tenure at the FDA, she also worked closely with Congress, the Department of Health and Human Services, the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC) and the Drug Enforcement Administration (DEA).\u003c/p\u003e\n\u003cp\u003eLisa is a frequent author and speaker on topics including:\u0026nbsp; digital health, advertising and promoting drugs and devices, remedying unfair competition in the drug and device space, women\u0026rsquo;s health issues, admissibility of 510(k)s in product liability lawsuits, preemption, in vitro diagnostics, the 21st Century Cures Act, and other topics. Lisa is Chambers ranked for Pharmaceutical/Medical Products Law. She also has been repeatedly recognized by Legal 500 as a Next Generation Partner and as a Recommended Key Lawyer for FDA Regulatory Law (2017, 2019, 2020, 2021, 2022, 2023, 2024) and for Government Relations (2016). Legal 500 has distinguished her for her expertise in digital health/AI and in pre-market strategies, and praised for her \u0026ldquo;unending enthusiasm to take on client\u0026rsquo;s causes as her own.\"\u003c/p\u003e","matters":["\u003cp\u003eFocus on Digital Health/Telehealth\u003c/p\u003e","\u003cp\u003eFocus on In Vitro Diagnostic Tests and Laboratory Developed Tests\u003c/p\u003e","\u003cp\u003eFDA/FTC regulation of advertising and promotion\u003c/p\u003e","\u003cp\u003ePre-market development (drugs and devices (including digital health products))\u003c/p\u003e","\u003cp\u003eFDA product submissions (drugs and devices (including digital health products))\u003c/p\u003e","\u003cp\u003eDevelops regulatory, legislative and litigation solutions for unfair competition in the drug/device space\u003c/p\u003e\n\u003cp\u003e- Lanham Act\u003c/p\u003e\n\u003cp\u003e- Unfair trade practice statutes (state and federal)\u003c/p\u003e","\u003cp\u003eEngages FDA and Congress on key issues related to FDA-regulated products\u003c/p\u003e","\u003cp\u003eResponds to FDA/FTC inquires, FDA warning letters, and FDA 483s\u003c/p\u003e","\u003cp\u003eExperience remedying cGMP issues at facilities making OTC and Rx drugs and cosmetics\u003c/p\u003e","\u003cp\u003eCo-Chairs Women's Health Initiative\u003c/p\u003e","\u003cp\u003eMember of Cannabis Steering Committee\u003c/p\u003e"],"recognitions":[{"title":"Next Generation Lawyer","detail":"Legal 500, 2017 and 2019"},{"title":"Recognition for Government Relations ","detail":"Legal 500, 2016"},{"title":"FDA Commissioner’s Special Citation, Issuance of the Draft Guidance for Laboratory Developed Tests ","detail":"FDA Award Ceremony, 2015"},{"title":"FDA Group Recognition Award, Publishing FDA Strategic Priorities 2014–2018 Document","detail":"FDA Award Ceremony, 2015"},{"title":"FDA Commissioner’s Special Citation, Issuance of the Unique Device Identification (UDI) System Final Rule ","detail":"FDA Award Ceremony, 2014"},{"title":"FDA Group Recognition Award, FDA Language Access Plan Working Group","detail":"FDA Award Ceremony, 2014"},{"title":"FDA Group Recognition Award, Good Guidance Practices-Best Practices Working Group (Group Leader)","detail":"FDA Award Ceremony, 2012"},{"title":"FDA Group Recognition Award, Menu Labeling Working Group","detail":"CFSAN/FDA Award Ceremony, 2011"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":11487}]},"capability_group_id":2},"created_at":"2025-07-09T20:54:25.000Z","updated_at":"2025-07-09T20:54:25.000Z","searchable_text":"Dwyer{{ FIELD }}{:title=\u0026gt;\"Next Generation Lawyer\", :detail=\u0026gt;\"Legal 500, 2017 and 2019\"}{{ FIELD }}{:title=\u0026gt;\"Recognition for Government Relations \", :detail=\u0026gt;\"Legal 500, 2016\"}{{ FIELD }}{:title=\u0026gt;\"FDA Commissioner’s Special Citation, Issuance of the Draft Guidance for Laboratory Developed Tests \", :detail=\u0026gt;\"FDA Award Ceremony, 2015\"}{{ FIELD }}{:title=\u0026gt;\"FDA Group Recognition Award, Publishing FDA Strategic Priorities 2014–2018 Document\", :detail=\u0026gt;\"FDA Award Ceremony, 2015\"}{{ FIELD }}{:title=\u0026gt;\"FDA Commissioner’s Special Citation, Issuance of the Unique Device Identification (UDI) System Final Rule \", :detail=\u0026gt;\"FDA Award Ceremony, 2014\"}{{ FIELD }}{:title=\u0026gt;\"FDA Group Recognition Award, FDA Language Access Plan Working Group\", :detail=\u0026gt;\"FDA Award Ceremony, 2014\"}{{ FIELD }}{:title=\u0026gt;\"FDA Group Recognition Award, Good Guidance Practices-Best Practices Working Group (Group Leader)\", :detail=\u0026gt;\"FDA Award Ceremony, 2012\"}{{ FIELD }}{:title=\u0026gt;\"FDA Group Recognition Award, Menu Labeling Working Group\", :detail=\u0026gt;\"CFSAN/FDA Award Ceremony, 2011\"}{{ FIELD }}Focus on Digital Health/Telehealth{{ FIELD }}Focus on In Vitro Diagnostic Tests and Laboratory Developed Tests{{ FIELD }}FDA/FTC regulation of advertising and promotion{{ FIELD }}Pre-market development (drugs and devices (including digital health products)){{ FIELD }}FDA product submissions (drugs and devices (including digital health products)){{ FIELD }}Develops regulatory, legislative and litigation solutions for unfair competition in the drug/device space\n- Lanham Act\n- Unfair trade practice statutes (state and federal){{ FIELD }}Engages FDA and Congress on key issues related to FDA-regulated products{{ FIELD }}Responds to FDA/FTC inquires, FDA warning letters, and FDA 483s{{ FIELD }}Experience remedying cGMP issues at facilities making OTC and Rx drugs and cosmetics{{ FIELD }}Co-Chairs Women's Health Initiative{{ FIELD }}Member of Cannabis Steering Committee{{ FIELD }}A partner in our FDA and Life Sciences practice, Lisa has almost 25 years of experience developing regulatory, legislative and litigation solutions for companies selling FDA-regulated products (i.e., drugs, devices, biologics, cosmetics, and tobacco).  She has served as an advisor to high-level public officials and C-suite executives on complex regulatory, policy, and litigation issues.\nPreviously, Lisa served as a Senior Policy Advisor in the FDA Commissioner’s Office and as the Deputy Chief of Staff to the Commissioner of Food and Drugs. In these roles, she provided strategic counsel on the agency’s most significant and complex issues. These included off-label marketing, mobile medical apps/digital health, opioid misuse and abuse, in vitro diagnostics and next generation sequencing, cosmetic legislation and regulation, and antimicrobial drug development and use. During her tenure at the FDA, she also worked closely with Congress, the Department of Health and Human Services, the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC) and the Drug Enforcement Administration (DEA).\nLisa is a frequent author and speaker on topics including:  digital health, advertising and promoting drugs and devices, remedying unfair competition in the drug and device space, women’s health issues, admissibility of 510(k)s in product liability lawsuits, preemption, in vitro diagnostics, the 21st Century Cures Act, and other topics. Lisa is Chambers ranked for Pharmaceutical/Medical Products Law. She also has been repeatedly recognized by Legal 500 as a Next Generation Partner and as a Recommended Key Lawyer for FDA Regulatory Law (2017, 2019, 2020, 2021, 2022, 2023, 2024) and for Government Relations (2016). Legal 500 has distinguished her for her expertise in digital health/AI and in pre-market strategies, and praised for her “unending enthusiasm to take on client’s causes as her own.\" Lisa M Dwyer Partner Next Generation Lawyer Legal 500, 2017 and 2019 Recognition for Government Relations  Legal 500, 2016 FDA Commissioner’s Special Citation, Issuance of the Draft Guidance for Laboratory Developed Tests  FDA Award Ceremony, 2015 FDA Group Recognition Award, Publishing FDA Strategic Priorities 2014–2018 Document FDA Award Ceremony, 2015 FDA Commissioner’s Special Citation, Issuance of the Unique Device Identification (UDI) System Final Rule  FDA Award Ceremony, 2014 FDA Group Recognition Award, FDA Language Access Plan Working Group FDA Award Ceremony, 2014 FDA Group Recognition Award, Good Guidance Practices-Best Practices Working Group (Group Leader) FDA Award Ceremony, 2012 FDA Group Recognition Award, Menu Labeling Working Group CFSAN/FDA Award Ceremony, 2011 Wesleyan University  George Washington University George Washington University Law School District of Columbia Massachusetts Pennsylvania Focus on Digital Health/Telehealth Focus on In Vitro Diagnostic Tests and Laboratory Developed Tests FDA/FTC regulation of advertising and promotion Pre-market development (drugs and devices (including digital health products)) FDA product submissions (drugs and devices (including digital health products)) Develops regulatory, legislative and litigation solutions for unfair competition in the drug/device space\n- Lanham Act\n- Unfair trade practice statutes (state and federal) Engages FDA and Congress on key issues related to FDA-regulated products Responds to FDA/FTC inquires, FDA warning letters, and FDA 483s Experience remedying cGMP issues at facilities making OTC and Rx drugs and cosmetics Co-Chairs Women's Health Initiative Member of Cannabis Steering Committee","searchable_name":"Lisa M. Dwyer","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":442773,"version":1,"owner_type":"Person","owner_id":5374,"payload":{"bio":"\u003cp\u003eShas advises clients on U.S economic/trade sanctions (OFAC), anti-money laundering requirements, and export control regulations.\u0026nbsp; In addition, Shas has vast expertise, both from his time in government and private practice,\u0026nbsp;advising on\u0026nbsp;a\u0026nbsp;range of regulatory and compliance issues facing\u0026nbsp;banks, hedge funds, investment advisors,\u0026nbsp;mutual funds, and accounting firms.\u0026nbsp; Shas has experience representing clients before OFAC, USTR, Commerce (BIS), SEC, PCAOB, FINRA, and the OCC.\u0026nbsp; His clients include large financial institutions, Fintech companies, and multi-national manufacturers and distributors.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003ePrior to joining the firm, Shas had a long career in US government and quasi-government agencies where he served in numerous senior level positions, including: Associate Director at the Public Company Accounting Oversight Board (PCAOB), Senior Sanctions Advisor at OFAC, and Senior Counsel at the US Securities \u0026amp; Exchange Commission and Federal Reserve Board. Shas also served as the head of the compliance examinations unit at Legg Mason, a global asset management firm.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAs an Associate Director at the PCAOB,\u0026nbsp;Shas negotiated numerous bilateral agreements with foreign regulators providing for cross-border audit oversight and represented the PCAOB in meetings with international audit standard setters. In particular, Shas was instrumental in negotiating an agreement with the Chinese authorities (CSRC and Ministry of Finance) on cross-border enforcement cooperation in 2013. He also participated in a short term secondment at the OECD, where he assisted its Corporate Affairs Division in updating its Principles of Corporate Governance (adopted by the G-20).\u003c/p\u003e\n\u003cp\u003eIn a prior capacity as a Senior Sanctions Advisor, Shas served as the Office of Foreign Asset Control\u0026rsquo;s primary liaison to the securities industry. While at OFAC, he developed compliance guidance for the securities industry, provided subject-matter expertise on securities- and banking-related matters, prepared recommendations regarding appropriate OFAC responses to potential violations of sanctions requirements by financial institutions, and presented at more than 40 conferences throughout the US on compliance with U.S. economic and trade sanctions. During the height of the financial crisis, while at the US Treasury Department, Shas participated in both the development and implementation of the Dodd-Frank Act. Among other areas, Shas\u0026nbsp;helped develop the US Treasury Department\u0026rsquo;s determination on whether to exempt foreign exchange swaps and forwards from the Commodity Exchange Act; he also helped develop the criteria for determining the designations of non-bank SIFIs.\u003c/p\u003e\n\u003cp\u003eEarlier in his career, as counsel in the Banking Supervision and Regulation Division of the Federal Reserve Board, he served as one of the lead lawyers on a seminal enforcement action brought against a global financial institution for violations of OFAC sanctions as well as deficiencies in its anti-money laundering program. This settled action marked the first in a series of actions brought by US regulators and law enforcement agencies against global foreign banking entities for violations of OFAC regulations due to conduct involving the \u0026ldquo;stripping\u0026rdquo; of the identities of sanctions targets in the processing of dollar clearing wire transactions.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEvents\u003c/strong\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eSpeaker, \"SEC Virtual Conference 2022: An Accounting \u0026amp; Reporting Update for Public Companies\" (\"Hot Button Issues for Public Companies\"), The Center for Professional Education, Inc., Washington, DC, May 20, 2022\"\u003c/li\u003e\n\u003cli\u003eSpeaker, Russian Sanctions - Business \u0026amp; Policy Implications, Electronic Transactions Associations, Washington, DC, March 9, 2022\u003c/li\u003e\n\u003cli\u003eSpeaker, \u0026ldquo;OFAC Webinar: Back to the Basics for Small to Midsized Banks,\u0026rdquo; BSA Coalition, Federal Reserve Bank of Richmond, Richmond, VA,\u0026nbsp;April 24, 2018\u003c/li\u003e\n\u003cli\u003eSpeaker, \u0026ldquo;Conducting KYC of Third Parties - Best Practices for Conducting Due Diligence,\u0026rdquo; Virginia Bankers Association, Fairfax, VA, April 17, 2018\u003c/li\u003e\n\u003cli\u003ePanelist, International Sanctions Compliance, Association of Certified Anti-Money Laundering Specialists, New Castle, DE, February 26, 2018\u003c/li\u003e\n\u003cli\u003eSpeaker, \u0026ldquo;The Challenges of Negotiating an Agreement with the Chinese Regulators on Cross-Border Audit Oversight,\u0026rdquo; China-US Business Alliance, New York City, January 23, 2018\u003c/li\u003e\n\u003cli\u003eSpeaker, Annual Anti-Money Laundering and Office of Foreign Assets Control Sanctions Year in Review, ACAMS Virginia Chapter Event, December 12, 2017\u003c/li\u003e\n\u003cli\u003eSpeaker, \u0026ldquo;Strategies for Effective Auditing and Due Diligence of Third Parties in China: Special Focus on Beneficial Ownership,\u0026rdquo; 8th Global Forum on Anti-Corruption Compliance in High Risk Markets, Washington, DC, July 25-26, 2017\u003c/li\u003e\n\u003cli\u003ePanelist, \u0026ldquo;Banking Compliance,\u0026rdquo; FCPA Roundtable Discussion, US-China Business Council (USCBC), Washington, DC, May 9, 2017\u003c/li\u003e\n\u003cli\u003eSpeaker, \u0026ldquo;Omnibus Accounts, Trusts and Other Unique Agreements Due Diligence Scenarios: How to Conduct Strong DD to Mitigate Your Risks,\u0026rdquo; Flagship Conference on Economic Sanctions Enforcement and Compliance, American Conference Institute, Mandarin Oriental Hotel, Washington, DC, April 24-26, 2017\u003c/li\u003e\n\u003cli\u003ePanelist, 2017 FCPA and Anti-Monopoly Enforcement Trends in China Roundtable Discussion,\u0026nbsp;US-China Business Council (USCBC), Washington, DC, April 5, 2017\u003c/li\u003e\n\u003cli\u003eSpeaker, Keynote Panel: Trump and Banking\u0026ndash;Predictions \u0026amp; Promises, 2017 Retail Banking Conference, at the Trump National Doral Miami Hotel in Miami, FL, March 22-24, 2017\u003c/li\u003e\n\u003cli\u003eWebinar: Changes in Lease Accounting Standards \u0026amp; Impact on Credit Agreements, February 22, 2017\u003c/li\u003e\n\u003cli\u003eSpeaker, \u0026ldquo;Current Focus of US Regulators\u0026mdash;Hot Buttons \u0026amp; Cross Border Issues,\u0026rdquo; and \u0026ldquo;PCAOB \u0026amp; Auditing Developments,\u0026rdquo; SEC Conference 2016: An Accounting \u0026amp; Reporting Update for US Listed Companies, CPE, Beijing, December 12-13, 2016\u003c/li\u003e\n\u003cli\u003ePanelist, Disclosure of Beneficial Ownership and Control in Asia: corporate practices, Asian Roundtable On Corporate Governance, OECD, October 25, 2016\u003c/li\u003e\n\u003cli\u003eSpeaker, EU Regulatory Equivalency, Cross-Border Inspections of Audit Firms in China, The Evolving Role of the Audit Committee and Other Developments Impacting Global Audit Quality, National Asian Pacific American Bar Association 2016 Southeast Regional Conference, Arlington, VA, September 30, 2016\u003c/li\u003e\n\u003cli\u003eSEC Conference 2016: An Accounting \u0026amp; Reporting Update for US Listed Companies, Center for Professional Education, June 2016: speaker on three panels: \u0026ldquo;Recent Auditing Developments,\u0026rdquo; \u0026ldquo;Update on SEC Enforcement Initiatives for Asia-Based Companies,\u0026rdquo; and \u0026ldquo;Corporate Governance Best Practices \u0026amp; the Role of the Audit Committee\u0026rdquo; June 16, 2016\u003c/li\u003e\n\u003cli\u003eACAMS Richmond Chapter Event: When Goods Go Bad: Trade Based Money Laundering, May 2016\u003c/li\u003e\n\u003cli\u003eOECD\u0026rsquo;s Asian Roundtables on Corporate Governance, (co-sponsored with the securities regulators in India and Thailand), 2014 and 2015\u003c/li\u003e\n\u003cli\u003eWebcast - The PCAOB \u0026amp; China: The Latest Regulatory Developments, 2014\u003c/li\u003e\n\u003cli\u003eFinancial Markets Securities Compliance Seminar, 2009\u003c/li\u003e\n\u003cli\u003eAnti-Money Laundering III for Financial Institutions, 2008\u003c/li\u003e\n\u003cli\u003eFutures Industry Association Law and Compliance Workshop, 2008\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e\u003cstrong\u003ePublications\u003c/strong\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eCo-author, AML and Sanctions Compliance Issues Facing Cryptocurrency Companies,\u0026nbsp;\u003cem\u003eCrowdfund Insider\u003c/em\u003e, June 4, 2018\u003c/li\u003e\n\u003cli\u003eCo-author, \u0026ldquo;Recent Developments in the PCAOB\u0026rsquo;s Standard-Setting and Related Rulemaking Agenda,\u0026rdquo; Parts 1 and 2, in 38\u0026nbsp;\u003cem\u003eSec. \u0026amp; Fed. Corp. L. Rep.\u003c/em\u003e\u0026nbsp;No. 11, and 39\u0026nbsp;\u003cem\u003eSec. \u0026amp; Fed. Corp. L. Rep.\u003c/em\u003e\u0026nbsp;No. 1 (Thomson Reuters), edited by Sam Wolff, February 15, 2017\u003c/li\u003e\n\u003cli\u003eContributor, Sarbanes-Oxley Act in Perspective,\u0026nbsp;\u003cem\u003eThomson Reuters\u003c/em\u003e, 2017 edition\u003c/li\u003e\n\u003cli\u003eCo-author, Trump Administration\u0026rsquo;s Impact on Financial Regulation and the SEC,\u0026nbsp;\u003cem\u003eLaw360\u003c/em\u003e, November 23, 2016\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e\u003cstrong\u003eAlerts\u003c/strong\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eTrump Administration Issues New Executive Order Against Venezuela to Prevent a \u0026ldquo;Fire Sale\u0026rdquo; Liquidation of Venezuela\u0026rsquo;s Critical Assets, May 23, 2018\u003c/li\u003e\n\u003cli\u003eForeign Investment in the US: An Overview of CFIUS, February 15, 2018\u003c/li\u003e\n\u003cli\u003eAttorney General Jeff Sessions Announces Return to Traditional Guidelines for Prosecuting Marijuana Crimes; Rescinds Cole Memo Referenced in FinCEN Guidance, January 16, 2018\u003c/li\u003e\n\u003cli\u003eNew CFIUS Legislation Proposed in Response to Chinese Investment, November 28, 2017\u003c/li\u003e\n\u003cli\u003eFinCEN Warns Banks on North Korean Schemes to Evade Sanctions, November 8, 2017\u003c/li\u003e\n\u003cli\u003eFinCEN Expands Its Geographic Targeting Orders and Issues Related Advisory, August 30, 2017\u003c/li\u003e\n\u003cli\u003eOFAC Announces $12 Million Settlement to Resolve Enforcement Action Against Non-US Companies Using US Dollars to Do Business With Iran, August 17, 2017\u003c/li\u003e\n\u003cli\u003ePCAOB Adopts New Audit Reporting Model, July 12, 2017\u003c/li\u003e\n\u003cli\u003eFinCEN Issues Advisory on SAR Reporting Obligations Involving Cyber Crime, November 7, 2016\u003c/li\u003e\n\u003cli\u003eFinCEN Expands Customer Due Diligence Requirements, June 22, 2016\u003c/li\u003e\n\u003cli\u003ePCAOB Reproposes Standards Relating to Auditor\u0026rsquo;s Reporting Model \u0026ndash; Narrows Scope of \u0026ldquo;Critical Audit Matters\u0026rdquo; and Drops \u0026ldquo;Other Information\u0026rdquo; Requirement, June 8, 2016\u003c/li\u003e\n\u003cli\u003ePCAOB Adopts New Audit Firm Disclosure Rules, May 17, 2016\u003c/li\u003e\n\u003c/ul\u003e","slug":"shaswat-das","email":"sdas@kslaw.com","phone":null,"matters":["\u003cp\u003ePrepared sanctions/export controls policies and conducted relevant sanctions/export controls training for largest private charter airline;\u003c/p\u003e","\u003cp\u003eProvided sanctions/AML guidance for first ever NFT real estate auction;\u003c/p\u003e","\u003cp\u003eSuccessfully represented non-U.S. based offshore operator of vessels before the U.S. State Department and other U.S. government agencies, in response to possible sanctions in connection with Nord Stream 2 Project;\u003c/p\u003e","\u003cp\u003eObtained favorable cautionary letter from OFAC on behalf of bank when the bank had been the subject of a cautionary letter only eight months earlier;\u003c/p\u003e","\u003cp\u003eAdvised marketing automation platform on sanctions-related matters in connection with largest sale of a private marketing software company in U.S. history;\u003c/p\u003e","\u003cp\u003eAdvised global wealth manager on multi-faceted project designed to assess relevant sanctions risk/exposure and assist the bank disassociate itself from high-risk Russia-related client accounts;\u003c/p\u003e","\u003cp\u003eAssisted multiple U.S. companies divest their interests in Russian operating companies or joint ventures;\u003c/p\u003e","\u003cp\u003eCoordinate internal and external responses to investigations by OFAC;\u0026nbsp;\u003c/p\u003e","\u003cp\u003eRepresent companies in the Fintech industry with respect to economic sanctions compliance and counseling;\u003c/p\u003e","\u003cp\u003eAdvised multi-national oil refinery on compliance with OFAC requirements in light of PdVSA designation;\u0026nbsp;\u003c/p\u003e","\u003cp\u003eAdvised clients in pharmaceutical and medical device industries navigate economic/sanctions regulations;\u003c/p\u003e","\u003cp\u003eAdvised large foreign airlines on U.S. sanctions obligations, including application of secondary sanctions;\u003c/p\u003e","\u003cp\u003eAdvised large, multi-national airline manufacturer on beneficial ownership obligations under the Bank Secrecy Act and OFAC regulations;\u003c/p\u003e","\u003cp\u003eReviewed OFAC and AML representations and warranties in U.S. and offshore fund formation and private placement agreements;\u003c/p\u003e","\u003cp\u003eRepresented a Texas-based bank in response to an Administrative Subpoena issued by OFAC regarding a funds/wire transfer in connection with the delivery of certain medical-related software for the benefit of an Iranian entity. The matter was favorably resolved for the client as OFAC issued a \u0026ldquo;no-action\u0026rdquo; letter upon the completion of its investigation and after reviewing our response;\u003c/p\u003e","\u003cp\u003eCounseled investment firm, specializing in investments in energy-related projects, on the applicability of US sanctions toward Venezuela with respect to a transaction involving payments to a Venezuelan entity (majority-owned by PdVSA) in US dollars for the extraction and sale of Venezuelan natural resources;\u003c/p\u003e","\u003cp\u003eAdvised large multi-national beverage company and its subsidiaries regarding the applicability of US sanctions with respect to its proposed business transactions in Venezuela and Cuba, including helping to obtain favorable interpretive guidance;\u003c/p\u003e","\u003cp\u003eCounseled large multi-national payment processor based in Latin America with respect to the application of US sanctions to its global operations;\u003c/p\u003e","\u003cp\u003eConducted due diligence for community bank as part of capital raising efforts;\u003c/p\u003e","\u003cp\u003eEvaluated proposed joint venture arrangements to assess compliance with US sanctions requirements;\u003c/p\u003e","\u003cp\u003eConducted AML and sanctions reviews in the context of mergers and acquisition, lending arrangements, and repurchase transactions;\u003c/p\u003e","\u003cp\u003eConducted analysis of client risk due to client activity in sanctioned countries and other high risk countries. Assist in developing a comprehensive cross-business view of AML and sanctions risk;\u003c/p\u003e","\u003cp\u003eDeveloped AML/sanctions compliance program for a provider of prepaid access utilizing toll road transponder devices, and conducted a risk assessment to create targeted procedures and internal controls;\u003c/p\u003e","\u003cp\u003eEvaluated AML and OFAC obligations of foreign bank client extending margin loans to non-US customers of a US introducing broker;\u003c/p\u003e","\u003cp\u003eAdvised on application of BSA/AML/Sanctions requirements to entities in diverse industries including telecommunications, investment companies and hedge funds; residential mortgage loan originators (RMLOs), and public REITS in cross border ventures;\u003c/p\u003e","\u003cp\u003eAdvised on US sanctions-related and export control issues involving the sale of goods by a European-based client with US subsidiaries to a Russian buyer;\u003c/p\u003e","\u003cp\u003eAddressed CIP and sanctions related issues raised by cash pooling arrangement for a large multi-national company;\u003c/p\u003e","\u003cp\u003ePrepared legal opinion on foreign based company\u0026rsquo;s proposed business expansion in sanctioned countries and US regulatory implications;\u003c/p\u003e","\u003cp\u003eSuccessfully obtained commodity classification determinations from US Department of Commerce on behalf of bio-tech client;\u003c/p\u003e","\u003cp\u003eAdvised large financial services company on export control requirements and implications relating to migration to organization-wide office suite/technology with data servers located outside of the US. Raised important \u0026ldquo;cloud computing\u0026rdquo; issues;\u003c/p\u003e","\u003cp\u003ePrepared comment letters on behalf of large trade association on various SEC rulemakings;\u003c/p\u003e","\u003cp\u003eAdvised on Rule 144A and Regulation S offering;\u003c/p\u003e","\u003cp\u003eRepresented PCAOB-registered accounting firm facing disciplinary action involving cross-border access to audit work papers;\u003c/p\u003e","\u003cp\u003eCounseled developer of search engine on AML/OFAC obligations of financial institutions;\u003c/p\u003e","\u003cp\u003eAdvised multi-national global industrial firm on compliance with Ukraine/Russian sanctions;\u003c/p\u003e","\u003cp\u003eAssisted multiple clients with obtaining exclusions from the Section 232 tariffs (BIS) imposed on steel/aluminum;\u003c/p\u003e","\u003cp\u003eAdvised clients on the application and impact of Section 301 tariffs (USTR);\u003c/p\u003e","\u003cp\u003eConducted US sanctions and PEP due diligence on behalf of client/buyer of real estate property in New York;\u003c/p\u003e","\u003cp\u003eObtained favorable determination that cryptocurrency company preparing an ICO did not need to register as an \"MSB\" under state law;\u003c/p\u003e","\u003cp\u003eRepresented medical/research center in response to FINRA request for information relating to possible insider trading violations.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":25,"guid":"25.capabilities","index":0,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":1,"source":"capabilities"},{"id":20,"guid":"20.capabilities","index":2,"source":"capabilities"},{"id":27,"guid":"27.capabilities","index":3,"source":"capabilities"},{"id":107,"guid":"107.capabilities","index":4,"source":"capabilities"},{"id":699,"guid":"699.smart_tags","index":5,"source":"smartTags"},{"id":109,"guid":"109.capabilities","index":6,"source":"capabilities"},{"id":1188,"guid":"1188.smart_tags","index":7,"source":"smartTags"},{"id":128,"guid":"128.capabilities","index":8,"source":"capabilities"},{"id":579,"guid":"579.smart_tags","index":9,"source":"smartTags"},{"id":803,"guid":"803.smart_tags","index":10,"source":"smartTags"},{"id":1327,"guid":"1327.smart_tags","index":11,"source":"smartTags"},{"id":1330,"guid":"1330.smart_tags","index":12,"source":"smartTags"}],"is_active":true,"last_name":"Das","nick_name":"Shaswat","clerkships":[],"first_name":"Shaswat","title_rank":9999,"updated_by":202,"law_schools":[{"id":1430,"meta":{"degree":"J.D.","honors":null,"is_law_school":1,"graduation_date":"1994-01-01 00:00:00 UTC"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"K.","name_suffix":"","recognitions":[{"title":"SEC Capital Markets Award, September 11, 2001","detail":"U.S. Securities and Exchange Commission"}],"linked_in_url":null,"seodescription":null,"primary_title_id":14,"translated_fields":{"en":{"bio":"\u003cp\u003eShas advises clients on U.S economic/trade sanctions (OFAC), anti-money laundering requirements, and export control regulations.\u0026nbsp; In addition, Shas has vast expertise, both from his time in government and private practice,\u0026nbsp;advising on\u0026nbsp;a\u0026nbsp;range of regulatory and compliance issues facing\u0026nbsp;banks, hedge funds, investment advisors,\u0026nbsp;mutual funds, and accounting firms.\u0026nbsp; Shas has experience representing clients before OFAC, USTR, Commerce (BIS), SEC, PCAOB, FINRA, and the OCC.\u0026nbsp; His clients include large financial institutions, Fintech companies, and multi-national manufacturers and distributors.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003ePrior to joining the firm, Shas had a long career in US government and quasi-government agencies where he served in numerous senior level positions, including: Associate Director at the Public Company Accounting Oversight Board (PCAOB), Senior Sanctions Advisor at OFAC, and Senior Counsel at the US Securities \u0026amp; Exchange Commission and Federal Reserve Board. Shas also served as the head of the compliance examinations unit at Legg Mason, a global asset management firm.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAs an Associate Director at the PCAOB,\u0026nbsp;Shas negotiated numerous bilateral agreements with foreign regulators providing for cross-border audit oversight and represented the PCAOB in meetings with international audit standard setters. In particular, Shas was instrumental in negotiating an agreement with the Chinese authorities (CSRC and Ministry of Finance) on cross-border enforcement cooperation in 2013. He also participated in a short term secondment at the OECD, where he assisted its Corporate Affairs Division in updating its Principles of Corporate Governance (adopted by the G-20).\u003c/p\u003e\n\u003cp\u003eIn a prior capacity as a Senior Sanctions Advisor, Shas served as the Office of Foreign Asset Control\u0026rsquo;s primary liaison to the securities industry. While at OFAC, he developed compliance guidance for the securities industry, provided subject-matter expertise on securities- and banking-related matters, prepared recommendations regarding appropriate OFAC responses to potential violations of sanctions requirements by financial institutions, and presented at more than 40 conferences throughout the US on compliance with U.S. economic and trade sanctions. During the height of the financial crisis, while at the US Treasury Department, Shas participated in both the development and implementation of the Dodd-Frank Act. Among other areas, Shas\u0026nbsp;helped develop the US Treasury Department\u0026rsquo;s determination on whether to exempt foreign exchange swaps and forwards from the Commodity Exchange Act; he also helped develop the criteria for determining the designations of non-bank SIFIs.\u003c/p\u003e\n\u003cp\u003eEarlier in his career, as counsel in the Banking Supervision and Regulation Division of the Federal Reserve Board, he served as one of the lead lawyers on a seminal enforcement action brought against a global financial institution for violations of OFAC sanctions as well as deficiencies in its anti-money laundering program. This settled action marked the first in a series of actions brought by US regulators and law enforcement agencies against global foreign banking entities for violations of OFAC regulations due to conduct involving the \u0026ldquo;stripping\u0026rdquo; of the identities of sanctions targets in the processing of dollar clearing wire transactions.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEvents\u003c/strong\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eSpeaker, \"SEC Virtual Conference 2022: An Accounting \u0026amp; Reporting Update for Public Companies\" (\"Hot Button Issues for Public Companies\"), The Center for Professional Education, Inc., Washington, DC, May 20, 2022\"\u003c/li\u003e\n\u003cli\u003eSpeaker, Russian Sanctions - Business \u0026amp; Policy Implications, Electronic Transactions Associations, Washington, DC, March 9, 2022\u003c/li\u003e\n\u003cli\u003eSpeaker, \u0026ldquo;OFAC Webinar: Back to the Basics for Small to Midsized Banks,\u0026rdquo; BSA Coalition, Federal Reserve Bank of Richmond, Richmond, VA,\u0026nbsp;April 24, 2018\u003c/li\u003e\n\u003cli\u003eSpeaker, \u0026ldquo;Conducting KYC of Third Parties - Best Practices for Conducting Due Diligence,\u0026rdquo; Virginia Bankers Association, Fairfax, VA, April 17, 2018\u003c/li\u003e\n\u003cli\u003ePanelist, International Sanctions Compliance, Association of Certified Anti-Money Laundering Specialists, New Castle, DE, February 26, 2018\u003c/li\u003e\n\u003cli\u003eSpeaker, \u0026ldquo;The Challenges of Negotiating an Agreement with the Chinese Regulators on Cross-Border Audit Oversight,\u0026rdquo; China-US Business Alliance, New York City, January 23, 2018\u003c/li\u003e\n\u003cli\u003eSpeaker, Annual Anti-Money Laundering and Office of Foreign Assets Control Sanctions Year in Review, ACAMS Virginia Chapter Event, December 12, 2017\u003c/li\u003e\n\u003cli\u003eSpeaker, \u0026ldquo;Strategies for Effective Auditing and Due Diligence of Third Parties in China: Special Focus on Beneficial Ownership,\u0026rdquo; 8th Global Forum on Anti-Corruption Compliance in High Risk Markets, Washington, DC, July 25-26, 2017\u003c/li\u003e\n\u003cli\u003ePanelist, \u0026ldquo;Banking Compliance,\u0026rdquo; FCPA Roundtable Discussion, US-China Business Council (USCBC), Washington, DC, May 9, 2017\u003c/li\u003e\n\u003cli\u003eSpeaker, \u0026ldquo;Omnibus Accounts, Trusts and Other Unique Agreements Due Diligence Scenarios: How to Conduct Strong DD to Mitigate Your Risks,\u0026rdquo; Flagship Conference on Economic Sanctions Enforcement and Compliance, American Conference Institute, Mandarin Oriental Hotel, Washington, DC, April 24-26, 2017\u003c/li\u003e\n\u003cli\u003ePanelist, 2017 FCPA and Anti-Monopoly Enforcement Trends in China Roundtable Discussion,\u0026nbsp;US-China Business Council (USCBC), Washington, DC, April 5, 2017\u003c/li\u003e\n\u003cli\u003eSpeaker, Keynote Panel: Trump and Banking\u0026ndash;Predictions \u0026amp; Promises, 2017 Retail Banking Conference, at the Trump National Doral Miami Hotel in Miami, FL, March 22-24, 2017\u003c/li\u003e\n\u003cli\u003eWebinar: Changes in Lease Accounting Standards \u0026amp; Impact on Credit Agreements, February 22, 2017\u003c/li\u003e\n\u003cli\u003eSpeaker, \u0026ldquo;Current Focus of US Regulators\u0026mdash;Hot Buttons \u0026amp; Cross Border Issues,\u0026rdquo; and \u0026ldquo;PCAOB \u0026amp; Auditing Developments,\u0026rdquo; SEC Conference 2016: An Accounting \u0026amp; Reporting Update for US Listed Companies, CPE, Beijing, December 12-13, 2016\u003c/li\u003e\n\u003cli\u003ePanelist, Disclosure of Beneficial Ownership and Control in Asia: corporate practices, Asian Roundtable On Corporate Governance, OECD, October 25, 2016\u003c/li\u003e\n\u003cli\u003eSpeaker, EU Regulatory Equivalency, Cross-Border Inspections of Audit Firms in China, The Evolving Role of the Audit Committee and Other Developments Impacting Global Audit Quality, National Asian Pacific American Bar Association 2016 Southeast Regional Conference, Arlington, VA, September 30, 2016\u003c/li\u003e\n\u003cli\u003eSEC Conference 2016: An Accounting \u0026amp; Reporting Update for US Listed Companies, Center for Professional Education, June 2016: speaker on three panels: \u0026ldquo;Recent Auditing Developments,\u0026rdquo; \u0026ldquo;Update on SEC Enforcement Initiatives for Asia-Based Companies,\u0026rdquo; and \u0026ldquo;Corporate Governance Best Practices \u0026amp; the Role of the Audit Committee\u0026rdquo; June 16, 2016\u003c/li\u003e\n\u003cli\u003eACAMS Richmond Chapter Event: When Goods Go Bad: Trade Based Money Laundering, May 2016\u003c/li\u003e\n\u003cli\u003eOECD\u0026rsquo;s Asian Roundtables on Corporate Governance, (co-sponsored with the securities regulators in India and Thailand), 2014 and 2015\u003c/li\u003e\n\u003cli\u003eWebcast - The PCAOB \u0026amp; China: The Latest Regulatory Developments, 2014\u003c/li\u003e\n\u003cli\u003eFinancial Markets Securities Compliance Seminar, 2009\u003c/li\u003e\n\u003cli\u003eAnti-Money Laundering III for Financial Institutions, 2008\u003c/li\u003e\n\u003cli\u003eFutures Industry Association Law and Compliance Workshop, 2008\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e\u003cstrong\u003ePublications\u003c/strong\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eCo-author, AML and Sanctions Compliance Issues Facing Cryptocurrency Companies,\u0026nbsp;\u003cem\u003eCrowdfund Insider\u003c/em\u003e, June 4, 2018\u003c/li\u003e\n\u003cli\u003eCo-author, \u0026ldquo;Recent Developments in the PCAOB\u0026rsquo;s Standard-Setting and Related Rulemaking Agenda,\u0026rdquo; Parts 1 and 2, in 38\u0026nbsp;\u003cem\u003eSec. \u0026amp; Fed. Corp. L. Rep.\u003c/em\u003e\u0026nbsp;No. 11, and 39\u0026nbsp;\u003cem\u003eSec. \u0026amp; Fed. Corp. L. Rep.\u003c/em\u003e\u0026nbsp;No. 1 (Thomson Reuters), edited by Sam Wolff, February 15, 2017\u003c/li\u003e\n\u003cli\u003eContributor, Sarbanes-Oxley Act in Perspective,\u0026nbsp;\u003cem\u003eThomson Reuters\u003c/em\u003e, 2017 edition\u003c/li\u003e\n\u003cli\u003eCo-author, Trump Administration\u0026rsquo;s Impact on Financial Regulation and the SEC,\u0026nbsp;\u003cem\u003eLaw360\u003c/em\u003e, November 23, 2016\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e\u003cstrong\u003eAlerts\u003c/strong\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eTrump Administration Issues New Executive Order Against Venezuela to Prevent a \u0026ldquo;Fire Sale\u0026rdquo; Liquidation of Venezuela\u0026rsquo;s Critical Assets, May 23, 2018\u003c/li\u003e\n\u003cli\u003eForeign Investment in the US: An Overview of CFIUS, February 15, 2018\u003c/li\u003e\n\u003cli\u003eAttorney General Jeff Sessions Announces Return to Traditional Guidelines for Prosecuting Marijuana Crimes; Rescinds Cole Memo Referenced in FinCEN Guidance, January 16, 2018\u003c/li\u003e\n\u003cli\u003eNew CFIUS Legislation Proposed in Response to Chinese Investment, November 28, 2017\u003c/li\u003e\n\u003cli\u003eFinCEN Warns Banks on North Korean Schemes to Evade Sanctions, November 8, 2017\u003c/li\u003e\n\u003cli\u003eFinCEN Expands Its Geographic Targeting Orders and Issues Related Advisory, August 30, 2017\u003c/li\u003e\n\u003cli\u003eOFAC Announces $12 Million Settlement to Resolve Enforcement Action Against Non-US Companies Using US Dollars to Do Business With Iran, August 17, 2017\u003c/li\u003e\n\u003cli\u003ePCAOB Adopts New Audit Reporting Model, July 12, 2017\u003c/li\u003e\n\u003cli\u003eFinCEN Issues Advisory on SAR Reporting Obligations Involving Cyber Crime, November 7, 2016\u003c/li\u003e\n\u003cli\u003eFinCEN Expands Customer Due Diligence Requirements, June 22, 2016\u003c/li\u003e\n\u003cli\u003ePCAOB Reproposes Standards Relating to Auditor\u0026rsquo;s Reporting Model \u0026ndash; Narrows Scope of \u0026ldquo;Critical Audit Matters\u0026rdquo; and Drops \u0026ldquo;Other Information\u0026rdquo; Requirement, June 8, 2016\u003c/li\u003e\n\u003cli\u003ePCAOB Adopts New Audit Firm Disclosure Rules, May 17, 2016\u003c/li\u003e\n\u003c/ul\u003e","matters":["\u003cp\u003ePrepared sanctions/export controls policies and conducted relevant sanctions/export controls training for largest private charter airline;\u003c/p\u003e","\u003cp\u003eProvided sanctions/AML guidance for first ever NFT real estate auction;\u003c/p\u003e","\u003cp\u003eSuccessfully represented non-U.S. based offshore operator of vessels before the U.S. State Department and other U.S. government agencies, in response to possible sanctions in connection with Nord Stream 2 Project;\u003c/p\u003e","\u003cp\u003eObtained favorable cautionary letter from OFAC on behalf of bank when the bank had been the subject of a cautionary letter only eight months earlier;\u003c/p\u003e","\u003cp\u003eAdvised marketing automation platform on sanctions-related matters in connection with largest sale of a private marketing software company in U.S. history;\u003c/p\u003e","\u003cp\u003eAdvised global wealth manager on multi-faceted project designed to assess relevant sanctions risk/exposure and assist the bank disassociate itself from high-risk Russia-related client accounts;\u003c/p\u003e","\u003cp\u003eAssisted multiple U.S. companies divest their interests in Russian operating companies or joint ventures;\u003c/p\u003e","\u003cp\u003eCoordinate internal and external responses to investigations by OFAC;\u0026nbsp;\u003c/p\u003e","\u003cp\u003eRepresent companies in the Fintech industry with respect to economic sanctions compliance and counseling;\u003c/p\u003e","\u003cp\u003eAdvised multi-national oil refinery on compliance with OFAC requirements in light of PdVSA designation;\u0026nbsp;\u003c/p\u003e","\u003cp\u003eAdvised clients in pharmaceutical and medical device industries navigate economic/sanctions regulations;\u003c/p\u003e","\u003cp\u003eAdvised large foreign airlines on U.S. sanctions obligations, including application of secondary sanctions;\u003c/p\u003e","\u003cp\u003eAdvised large, multi-national airline manufacturer on beneficial ownership obligations under the Bank Secrecy Act and OFAC regulations;\u003c/p\u003e","\u003cp\u003eReviewed OFAC and AML representations and warranties in U.S. and offshore fund formation and private placement agreements;\u003c/p\u003e","\u003cp\u003eRepresented a Texas-based bank in response to an Administrative Subpoena issued by OFAC regarding a funds/wire transfer in connection with the delivery of certain medical-related software for the benefit of an Iranian entity. The matter was favorably resolved for the client as OFAC issued a \u0026ldquo;no-action\u0026rdquo; letter upon the completion of its investigation and after reviewing our response;\u003c/p\u003e","\u003cp\u003eCounseled investment firm, specializing in investments in energy-related projects, on the applicability of US sanctions toward Venezuela with respect to a transaction involving payments to a Venezuelan entity (majority-owned by PdVSA) in US dollars for the extraction and sale of Venezuelan natural resources;\u003c/p\u003e","\u003cp\u003eAdvised large multi-national beverage company and its subsidiaries regarding the applicability of US sanctions with respect to its proposed business transactions in Venezuela and Cuba, including helping to obtain favorable interpretive guidance;\u003c/p\u003e","\u003cp\u003eCounseled large multi-national payment processor based in Latin America with respect to the application of US sanctions to its global operations;\u003c/p\u003e","\u003cp\u003eConducted due diligence for community bank as part of capital raising efforts;\u003c/p\u003e","\u003cp\u003eEvaluated proposed joint venture arrangements to assess compliance with US sanctions requirements;\u003c/p\u003e","\u003cp\u003eConducted AML and sanctions reviews in the context of mergers and acquisition, lending arrangements, and repurchase transactions;\u003c/p\u003e","\u003cp\u003eConducted analysis of client risk due to client activity in sanctioned countries and other high risk countries. Assist in developing a comprehensive cross-business view of AML and sanctions risk;\u003c/p\u003e","\u003cp\u003eDeveloped AML/sanctions compliance program for a provider of prepaid access utilizing toll road transponder devices, and conducted a risk assessment to create targeted procedures and internal controls;\u003c/p\u003e","\u003cp\u003eEvaluated AML and OFAC obligations of foreign bank client extending margin loans to non-US customers of a US introducing broker;\u003c/p\u003e","\u003cp\u003eAdvised on application of BSA/AML/Sanctions requirements to entities in diverse industries including telecommunications, investment companies and hedge funds; residential mortgage loan originators (RMLOs), and public REITS in cross border ventures;\u003c/p\u003e","\u003cp\u003eAdvised on US sanctions-related and export control issues involving the sale of goods by a European-based client with US subsidiaries to a Russian buyer;\u003c/p\u003e","\u003cp\u003eAddressed CIP and sanctions related issues raised by cash pooling arrangement for a large multi-national company;\u003c/p\u003e","\u003cp\u003ePrepared legal opinion on foreign based company\u0026rsquo;s proposed business expansion in sanctioned countries and US regulatory implications;\u003c/p\u003e","\u003cp\u003eSuccessfully obtained commodity classification determinations from US Department of Commerce on behalf of bio-tech client;\u003c/p\u003e","\u003cp\u003eAdvised large financial services company on export control requirements and implications relating to migration to organization-wide office suite/technology with data servers located outside of the US. Raised important \u0026ldquo;cloud computing\u0026rdquo; issues;\u003c/p\u003e","\u003cp\u003ePrepared comment letters on behalf of large trade association on various SEC rulemakings;\u003c/p\u003e","\u003cp\u003eAdvised on Rule 144A and Regulation S offering;\u003c/p\u003e","\u003cp\u003eRepresented PCAOB-registered accounting firm facing disciplinary action involving cross-border access to audit work papers;\u003c/p\u003e","\u003cp\u003eCounseled developer of search engine on AML/OFAC obligations of financial institutions;\u003c/p\u003e","\u003cp\u003eAdvised multi-national global industrial firm on compliance with Ukraine/Russian sanctions;\u003c/p\u003e","\u003cp\u003eAssisted multiple clients with obtaining exclusions from the Section 232 tariffs (BIS) imposed on steel/aluminum;\u003c/p\u003e","\u003cp\u003eAdvised clients on the application and impact of Section 301 tariffs (USTR);\u003c/p\u003e","\u003cp\u003eConducted US sanctions and PEP due diligence on behalf of client/buyer of real estate property in New York;\u003c/p\u003e","\u003cp\u003eObtained favorable determination that cryptocurrency company preparing an ICO did not need to register as an \"MSB\" under state law;\u003c/p\u003e","\u003cp\u003eRepresented medical/research center in response to FINRA request for information relating to possible insider trading violations.\u003c/p\u003e"],"recognitions":[{"title":"SEC Capital Markets Award, September 11, 2001","detail":"U.S. Securities and Exchange Commission"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":12366}]},"capability_group_id":2},"created_at":"2025-11-13T04:56:52.000Z","updated_at":"2025-11-13T04:56:52.000Z","searchable_text":"Das{{ FIELD }}{:title=\u0026gt;\"SEC Capital Markets Award, September 11, 2001\", :detail=\u0026gt;\"U.S. Securities and Exchange Commission\"}{{ FIELD }}Prepared sanctions/export controls policies and conducted relevant sanctions/export controls training for largest private charter airline;{{ FIELD }}Provided sanctions/AML guidance for first ever NFT real estate auction;{{ FIELD }}Successfully represented non-U.S. based offshore operator of vessels before the U.S. State Department and other U.S. government agencies, in response to possible sanctions in connection with Nord Stream 2 Project;{{ FIELD }}Obtained favorable cautionary letter from OFAC on behalf of bank when the bank had been the subject of a cautionary letter only eight months earlier;{{ FIELD }}Advised marketing automation platform on sanctions-related matters in connection with largest sale of a private marketing software company in U.S. history;{{ FIELD }}Advised global wealth manager on multi-faceted project designed to assess relevant sanctions risk/exposure and assist the bank disassociate itself from high-risk Russia-related client accounts;{{ FIELD }}Assisted multiple U.S. companies divest their interests in Russian operating companies or joint ventures;{{ FIELD }}Coordinate internal and external responses to investigations by OFAC; {{ FIELD }}Represent companies in the Fintech industry with respect to economic sanctions compliance and counseling;{{ FIELD }}Advised multi-national oil refinery on compliance with OFAC requirements in light of PdVSA designation; {{ FIELD }}Advised clients in pharmaceutical and medical device industries navigate economic/sanctions regulations;{{ FIELD }}Advised large foreign airlines on U.S. sanctions obligations, including application of secondary sanctions;{{ FIELD }}Advised large, multi-national airline manufacturer on beneficial ownership obligations under the Bank Secrecy Act and OFAC regulations;{{ FIELD }}Reviewed OFAC and AML representations and warranties in U.S. and offshore fund formation and private placement agreements;{{ FIELD }}Represented a Texas-based bank in response to an Administrative Subpoena issued by OFAC regarding a funds/wire transfer in connection with the delivery of certain medical-related software for the benefit of an Iranian entity. The matter was favorably resolved for the client as OFAC issued a “no-action” letter upon the completion of its investigation and after reviewing our response;{{ FIELD }}Counseled investment firm, specializing in investments in energy-related projects, on the applicability of US sanctions toward Venezuela with respect to a transaction involving payments to a Venezuelan entity (majority-owned by PdVSA) in US dollars for the extraction and sale of Venezuelan natural resources;{{ FIELD }}Advised large multi-national beverage company and its subsidiaries regarding the applicability of US sanctions with respect to its proposed business transactions in Venezuela and Cuba, including helping to obtain favorable interpretive guidance;{{ FIELD }}Counseled large multi-national payment processor based in Latin America with respect to the application of US sanctions to its global operations;{{ FIELD }}Conducted due diligence for community bank as part of capital raising efforts;{{ FIELD }}Evaluated proposed joint venture arrangements to assess compliance with US sanctions requirements;{{ FIELD }}Conducted AML and sanctions reviews in the context of mergers and acquisition, lending arrangements, and repurchase transactions;{{ FIELD }}Conducted analysis of client risk due to client activity in sanctioned countries and other high risk countries. Assist in developing a comprehensive cross-business view of AML and sanctions risk;{{ FIELD }}Developed AML/sanctions compliance program for a provider of prepaid access utilizing toll road transponder devices, and conducted a risk assessment to create targeted procedures and internal controls;{{ FIELD }}Evaluated AML and OFAC obligations of foreign bank client extending margin loans to non-US customers of a US introducing broker;{{ FIELD }}Advised on application of BSA/AML/Sanctions requirements to entities in diverse industries including telecommunications, investment companies and hedge funds; residential mortgage loan originators (RMLOs), and public REITS in cross border ventures;{{ FIELD }}Advised on US sanctions-related and export control issues involving the sale of goods by a European-based client with US subsidiaries to a Russian buyer;{{ FIELD }}Addressed CIP and sanctions related issues raised by cash pooling arrangement for a large multi-national company;{{ FIELD }}Prepared legal opinion on foreign based company’s proposed business expansion in sanctioned countries and US regulatory implications;{{ FIELD }}Successfully obtained commodity classification determinations from US Department of Commerce on behalf of bio-tech client;{{ FIELD }}Advised large financial services company on export control requirements and implications relating to migration to organization-wide office suite/technology with data servers located outside of the US. Raised important “cloud computing” issues;{{ FIELD }}Prepared comment letters on behalf of large trade association on various SEC rulemakings;{{ FIELD }}Advised on Rule 144A and Regulation S offering;{{ FIELD }}Represented PCAOB-registered accounting firm facing disciplinary action involving cross-border access to audit work papers;{{ FIELD }}Counseled developer of search engine on AML/OFAC obligations of financial institutions;{{ FIELD }}Advised multi-national global industrial firm on compliance with Ukraine/Russian sanctions;{{ FIELD }}Assisted multiple clients with obtaining exclusions from the Section 232 tariffs (BIS) imposed on steel/aluminum;{{ FIELD }}Advised clients on the application and impact of Section 301 tariffs (USTR);{{ FIELD }}Conducted US sanctions and PEP due diligence on behalf of client/buyer of real estate property in New York;{{ FIELD }}Obtained favorable determination that cryptocurrency company preparing an ICO did not need to register as an \"MSB\" under state law;{{ FIELD }}Represented medical/research center in response to FINRA request for information relating to possible insider trading violations.{{ FIELD }}Shas advises clients on U.S economic/trade sanctions (OFAC), anti-money laundering requirements, and export control regulations.  In addition, Shas has vast expertise, both from his time in government and private practice, advising on a range of regulatory and compliance issues facing banks, hedge funds, investment advisors, mutual funds, and accounting firms.  Shas has experience representing clients before OFAC, USTR, Commerce (BIS), SEC, PCAOB, FINRA, and the OCC.  His clients include large financial institutions, Fintech companies, and multi-national manufacturers and distributors.\nPrior to joining the firm, Shas had a long career in US government and quasi-government agencies where he served in numerous senior level positions, including: Associate Director at the Public Company Accounting Oversight Board (PCAOB), Senior Sanctions Advisor at OFAC, and Senior Counsel at the US Securities \u0026amp; Exchange Commission and Federal Reserve Board. Shas also served as the head of the compliance examinations unit at Legg Mason, a global asset management firm. \nAs an Associate Director at the PCAOB, Shas negotiated numerous bilateral agreements with foreign regulators providing for cross-border audit oversight and represented the PCAOB in meetings with international audit standard setters. In particular, Shas was instrumental in negotiating an agreement with the Chinese authorities (CSRC and Ministry of Finance) on cross-border enforcement cooperation in 2013. He also participated in a short term secondment at the OECD, where he assisted its Corporate Affairs Division in updating its Principles of Corporate Governance (adopted by the G-20).\nIn a prior capacity as a Senior Sanctions Advisor, Shas served as the Office of Foreign Asset Control’s primary liaison to the securities industry. While at OFAC, he developed compliance guidance for the securities industry, provided subject-matter expertise on securities- and banking-related matters, prepared recommendations regarding appropriate OFAC responses to potential violations of sanctions requirements by financial institutions, and presented at more than 40 conferences throughout the US on compliance with U.S. economic and trade sanctions. During the height of the financial crisis, while at the US Treasury Department, Shas participated in both the development and implementation of the Dodd-Frank Act. Among other areas, Shas helped develop the US Treasury Department’s determination on whether to exempt foreign exchange swaps and forwards from the Commodity Exchange Act; he also helped develop the criteria for determining the designations of non-bank SIFIs.\nEarlier in his career, as counsel in the Banking Supervision and Regulation Division of the Federal Reserve Board, he served as one of the lead lawyers on a seminal enforcement action brought against a global financial institution for violations of OFAC sanctions as well as deficiencies in its anti-money laundering program. This settled action marked the first in a series of actions brought by US regulators and law enforcement agencies against global foreign banking entities for violations of OFAC regulations due to conduct involving the “stripping” of the identities of sanctions targets in the processing of dollar clearing wire transactions.\nEvents\n\nSpeaker, \"SEC Virtual Conference 2022: An Accounting \u0026amp; Reporting Update for Public Companies\" (\"Hot Button Issues for Public Companies\"), The Center for Professional Education, Inc., Washington, DC, May 20, 2022\"\nSpeaker, Russian Sanctions - Business \u0026amp; Policy Implications, Electronic Transactions Associations, Washington, DC, March 9, 2022\nSpeaker, “OFAC Webinar: Back to the Basics for Small to Midsized Banks,” BSA Coalition, Federal Reserve Bank of Richmond, Richmond, VA, April 24, 2018\nSpeaker, “Conducting KYC of Third Parties - Best Practices for Conducting Due Diligence,” Virginia Bankers Association, Fairfax, VA, April 17, 2018\nPanelist, International Sanctions Compliance, Association of Certified Anti-Money Laundering Specialists, New Castle, DE, February 26, 2018\nSpeaker, “The Challenges of Negotiating an Agreement with the Chinese Regulators on Cross-Border Audit Oversight,” China-US Business Alliance, New York City, January 23, 2018\nSpeaker, Annual Anti-Money Laundering and Office of Foreign Assets Control Sanctions Year in Review, ACAMS Virginia Chapter Event, December 12, 2017\nSpeaker, “Strategies for Effective Auditing and Due Diligence of Third Parties in China: Special Focus on Beneficial Ownership,” 8th Global Forum on Anti-Corruption Compliance in High Risk Markets, Washington, DC, July 25-26, 2017\nPanelist, “Banking Compliance,” FCPA Roundtable Discussion, US-China Business Council (USCBC), Washington, DC, May 9, 2017\nSpeaker, “Omnibus Accounts, Trusts and Other Unique Agreements Due Diligence Scenarios: How to Conduct Strong DD to Mitigate Your Risks,” Flagship Conference on Economic Sanctions Enforcement and Compliance, American Conference Institute, Mandarin Oriental Hotel, Washington, DC, April 24-26, 2017\nPanelist, 2017 FCPA and Anti-Monopoly Enforcement Trends in China Roundtable Discussion, US-China Business Council (USCBC), Washington, DC, April 5, 2017\nSpeaker, Keynote Panel: Trump and Banking–Predictions \u0026amp; Promises, 2017 Retail Banking Conference, at the Trump National Doral Miami Hotel in Miami, FL, March 22-24, 2017\nWebinar: Changes in Lease Accounting Standards \u0026amp; Impact on Credit Agreements, February 22, 2017\nSpeaker, “Current Focus of US Regulators—Hot Buttons \u0026amp; Cross Border Issues,” and “PCAOB \u0026amp; Auditing Developments,” SEC Conference 2016: An Accounting \u0026amp; Reporting Update for US Listed Companies, CPE, Beijing, December 12-13, 2016\nPanelist, Disclosure of Beneficial Ownership and Control in Asia: corporate practices, Asian Roundtable On Corporate Governance, OECD, October 25, 2016\nSpeaker, EU Regulatory Equivalency, Cross-Border Inspections of Audit Firms in China, The Evolving Role of the Audit Committee and Other Developments Impacting Global Audit Quality, National Asian Pacific American Bar Association 2016 Southeast Regional Conference, Arlington, VA, September 30, 2016\nSEC Conference 2016: An Accounting \u0026amp; Reporting Update for US Listed Companies, Center for Professional Education, June 2016: speaker on three panels: “Recent Auditing Developments,” “Update on SEC Enforcement Initiatives for Asia-Based Companies,” and “Corporate Governance Best Practices \u0026amp; the Role of the Audit Committee” June 16, 2016\nACAMS Richmond Chapter Event: When Goods Go Bad: Trade Based Money Laundering, May 2016\nOECD’s Asian Roundtables on Corporate Governance, (co-sponsored with the securities regulators in India and Thailand), 2014 and 2015\nWebcast - The PCAOB \u0026amp; China: The Latest Regulatory Developments, 2014\nFinancial Markets Securities Compliance Seminar, 2009\nAnti-Money Laundering III for Financial Institutions, 2008\nFutures Industry Association Law and Compliance Workshop, 2008\n\nPublications\n\nCo-author, AML and Sanctions Compliance Issues Facing Cryptocurrency Companies, Crowdfund Insider, June 4, 2018\nCo-author, “Recent Developments in the PCAOB’s Standard-Setting and Related Rulemaking Agenda,” Parts 1 and 2, in 38 Sec. \u0026amp; Fed. Corp. L. Rep. No. 11, and 39 Sec. \u0026amp; Fed. Corp. L. Rep. No. 1 (Thomson Reuters), edited by Sam Wolff, February 15, 2017\nContributor, Sarbanes-Oxley Act in Perspective, Thomson Reuters, 2017 edition\nCo-author, Trump Administration’s Impact on Financial Regulation and the SEC, Law360, November 23, 2016\n\nAlerts\n\nTrump Administration Issues New Executive Order Against Venezuela to Prevent a “Fire Sale” Liquidation of Venezuela’s Critical Assets, May 23, 2018\nForeign Investment in the US: An Overview of CFIUS, February 15, 2018\nAttorney General Jeff Sessions Announces Return to Traditional Guidelines for Prosecuting Marijuana Crimes; Rescinds Cole Memo Referenced in FinCEN Guidance, January 16, 2018\nNew CFIUS Legislation Proposed in Response to Chinese Investment, November 28, 2017\nFinCEN Warns Banks on North Korean Schemes to Evade Sanctions, November 8, 2017\nFinCEN Expands Its Geographic Targeting Orders and Issues Related Advisory, August 30, 2017\nOFAC Announces $12 Million Settlement to Resolve Enforcement Action Against Non-US Companies Using US Dollars to Do Business With Iran, August 17, 2017\nPCAOB Adopts New Audit Reporting Model, July 12, 2017\nFinCEN Issues Advisory on SAR Reporting Obligations Involving Cyber Crime, November 7, 2016\nFinCEN Expands Customer Due Diligence Requirements, June 22, 2016\nPCAOB Reproposes Standards Relating to Auditor’s Reporting Model – Narrows Scope of “Critical Audit Matters” and Drops “Other Information” Requirement, June 8, 2016\nPCAOB Adopts New Audit Firm Disclosure Rules, May 17, 2016\n Counsel SEC Capital Markets Award, September 11, 2001 U.S. Securities and Exchange Commission University of Virginia University of Virginia School of Law Northeastern University Northeastern University School of Law District of Columbia Maryland UVA Asian and Asian Pacific American Alumni Network (Board member) The Collegiate Schools Alumni Board Member Georgetown University Law Center, Adjunct Professor Prepared sanctions/export controls policies and conducted relevant sanctions/export controls training for largest private charter airline; Provided sanctions/AML guidance for first ever NFT real estate auction; Successfully represented non-U.S. based offshore operator of vessels before the U.S. State Department and other U.S. government agencies, in response to possible sanctions in connection with Nord Stream 2 Project; Obtained favorable cautionary letter from OFAC on behalf of bank when the bank had been the subject of a cautionary letter only eight months earlier; Advised marketing automation platform on sanctions-related matters in connection with largest sale of a private marketing software company in U.S. history; Advised global wealth manager on multi-faceted project designed to assess relevant sanctions risk/exposure and assist the bank disassociate itself from high-risk Russia-related client accounts; Assisted multiple U.S. companies divest their interests in Russian operating companies or joint ventures; Coordinate internal and external responses to investigations by OFAC;  Represent companies in the Fintech industry with respect to economic sanctions compliance and counseling; Advised multi-national oil refinery on compliance with OFAC requirements in light of PdVSA designation;  Advised clients in pharmaceutical and medical device industries navigate economic/sanctions regulations; Advised large foreign airlines on U.S. sanctions obligations, including application of secondary sanctions; Advised large, multi-national airline manufacturer on beneficial ownership obligations under the Bank Secrecy Act and OFAC regulations; Reviewed OFAC and AML representations and warranties in U.S. and offshore fund formation and private placement agreements; Represented a Texas-based bank in response to an Administrative Subpoena issued by OFAC regarding a funds/wire transfer in connection with the delivery of certain medical-related software for the benefit of an Iranian entity. The matter was favorably resolved for the client as OFAC issued a “no-action” letter upon the completion of its investigation and after reviewing our response; Counseled investment firm, specializing in investments in energy-related projects, on the applicability of US sanctions toward Venezuela with respect to a transaction involving payments to a Venezuelan entity (majority-owned by PdVSA) in US dollars for the extraction and sale of Venezuelan natural resources; Advised large multi-national beverage company and its subsidiaries regarding the applicability of US sanctions with respect to its proposed business transactions in Venezuela and Cuba, including helping to obtain favorable interpretive guidance; Counseled large multi-national payment processor based in Latin America with respect to the application of US sanctions to its global operations; Conducted due diligence for community bank as part of capital raising efforts; Evaluated proposed joint venture arrangements to assess compliance with US sanctions requirements; Conducted AML and sanctions reviews in the context of mergers and acquisition, lending arrangements, and repurchase transactions; Conducted analysis of client risk due to client activity in sanctioned countries and other high risk countries. Assist in developing a comprehensive cross-business view of AML and sanctions risk; Developed AML/sanctions compliance program for a provider of prepaid access utilizing toll road transponder devices, and conducted a risk assessment to create targeted procedures and internal controls; Evaluated AML and OFAC obligations of foreign bank client extending margin loans to non-US customers of a US introducing broker; Advised on application of BSA/AML/Sanctions requirements to entities in diverse industries including telecommunications, investment companies and hedge funds; residential mortgage loan originators (RMLOs), and public REITS in cross border ventures; Advised on US sanctions-related and export control issues involving the sale of goods by a European-based client with US subsidiaries to a Russian buyer; Addressed CIP and sanctions related issues raised by cash pooling arrangement for a large multi-national company; Prepared legal opinion on foreign based company’s proposed business expansion in sanctioned countries and US regulatory implications; Successfully obtained commodity classification determinations from US Department of Commerce on behalf of bio-tech client; Advised large financial services company on export control requirements and implications relating to migration to organization-wide office suite/technology with data servers located outside of the US. Raised important “cloud computing” issues; Prepared comment letters on behalf of large trade association on various SEC rulemakings; Advised on Rule 144A and Regulation S offering; Represented PCAOB-registered accounting firm facing disciplinary action involving cross-border access to audit work papers; Counseled developer of search engine on AML/OFAC obligations of financial institutions; Advised multi-national global industrial firm on compliance with Ukraine/Russian sanctions; Assisted multiple clients with obtaining exclusions from the Section 232 tariffs (BIS) imposed on steel/aluminum; Advised clients on the application and impact of Section 301 tariffs (USTR); Conducted US sanctions and PEP due diligence on behalf of client/buyer of real estate property in New York; Obtained favorable determination that cryptocurrency company preparing an ICO did not need to register as an \"MSB\" under state law; Represented medical/research center in response to FINRA request for information relating to possible insider trading violations.","searchable_name":"Shaswat K. Das","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":443116,"version":1,"owner_type":"Person","owner_id":7201,"payload":{"bio":"\u003cp\u003eAkash\u0026nbsp;represents\u0026nbsp;companies in complex litigation and government investigations. He\u0026nbsp;possesses\u0026nbsp;a breadth\u0026nbsp;of litigation and enforcement experience informed by six years of service as both an Assistant United States Attorney in the Northern District of Georgia and Senior Litigation Counsel at the Consumer Financial Protection Bureau\u0026nbsp;handling litigations and investigations\u0026nbsp;in the healthcare and financial sectors. Before his career\u0026nbsp;in government, Akash also spent\u0026nbsp;nearly eight years as a litigator at two global law firms.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eAs an Assistant United States Attorney in the Northern District of Georgia, Akash litigated\u0026nbsp;and investigated an array of False Claims Act matters, including those\u0026nbsp;involving kickbacks, medically unnecessary services, and violations of federal cybersecurity requirements. During his tenure, he\u0026nbsp;co-tried a case resulting in\u0026nbsp;a $27 million judgment\u0026nbsp;against a Georgia doctor and his medical practice for violating the False Claims Act.\u003c/p\u003e\n\u003cp\u003eAs a Senior Litigation Counsel at the Consumer Financial Protection Bureau, Akash litigated and investigated violations of consumer financial law. His experience included investigating the data security practices of a large financial services provider that experienced a data breach and\u0026nbsp;litigating a complex action alongside several State Attorney General\u0026nbsp;Offices.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eEarlier in private practice, Akash worked on complex commercial, financial, and intellectual property litigation in federal and state venues across the country.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAkash received his J.D. from Vanderbilt University Law School, where he was on the editorial board of the Vanderbilt Journal of Transnational Law and a Moot Court Board member. He\u0026nbsp;also received his LL.M. in International Legal Studies from New York University School of Law and his\u0026nbsp;B.A. in Political Science with honors from the University of Rochester.\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u003c/p\u003e","slug":"akash-desai","email":"adesai@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":24,"guid":"24.capabilities","index":0,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":1,"source":"capabilities"},{"id":5,"guid":"5.capabilities","index":2,"source":"capabilities"},{"id":6,"guid":"6.capabilities","index":3,"source":"capabilities"},{"id":107,"guid":"107.capabilities","index":4,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":5,"source":"capabilities"},{"id":1180,"guid":"1180.smart_tags","index":6,"source":"smartTags"},{"id":952,"guid":"952.smart_tags","index":7,"source":"smartTags"},{"id":740,"guid":"740.smart_tags","index":8,"source":"smartTags"}],"is_active":true,"last_name":"Desai","nick_name":"Akash","clerkships":[{"name":"Law Clerk, Hon. Jon P. McCalla, U.S. District Court for the Western District of Tennessee","years_held":"2004 - 2005"},{"name":"Law Clerk, Hon. Aleta A. Trauger, U.S. District Court for the Middle District of Tennessee","years_held":"2011 - 2013"},{"name":"Law Clerk, Hon. S. Martin Teel, Jr., U.S. Bankruptcy Court for the District of Columbia","years_held":"2011 - 2011"}],"first_name":"Akash","title_rank":9999,"updated_by":202,"law_schools":[{"id":2442,"meta":{"degree":"J.D.","honors":"","is_law_school":"1","graduation_date":"2004-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null},{"id":1406,"meta":{"degree":"LL.M.","honors":"","is_law_school":"1","graduation_date":"2009-01-01 00:00:00"},"order":2,"pin_order":null,"pin_expiration":null}],"middle_name":" ","name_suffix":"","recognitions":null,"linked_in_url":null,"seodescription":null,"primary_title_id":14,"translated_fields":{"en":{"bio":"\u003cp\u003eAkash\u0026nbsp;represents\u0026nbsp;companies in complex litigation and government investigations. He\u0026nbsp;possesses\u0026nbsp;a breadth\u0026nbsp;of litigation and enforcement experience informed by six years of service as both an Assistant United States Attorney in the Northern District of Georgia and Senior Litigation Counsel at the Consumer Financial Protection Bureau\u0026nbsp;handling litigations and investigations\u0026nbsp;in the healthcare and financial sectors. Before his career\u0026nbsp;in government, Akash also spent\u0026nbsp;nearly eight years as a litigator at two global law firms.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eAs an Assistant United States Attorney in the Northern District of Georgia, Akash litigated\u0026nbsp;and investigated an array of False Claims Act matters, including those\u0026nbsp;involving kickbacks, medically unnecessary services, and violations of federal cybersecurity requirements. During his tenure, he\u0026nbsp;co-tried a case resulting in\u0026nbsp;a $27 million judgment\u0026nbsp;against a Georgia doctor and his medical practice for violating the False Claims Act.\u003c/p\u003e\n\u003cp\u003eAs a Senior Litigation Counsel at the Consumer Financial Protection Bureau, Akash litigated and investigated violations of consumer financial law. His experience included investigating the data security practices of a large financial services provider that experienced a data breach and\u0026nbsp;litigating a complex action alongside several State Attorney General\u0026nbsp;Offices.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eEarlier in private practice, Akash worked on complex commercial, financial, and intellectual property litigation in federal and state venues across the country.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAkash received his J.D. from Vanderbilt University Law School, where he was on the editorial board of the Vanderbilt Journal of Transnational Law and a Moot Court Board member. He\u0026nbsp;also received his LL.M. in International Legal Studies from New York University School of Law and his\u0026nbsp;B.A. in Political Science with honors from the University of Rochester.\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u003c/p\u003e"},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":12899}]},"capability_group_id":2},"created_at":"2025-11-19T16:33:25.000Z","updated_at":"2025-11-19T16:33:25.000Z","searchable_text":"Desai{{ FIELD }}Akash represents companies in complex litigation and government investigations. He possesses a breadth of litigation and enforcement experience informed by six years of service as both an Assistant United States Attorney in the Northern District of Georgia and Senior Litigation Counsel at the Consumer Financial Protection Bureau handling litigations and investigations in the healthcare and financial sectors. Before his career in government, Akash also spent nearly eight years as a litigator at two global law firms. \nAs an Assistant United States Attorney in the Northern District of Georgia, Akash litigated and investigated an array of False Claims Act matters, including those involving kickbacks, medically unnecessary services, and violations of federal cybersecurity requirements. During his tenure, he co-tried a case resulting in a $27 million judgment against a Georgia doctor and his medical practice for violating the False Claims Act.\nAs a Senior Litigation Counsel at the Consumer Financial Protection Bureau, Akash litigated and investigated violations of consumer financial law. His experience included investigating the data security practices of a large financial services provider that experienced a data breach and litigating a complex action alongside several State Attorney General Offices. \nEarlier in private practice, Akash worked on complex commercial, financial, and intellectual property litigation in federal and state venues across the country. \nAkash received his J.D. from Vanderbilt University Law School, where he was on the editorial board of the Vanderbilt Journal of Transnational Law and a Moot Court Board member. He also received his LL.M. in International Legal Studies from New York University School of Law and his B.A. in Political Science with honors from the University of Rochester.     Counsel University of Rochester  Vanderbilt University Vanderbilt University School of Law New York University New York University School of Law Georgia New York Law Clerk, Hon. Jon P. McCalla, U.S. District Court for the Western District of Tennessee Law Clerk, Hon. Aleta A. Trauger, U.S. District Court for the Middle District of Tennessee Law Clerk, Hon. S. Martin Teel, Jr., U.S. Bankruptcy Court for the District of Columbia","searchable_name":"Akash Desai","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":447915,"version":1,"owner_type":"Person","owner_id":6448,"payload":{"bio":"\u003cp\u003eJustin Dews is counsel in King \u0026amp; Spalding\u0026rsquo;s New York office\u0026nbsp;and a member of the firm\u0026rsquo;s Government Matters, Special Matters and Investigations, and Government Advocacy and Public Policy\u0026nbsp;practices.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eJustin focuses his practice on government investigations, congressional investigations, white collar criminal investigations, and corporate internal investigations.\u0026nbsp; Justin\u0026rsquo;s experience advising chief executives in federal and state government helps him resolve his clients\u0026rsquo; most complex and sensitive problems. \u0026nbsp;Prior to joining King \u0026amp; Spalding, Justin served as Associate Counsel in the White House Counsel\u0026rsquo;s Office and as Senior Counsel in the Counsel\u0026rsquo;s Office of New Jersey Governor Phil Murphy.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eJustin graduated from the Harvard Law School, where he was the Business \u0026amp;\u0026nbsp;\u003cem\u003eBluebook\u003c/em\u003e\u0026nbsp;Chair of the\u0026nbsp;\u003cem\u003eHarvard Law Review\u003c/em\u003e.\u003c/p\u003e","slug":"justin-dews","email":"jdews@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":81,"guid":"81.capabilities","index":0,"source":"capabilities"},{"id":23,"guid":"23.capabilities","index":1,"source":"capabilities"},{"id":687,"guid":"687.smart_tags","index":2,"source":"smartTags"},{"id":11,"guid":"11.capabilities","index":3,"source":"capabilities"},{"id":111,"guid":"111.capabilities","index":4,"source":"capabilities"},{"id":750,"guid":"750.smart_tags","index":5,"source":"smartTags"},{"id":766,"guid":"766.smart_tags","index":6,"source":"smartTags"},{"id":1434,"guid":"1434.smart_tags","index":7,"source":"smartTags"}],"is_active":true,"last_name":"Dews","nick_name":"Justin","clerkships":[{"name":"Law Clerk, Hon. Joseph A. Greenaway, Jr., U.S. Court of Appeals for the Third Circuit","years_held":"2016 - 2017"}],"first_name":"Justin","title_rank":9999,"updated_by":202,"law_schools":[{"id":824,"meta":{"degree":"J.D.","honors":"","is_law_school":"1","graduation_date":"2015-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":" ","name_suffix":"","recognitions":null,"linked_in_url":"https://www.linkedin.com/in/justin-dews-318b45113/","seodescription":null,"primary_title_id":14,"translated_fields":{"en":{"bio":"\u003cp\u003eJustin Dews is counsel in King \u0026amp; Spalding\u0026rsquo;s New York office\u0026nbsp;and a member of the firm\u0026rsquo;s Government Matters, Special Matters and Investigations, and Government Advocacy and Public Policy\u0026nbsp;practices.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eJustin focuses his practice on government investigations, congressional investigations, white collar criminal investigations, and corporate internal investigations.\u0026nbsp; Justin\u0026rsquo;s experience advising chief executives in federal and state government helps him resolve his clients\u0026rsquo; most complex and sensitive problems. \u0026nbsp;Prior to joining King \u0026amp; Spalding, Justin served as Associate Counsel in the White House Counsel\u0026rsquo;s Office and as Senior Counsel in the Counsel\u0026rsquo;s Office of New Jersey Governor Phil Murphy.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eJustin graduated from the Harvard Law School, where he was the Business \u0026amp;\u0026nbsp;\u003cem\u003eBluebook\u003c/em\u003e\u0026nbsp;Chair of the\u0026nbsp;\u003cem\u003eHarvard Law Review\u003c/em\u003e.\u003c/p\u003e"},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":10486}]},"capability_group_id":2},"created_at":"2026-04-28T21:20:10.000Z","updated_at":"2026-04-28T21:20:10.000Z","searchable_text":"Dews{{ FIELD }}Justin Dews is counsel in King \u0026amp; Spalding’s New York office and a member of the firm’s Government Matters, Special Matters and Investigations, and Government Advocacy and Public Policy practices.\nJustin focuses his practice on government investigations, congressional investigations, white collar criminal investigations, and corporate internal investigations.  Justin’s experience advising chief executives in federal and state government helps him resolve his clients’ most complex and sensitive problems.  Prior to joining King \u0026amp; Spalding, Justin served as Associate Counsel in the White House Counsel’s Office and as Senior Counsel in the Counsel’s Office of New Jersey Governor Phil Murphy. \nJustin graduated from the Harvard Law School, where he was the Business \u0026amp; Bluebook Chair of the Harvard Law Review. Counsel Harvard University Harvard Law School Harvard University Harvard Law School U.S. Court of Appeals for the Third Circuit U.S. District Court for the District of New Jersey New Jersey New York Law Clerk, Hon. Joseph A. Greenaway, Jr., U.S. Court of Appeals for the Third Circuit","searchable_name":"Justin Dews","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":445240,"version":1,"owner_type":"Person","owner_id":4051,"payload":{"bio":"\u003cp\u003eAna Daily provides strategic counsel and advocacy\u0026nbsp;in high-stakes matters and regularly helps clients navigate investigations involving federal, state, and international enforcement authorities as well as\u0026nbsp;sensitive internal reviews, with a\u0026nbsp;focus on financial services and AI / technology-related issues.\u003c/p\u003e\n\u003cp\u003eAna represents global companies, financial institutions, and high-growth firms in investigations by the Department of Justice, the Department of the Treasury / OFAC, State Attorneys General, Congress, and other federal and state regulators. Her work involves managing parallel proceedings, preparing senior executives for public hearings and congressional testimony,\u0026nbsp;advising clients during fast-moving crises,\u0026nbsp;and guiding companies in\u0026nbsp;strengthening compliance programs, internal controls, and risk-mitigation strategies. In addition, Ana has experience with cross-border investigations involving\u0026nbsp;multi-jurisdictional risk and\u0026nbsp;has represented clients in complex litigation.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eAna advises technology clients on assessing and managing risks in emerging technologies, including developing and maintaining effective AI, platform-governance, and privacy compliance programs. She counsels banking and fintech clients on sanctions, AML, and money-transmission requirements. Ana also represents clients in government investigations related to\u0026nbsp;the False Claims Act, environmental incidents, data privacy and cybersecurity incidents, and consumer protection.\u003c/p\u003e\n\u003cp\u003eAna speaks Serbian\u0026nbsp;and has represented clients based and involved in the region.\u003c/p\u003e","slug":"ana-daily","email":"adaily@kslaw.com","phone":null,"matters":["\u003cp\u003e\u003cstrong\u003eAna\u0026rsquo;s experience includes advising:\u003c/strong\u003e\u003c/p\u003e","\u003cp\u003eMultiple major technology companies in congressional, state attorneys general, and internal investigations related to AI, content moderation, election integrity, national security, and antitrust issues\u003c/p\u003e","\u003cp\u003eSenior executives, in preparation for testimony before congress and in public hearings\u003c/p\u003e","\u003cp\u003eMultiple large universities in congressional oversight investigations before House and Senate committees on a wide range of issues\u003c/p\u003e","\u003cp\u003eA multinational manufacturing conglomerate in DOJ and EPA investigations involving PFAS-related issues\u003c/p\u003e","\u003cp\u003eA healthcare company in a DOJ investigation involving False Claims Act allegations\u003c/p\u003e","\u003cp\u003eMultiple companies across industries \u0026mdash; including technology, consumer products, and healthcare \u0026mdash; in State Attorneys General investigations involving consumer-protection, marketing, and business-practice concerns\u003c/p\u003e","\u003cp\u003eA major foreign financial institution in a cross-border internal investigation and related litigation in the Southern District of New York and the Second Circuit involving sanctions exposure and money-laundering allegations\u003c/p\u003e","\u003cp\u003eA large technology company in civil litigation related to teen mental health\u003c/p\u003e","\u003cp\u003eA credit reporting agency in federal and state investigations arising out of a large-scale cybersecurity incident\u003c/p\u003e","\u003cp\u003eA multinational retail corporation in an internal investigation into potential conflicts of interest and employee-misconduct issues\u003c/p\u003e","\u003cp\u003eA major U.S. bank in responding to requests from multiple prudential regulators in relation to its compliance program\u003c/p\u003e","\u003cp\u003eFinTech clients on compliance with federal and state money-transmission laws, BSA/AML requirements, and in related regulatory examinations\u003c/p\u003e","\u003cp\u003eA variety of clients in OFAC-related inquiries involving sanctions compliance, trade restrictions, and geopolitical risk\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":11,"guid":"11.capabilities","index":0,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":1,"source":"capabilities"},{"id":107,"guid":"107.capabilities","index":2,"source":"capabilities"},{"id":687,"guid":"687.smart_tags","index":3,"source":"smartTags"},{"id":111,"guid":"111.capabilities","index":4,"source":"capabilities"},{"id":118,"guid":"118.capabilities","index":5,"source":"capabilities"},{"id":750,"guid":"750.smart_tags","index":6,"source":"smartTags"},{"id":973,"guid":"973.smart_tags","index":7,"source":"smartTags"},{"id":113,"guid":"113.capabilities","index":8,"source":"capabilities"},{"id":127,"guid":"127.capabilities","index":9,"source":"capabilities"},{"id":1015,"guid":"1015.smart_tags","index":10,"source":"smartTags"},{"id":952,"guid":"952.smart_tags","index":11,"source":"smartTags"},{"id":699,"guid":"699.smart_tags","index":12,"source":"smartTags"},{"id":765,"guid":"765.smart_tags","index":13,"source":"smartTags"},{"id":1188,"guid":"1188.smart_tags","index":14,"source":"smartTags"}],"is_active":true,"last_name":"Daily","nick_name":"Ana","clerkships":[{"name":"Intern, Judge Collyer, U.S. District Court for the District of Columbia","years_held":"2015"}],"first_name":"Ana","title_rank":9999,"updated_by":35,"law_schools":[{"id":755,"meta":{"degree":"J.D.","honors":"","is_law_school":"1","graduation_date":null},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"B.","name_suffix":"","recognitions":null,"linked_in_url":null,"seodescription":null,"primary_title_id":75,"translated_fields":{"en":{"bio":"\u003cp\u003eAna Daily provides strategic counsel and advocacy\u0026nbsp;in high-stakes matters and regularly helps clients navigate investigations involving federal, state, and international enforcement authorities as well as\u0026nbsp;sensitive internal reviews, with a\u0026nbsp;focus on financial services and AI / technology-related issues.\u003c/p\u003e\n\u003cp\u003eAna represents global companies, financial institutions, and high-growth firms in investigations by the Department of Justice, the Department of the Treasury / OFAC, State Attorneys General, Congress, and other federal and state regulators. Her work involves managing parallel proceedings, preparing senior executives for public hearings and congressional testimony,\u0026nbsp;advising clients during fast-moving crises,\u0026nbsp;and guiding companies in\u0026nbsp;strengthening compliance programs, internal controls, and risk-mitigation strategies. In addition, Ana has experience with cross-border investigations involving\u0026nbsp;multi-jurisdictional risk and\u0026nbsp;has represented clients in complex litigation.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eAna advises technology clients on assessing and managing risks in emerging technologies, including developing and maintaining effective AI, platform-governance, and privacy compliance programs. She counsels banking and fintech clients on sanctions, AML, and money-transmission requirements. Ana also represents clients in government investigations related to\u0026nbsp;the False Claims Act, environmental incidents, data privacy and cybersecurity incidents, and consumer protection.\u003c/p\u003e\n\u003cp\u003eAna speaks Serbian\u0026nbsp;and has represented clients based and involved in the region.\u003c/p\u003e","matters":["\u003cp\u003e\u003cstrong\u003eAna\u0026rsquo;s experience includes advising:\u003c/strong\u003e\u003c/p\u003e","\u003cp\u003eMultiple major technology companies in congressional, state attorneys general, and internal investigations related to AI, content moderation, election integrity, national security, and antitrust issues\u003c/p\u003e","\u003cp\u003eSenior executives, in preparation for testimony before congress and in public hearings\u003c/p\u003e","\u003cp\u003eMultiple large universities in congressional oversight investigations before House and Senate committees on a wide range of issues\u003c/p\u003e","\u003cp\u003eA multinational manufacturing conglomerate in DOJ and EPA investigations involving PFAS-related issues\u003c/p\u003e","\u003cp\u003eA healthcare company in a DOJ investigation involving False Claims Act allegations\u003c/p\u003e","\u003cp\u003eMultiple companies across industries \u0026mdash; including technology, consumer products, and healthcare \u0026mdash; in State Attorneys General investigations involving consumer-protection, marketing, and business-practice concerns\u003c/p\u003e","\u003cp\u003eA major foreign financial institution in a cross-border internal investigation and related litigation in the Southern District of New York and the Second Circuit involving sanctions exposure and money-laundering allegations\u003c/p\u003e","\u003cp\u003eA large technology company in civil litigation related to teen mental health\u003c/p\u003e","\u003cp\u003eA credit reporting agency in federal and state investigations arising out of a large-scale cybersecurity incident\u003c/p\u003e","\u003cp\u003eA multinational retail corporation in an internal investigation into potential conflicts of interest and employee-misconduct issues\u003c/p\u003e","\u003cp\u003eA major U.S. bank in responding to requests from multiple prudential regulators in relation to its compliance program\u003c/p\u003e","\u003cp\u003eFinTech clients on compliance with federal and state money-transmission laws, BSA/AML requirements, and in related regulatory examinations\u003c/p\u003e","\u003cp\u003eA variety of clients in OFAC-related inquiries involving sanctions compliance, trade restrictions, and geopolitical risk\u003c/p\u003e"]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":12009}]},"capability_group_id":2},"created_at":"2026-01-23T21:54:45.000Z","updated_at":"2026-01-23T21:54:45.000Z","searchable_text":"Daily{{ FIELD }}Ana’s experience includes advising:{{ FIELD }}Multiple major technology companies in congressional, state attorneys general, and internal investigations related to AI, content moderation, election integrity, national security, and antitrust issues{{ FIELD }}Senior executives, in preparation for testimony before congress and in public hearings{{ FIELD }}Multiple large universities in congressional oversight investigations before House and Senate committees on a wide range of issues{{ FIELD }}A multinational manufacturing conglomerate in DOJ and EPA investigations involving PFAS-related issues{{ FIELD }}A healthcare company in a DOJ investigation involving False Claims Act allegations{{ FIELD }}Multiple companies across industries — including technology, consumer products, and healthcare — in State Attorneys General investigations involving consumer-protection, marketing, and business-practice concerns{{ FIELD }}A major foreign financial institution in a cross-border internal investigation and related litigation in the Southern District of New York and the Second Circuit involving sanctions exposure and money-laundering allegations{{ FIELD }}A large technology company in civil litigation related to teen mental health{{ FIELD }}A credit reporting agency in federal and state investigations arising out of a large-scale cybersecurity incident{{ FIELD }}A multinational retail corporation in an internal investigation into potential conflicts of interest and employee-misconduct issues{{ FIELD }}A major U.S. bank in responding to requests from multiple prudential regulators in relation to its compliance program{{ FIELD }}FinTech clients on compliance with federal and state money-transmission laws, BSA/AML requirements, and in related regulatory examinations{{ FIELD }}A variety of clients in OFAC-related inquiries involving sanctions compliance, trade restrictions, and geopolitical risk{{ FIELD }}Ana Daily provides strategic counsel and advocacy in high-stakes matters and regularly helps clients navigate investigations involving federal, state, and international enforcement authorities as well as sensitive internal reviews, with a focus on financial services and AI / technology-related issues.\nAna represents global companies, financial institutions, and high-growth firms in investigations by the Department of Justice, the Department of the Treasury / OFAC, State Attorneys General, Congress, and other federal and state regulators. Her work involves managing parallel proceedings, preparing senior executives for public hearings and congressional testimony, advising clients during fast-moving crises, and guiding companies in strengthening compliance programs, internal controls, and risk-mitigation strategies. In addition, Ana has experience with cross-border investigations involving multi-jurisdictional risk and has represented clients in complex litigation. \nAna advises technology clients on assessing and managing risks in emerging technologies, including developing and maintaining effective AI, platform-governance, and privacy compliance programs. She counsels banking and fintech clients on sanctions, AML, and money-transmission requirements. Ana also represents clients in government investigations related to the False Claims Act, environmental incidents, data privacy and cybersecurity incidents, and consumer protection.\nAna speaks Serbian and has represented clients based and involved in the region. Senior Associate George Washington University George Washington University Law School Georgetown University Georgetown University Law Center U.S. Court of Appeals for the Second Circuit U.S. District Court for the Eastern District of New York U.S. District Court for the Southern District of New York Georgia New York Women's White Collar Defense Association Intern, Judge Collyer, U.S. District Court for the District of Columbia Ana’s experience includes advising: Multiple major technology companies in congressional, state attorneys general, and internal investigations related to AI, content moderation, election integrity, national security, and antitrust issues Senior executives, in preparation for testimony before congress and in public hearings Multiple large universities in congressional oversight investigations before House and Senate committees on a wide range of issues A multinational manufacturing conglomerate in DOJ and EPA investigations involving PFAS-related issues A healthcare company in a DOJ investigation involving False Claims Act allegations Multiple companies across industries — including technology, consumer products, and healthcare — in State Attorneys General investigations involving consumer-protection, marketing, and business-practice concerns A major foreign financial institution in a cross-border internal investigation and related litigation in the Southern District of New York and the Second Circuit involving sanctions exposure and money-laundering allegations A large technology company in civil litigation related to teen mental health A credit reporting agency in federal and state investigations arising out of a large-scale cybersecurity incident A multinational retail corporation in an internal investigation into potential conflicts of interest and employee-misconduct issues A major U.S. bank in responding to requests from multiple prudential regulators in relation to its compliance program FinTech clients on compliance with federal and state money-transmission laws, BSA/AML requirements, and in related regulatory examinations A variety of clients in OFAC-related inquiries involving sanctions compliance, trade restrictions, and geopolitical risk","searchable_name":"Ana B. Daily","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":35,"capability_group_featured":null,"home_page_featured":null},{"id":426723,"version":1,"owner_type":"Person","owner_id":5435,"payload":{"bio":"\u003cp\u003eAlex is an Associate in our Special Matters and Government Investigations practice and is licensed to practice in Texas and England and Wales. Alex represents clients involved in complex, multi-jurisdictional disputes and government investigations. Alex has experience representing corporations and individuals in matters involving a wide range of criminal and regulatory misconduct including cybersecurity, financial crime, bribery and corruption, and violations of environmental and healthcare laws and regulations. The majority of Alex\u0026rsquo;s experience involves more than one jurisdiction.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003ePrior to joining King \u0026amp; Spalding, Alex began practicing as a barrister in London, United Kingdom, where he gained experience prosecuting and defending.\u0026nbsp;Alex built upon his trial experience by joining a large international U.S. firm in London, where Alex defended corporations and individuals facing complex global criminal and regulatory investigations and disputes.\u003c/p\u003e\n\u003cp\u003eSince joining King \u0026amp; Spalding in 2018, Alex\u0026rsquo;s practice has evolved to focus on cybercrime to complement his experience representing clients in investigations and prosecutions alleging corruption, anti-trust offences, fraud, money laundering, false accounting and other allegations of criminal and regulatory misconduct. Alex has experience in matters involving extradition and mutual legal assistance, proceeds of crime and international sanctions.\u003c/p\u003e\n\u003cp\u003eMost recently, Alex\u0026rsquo;s cybersecurity investigations work has involved: investigating cybersecurity breaches and the associated incident response; attribution of systematic and targeted compromise of an opposing party\u0026rsquo;s email servers, responding to allegations related to a technically complex and vast multi-jurisdictional compromise of mobile devices; investigating and identifying potential weaknesses in malware which utilizes unique attributes to resist common take down measures. Alex also advises clients seeking to invest in critical infrastructure assets of importance to United States\u0026rsquo; national security.\u003c/p\u003e\n\u003cp\u003eAlex\u0026rsquo;s experience practicing in two of the most active enforcement jurisdictions - the United States and the United Kingdom - benefits clients facing investigations in multiple jurisdictions.\u003c/p\u003e\n\u003cp\u003eIn addition to investigations work, Alex has designed, implemented and tested compliance processes and advised on pre/post-acquisition due diligence in the areas covered by his investigations practice.\u003c/p\u003e\n\u003cp\u003eAlex has represented clients in interviews with government authorities (both as suspects and as witnesses) and has conducted interviews on behalf of corporations when conducting internal investigations.\u003c/p\u003e\n\u003cp\u003eAlex is experienced in all aspects of the investigation process, both internal investigation and investigations conducted by enforcement authorities. Alex\u0026rsquo;s comfort with new and emerging technology ensures he is on top of the various challenges posed by a corporation's use of technology and electronic data. Alex has conducted internal investigations on a wide range of matters, including those related to cyber-crimes, bribery and corruption, and fraud allegations related to healthcare, accounting, emissions, bankruptcy, tax, and real estate, among other areas.\u003c/p\u003e\n\u003cp\u003eAlex represents clients across various industries including technology, energy, automotive, financial services, healthcare, construction, retail and food and beverage industries.\u003c/p\u003e","slug":"alexander-davey","email":"adavey@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":11,"guid":"11.capabilities","index":0,"source":"capabilities"},{"id":102,"guid":"102.capabilities","index":1,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":2,"source":"capabilities"},{"id":780,"guid":"780.smart_tags","index":3,"source":"smartTags"},{"id":20,"guid":"20.capabilities","index":4,"source":"capabilities"},{"id":766,"guid":"766.smart_tags","index":5,"source":"smartTags"},{"id":952,"guid":"952.smart_tags","index":6,"source":"smartTags"},{"id":1197,"guid":"1197.smart_tags","index":7,"source":"smartTags"},{"id":106,"guid":"106.capabilities","index":8,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":9,"source":"capabilities"},{"id":24,"guid":"24.capabilities","index":10,"source":"capabilities"}],"is_active":true,"last_name":"Davey","nick_name":"Alex","clerkships":[],"first_name":"Alexander","title_rank":9999,"updated_by":34,"law_schools":[],"middle_name":" ","name_suffix":"","recognitions":null,"linked_in_url":null,"seodescription":null,"primary_title_id":75,"translated_fields":{"en":{"bio":"\u003cp\u003eAlex is an Associate in our Special Matters and Government Investigations practice and is licensed to practice in Texas and England and Wales. Alex represents clients involved in complex, multi-jurisdictional disputes and government investigations. Alex has experience representing corporations and individuals in matters involving a wide range of criminal and regulatory misconduct including cybersecurity, financial crime, bribery and corruption, and violations of environmental and healthcare laws and regulations. The majority of Alex\u0026rsquo;s experience involves more than one jurisdiction.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003ePrior to joining King \u0026amp; Spalding, Alex began practicing as a barrister in London, United Kingdom, where he gained experience prosecuting and defending.\u0026nbsp;Alex built upon his trial experience by joining a large international U.S. firm in London, where Alex defended corporations and individuals facing complex global criminal and regulatory investigations and disputes.\u003c/p\u003e\n\u003cp\u003eSince joining King \u0026amp; Spalding in 2018, Alex\u0026rsquo;s practice has evolved to focus on cybercrime to complement his experience representing clients in investigations and prosecutions alleging corruption, anti-trust offences, fraud, money laundering, false accounting and other allegations of criminal and regulatory misconduct. Alex has experience in matters involving extradition and mutual legal assistance, proceeds of crime and international sanctions.\u003c/p\u003e\n\u003cp\u003eMost recently, Alex\u0026rsquo;s cybersecurity investigations work has involved: investigating cybersecurity breaches and the associated incident response; attribution of systematic and targeted compromise of an opposing party\u0026rsquo;s email servers, responding to allegations related to a technically complex and vast multi-jurisdictional compromise of mobile devices; investigating and identifying potential weaknesses in malware which utilizes unique attributes to resist common take down measures. Alex also advises clients seeking to invest in critical infrastructure assets of importance to United States\u0026rsquo; national security.\u003c/p\u003e\n\u003cp\u003eAlex\u0026rsquo;s experience practicing in two of the most active enforcement jurisdictions - the United States and the United Kingdom - benefits clients facing investigations in multiple jurisdictions.\u003c/p\u003e\n\u003cp\u003eIn addition to investigations work, Alex has designed, implemented and tested compliance processes and advised on pre/post-acquisition due diligence in the areas covered by his investigations practice.\u003c/p\u003e\n\u003cp\u003eAlex has represented clients in interviews with government authorities (both as suspects and as witnesses) and has conducted interviews on behalf of corporations when conducting internal investigations.\u003c/p\u003e\n\u003cp\u003eAlex is experienced in all aspects of the investigation process, both internal investigation and investigations conducted by enforcement authorities. Alex\u0026rsquo;s comfort with new and emerging technology ensures he is on top of the various challenges posed by a corporation's use of technology and electronic data. Alex has conducted internal investigations on a wide range of matters, including those related to cyber-crimes, bribery and corruption, and fraud allegations related to healthcare, accounting, emissions, bankruptcy, tax, and real estate, among other areas.\u003c/p\u003e\n\u003cp\u003eAlex represents clients across various industries including technology, energy, automotive, financial services, healthcare, construction, retail and food and beverage industries.\u003c/p\u003e"},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":6586}]},"capability_group_id":2},"created_at":"2025-05-26T04:56:21.000Z","updated_at":"2025-05-26T04:56:21.000Z","searchable_text":"Davey{{ FIELD }}Alex is an Associate in our Special Matters and Government Investigations practice and is licensed to practice in Texas and England and Wales. Alex represents clients involved in complex, multi-jurisdictional disputes and government investigations. Alex has experience representing corporations and individuals in matters involving a wide range of criminal and regulatory misconduct including cybersecurity, financial crime, bribery and corruption, and violations of environmental and healthcare laws and regulations. The majority of Alex’s experience involves more than one jurisdiction.\nPrior to joining King \u0026amp; Spalding, Alex began practicing as a barrister in London, United Kingdom, where he gained experience prosecuting and defending. Alex built upon his trial experience by joining a large international U.S. firm in London, where Alex defended corporations and individuals facing complex global criminal and regulatory investigations and disputes.\nSince joining King \u0026amp; Spalding in 2018, Alex’s practice has evolved to focus on cybercrime to complement his experience representing clients in investigations and prosecutions alleging corruption, anti-trust offences, fraud, money laundering, false accounting and other allegations of criminal and regulatory misconduct. Alex has experience in matters involving extradition and mutual legal assistance, proceeds of crime and international sanctions.\nMost recently, Alex’s cybersecurity investigations work has involved: investigating cybersecurity breaches and the associated incident response; attribution of systematic and targeted compromise of an opposing party’s email servers, responding to allegations related to a technically complex and vast multi-jurisdictional compromise of mobile devices; investigating and identifying potential weaknesses in malware which utilizes unique attributes to resist common take down measures. Alex also advises clients seeking to invest in critical infrastructure assets of importance to United States’ national security.\nAlex’s experience practicing in two of the most active enforcement jurisdictions - the United States and the United Kingdom - benefits clients facing investigations in multiple jurisdictions.\nIn addition to investigations work, Alex has designed, implemented and tested compliance processes and advised on pre/post-acquisition due diligence in the areas covered by his investigations practice.\nAlex has represented clients in interviews with government authorities (both as suspects and as witnesses) and has conducted interviews on behalf of corporations when conducting internal investigations.\nAlex is experienced in all aspects of the investigation process, both internal investigation and investigations conducted by enforcement authorities. Alex’s comfort with new and emerging technology ensures he is on top of the various challenges posed by a corporation's use of technology and electronic data. Alex has conducted internal investigations on a wide range of matters, including those related to cyber-crimes, bribery and corruption, and fraud allegations related to healthcare, accounting, emissions, bankruptcy, tax, and real estate, among other areas.\nAlex represents clients across various industries including technology, energy, automotive, financial services, healthcare, construction, retail and food and beverage industries. Senior Associate University of East Anglia University of East Anglia University of Law, London University of Law, London Texas England and Wales","searchable_name":"Alexander Davey (Alex)","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":34,"capability_group_featured":null,"home_page_featured":null},{"id":426488,"version":1,"owner_type":"Person","owner_id":3854,"payload":{"bio":"\u003cp\u003eKalle Deyette is a\u0026nbsp;senior associate\u0026nbsp;in King \u0026amp; Spalding\u0026rsquo;s Washington, D.C., office and is a member of the FDA and Life Sciences practice.\u0026nbsp; Kalle focuses her practice on the regulation of medical devices and pharmaceutical manufacturers, as well as healthcare providers and suppliers.\u0026nbsp; Her expertise is concentrated on healthcare fraud and abuse and compliance, including analyzing arrangements under the Anti-Kickback Statute and assisting with government investigations and internal investigations into alleged violations of company policy and federal law. \u0026nbsp;Kalle also provides counsel to both the Ad Hoc State Law Compliance Group on a variety of laws and regulations, including state transparency and disclosure laws, and the International Marketing and Disclosure Compliance Group on a variety of international laws, regulations, and industry codes.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eKalle graduated from Saint Louis University School of Law, where she served as the Notes and Comments editor of the Saint Louis University Journal of Health Law \u0026amp; Policy.\u003c/p\u003e","slug":"kalle-deyette","email":"kdeyette@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":21,"guid":"21.capabilities","index":0,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":1,"source":"capabilities"}],"is_active":true,"last_name":"Deyette","nick_name":"Kalle","clerkships":[],"first_name":"Kalle","title_rank":9999,"updated_by":101,"law_schools":[{"id":1732,"meta":{"degree":"J.D.","honors":"magna cum laude","is_law_school":1,"graduation_date":"2015-01-01 00:00:00 UTC"},"order":0,"pin_order":null,"pin_expiration":null}],"middle_name":"E.","name_suffix":"","recognitions":null,"linked_in_url":null,"seodescription":null,"primary_title_id":75,"translated_fields":{"en":{"bio":"\u003cp\u003eKalle Deyette is a\u0026nbsp;senior associate\u0026nbsp;in King \u0026amp; Spalding\u0026rsquo;s Washington, D.C., office and is a member of the FDA and Life Sciences practice.\u0026nbsp; Kalle focuses her practice on the regulation of medical devices and pharmaceutical manufacturers, as well as healthcare providers and suppliers.\u0026nbsp; Her expertise is concentrated on healthcare fraud and abuse and compliance, including analyzing arrangements under the Anti-Kickback Statute and assisting with government investigations and internal investigations into alleged violations of company policy and federal law. \u0026nbsp;Kalle also provides counsel to both the Ad Hoc State Law Compliance Group on a variety of laws and regulations, including state transparency and disclosure laws, and the International Marketing and Disclosure Compliance Group on a variety of international laws, regulations, and industry codes.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eKalle graduated from Saint Louis University School of Law, where she served as the Notes and Comments editor of the Saint Louis University Journal of Health Law \u0026amp; Policy.\u003c/p\u003e"},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":816}]},"capability_group_id":2},"created_at":"2025-05-26T04:53:46.000Z","updated_at":"2025-05-26T04:53:46.000Z","searchable_text":"Deyette{{ FIELD }}Kalle Deyette is a senior associate in King \u0026amp; Spalding’s Washington, D.C., office and is a member of the FDA and Life Sciences practice.  Kalle focuses her practice on the regulation of medical devices and pharmaceutical manufacturers, as well as healthcare providers and suppliers.  Her expertise is concentrated on healthcare fraud and abuse and compliance, including analyzing arrangements under the Anti-Kickback Statute and assisting with government investigations and internal investigations into alleged violations of company policy and federal law.  Kalle also provides counsel to both the Ad Hoc State Law Compliance Group on a variety of laws and regulations, including state transparency and disclosure laws, and the International Marketing and Disclosure Compliance Group on a variety of international laws, regulations, and industry codes.\nKalle graduated from Saint Louis University School of Law, where she served as the Notes and Comments editor of the Saint Louis University Journal of Health Law \u0026amp; Policy. Senior Associate Saint Louis University Saint Louis University School of Law Saint Louis University Saint Louis University School of Law District of Columbia Missouri","searchable_name":"Kalle E. Deyette","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":101,"capability_group_featured":null,"home_page_featured":null},{"id":427230,"version":1,"owner_type":"Person","owner_id":6515,"payload":{"bio":"\u003cp\u003eNadia Doherty is an associate in the Special Matters and Government Investigations practice in King \u0026amp; Spalding's Washington, D.C. office. Her\u0026nbsp;practice focuses primarily on government investigations, internal investigations, and white-collar criminal defense.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eNadia earned her law degree from the University of Virginia School of Law, where she served as a student attorney in the Prosecution Clinic, a LawTech Center fellow, and President of the Law, Innovation, Security, \u0026amp; Technology society. Prior to joining King \u0026amp; Spalding, Nadia interned with the United States Attorney's Office for the District of Maryland and Department of Justice Office of Legislative Affairs. She earned her B.A. in Government \u0026amp; Politics, as well as Criminology \u0026amp; Criminal Justice, from the University of Maryland College Park.\u003c/p\u003e","slug":"nadia-doherty","email":"ndoherty@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":11,"guid":"11.capabilities","index":0,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":1,"source":"capabilities"},{"id":6,"guid":"6.capabilities","index":2,"source":"capabilities"},{"id":20,"guid":"20.capabilities","index":3,"source":"capabilities"},{"id":118,"guid":"118.capabilities","index":4,"source":"capabilities"}],"is_active":true,"last_name":"Doherty","nick_name":"Nadia","clerkships":[],"first_name":"Nadia","title_rank":9999,"updated_by":202,"law_schools":[{"id":2410,"meta":{"degree":"J.D.","honors":null,"is_law_school":1,"graduation_date":"2024-01-01 00:00:00 UTC"},"order":2,"pin_order":null,"pin_expiration":null}],"middle_name":"Alexandra","name_suffix":"","recognitions":null,"linked_in_url":null,"seodescription":null,"primary_title_id":2,"translated_fields":{"en":{"bio":"\u003cp\u003eNadia Doherty is an associate in the Special Matters and Government Investigations practice in King \u0026amp; Spalding's Washington, D.C. office. Her\u0026nbsp;practice focuses primarily on government investigations, internal investigations, and white-collar criminal defense.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eNadia earned her law degree from the University of Virginia School of Law, where she served as a student attorney in the Prosecution Clinic, a LawTech Center fellow, and President of the Law, Innovation, Security, \u0026amp; Technology society. Prior to joining King \u0026amp; Spalding, Nadia interned with the United States Attorney's Office for the District of Maryland and Department of Justice Office of Legislative Affairs. She earned her B.A. in Government \u0026amp; Politics, as well as Criminology \u0026amp; Criminal Justice, from the University of Maryland College Park.\u003c/p\u003e"},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":12328}]},"capability_group_id":2},"created_at":"2025-05-26T04:59:21.000Z","updated_at":"2025-05-26T04:59:21.000Z","searchable_text":"Doherty{{ FIELD }}Nadia Doherty is an associate in the Special Matters and Government Investigations practice in King \u0026amp; Spalding's Washington, D.C. office. Her practice focuses primarily on government investigations, internal investigations, and white-collar criminal defense. \nNadia earned her law degree from the University of Virginia School of Law, where she served as a student attorney in the Prosecution Clinic, a LawTech Center fellow, and President of the Law, Innovation, Security, \u0026amp; Technology society. Prior to joining King \u0026amp; Spalding, Nadia interned with the United States Attorney's Office for the District of Maryland and Department of Justice Office of Legislative Affairs. She earned her B.A. in Government \u0026amp; Politics, as well as Criminology \u0026amp; Criminal Justice, from the University of Maryland College Park. Associate University of Maryland-College Park  University of Maryland-College Park  University of Virginia University of Virginia School of Law District of Columbia","searchable_name":"Nadia Alexandra Doherty","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null}]}}